Recombinant non-pathogenic marek's disease virus constructs encoding multiple heterologous antigens

Abstract

The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.

Description

[0001] RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING MULTIPLE HETEROLOGOUS ANTIGENS

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority under 35 U.S.C. § 1 19(e) of provisional applications

[0004] U.S. Serial No. 62 / 571 ,524 filed October 12, 2017, and U.S. Serial No. 62 / 729,673, filed September 1 1 , 2018, the contents of both of which are hereby incorporated by reference in their entireties.

[0005] FIELD OF THE INVENTION The present invention relates to novel recombinant multivalent recombinant non-pathogenic Marek's Disease virus constructs encoding and expressing foreign antigens from three or more avian viruses and methods of employing these multivalent recombinant nonpathogenic Marek's Disease virus constructs in poultry vaccines. BACKGROUND OF THE INVENTION

[0006] Pathogenic poultry viruses are not only debilitating to chickens, but they also are costly to chicken breeders because most of the resulting diseases are contagious and the poultry industry relies heavily on confined, large-scale breeding facilities. Vaccinating young chicks is often the only viable means to combat these viruses. Although attenuated or killed poultry viral vaccines remain important in the market place, in recent years significant resources have been expended on developing vaccines containing recombinant viral constructs which express pathogenic viral protein antigens. Furthermore, substantial efforts have been made to construct stable and efficacious multivalent recombinant non-pathogenic Marek's Disease virus (abbreviated as rMDVnp) vectors that express foreign genes from multiple viral pathogens. Such multivalent vaccines would serve to minimize the number of injections given to the chicks and thereby, reduce discomfort and stress on the vaccinated chick, as well as significantly reduce costs in labor and materials. Vaccinating with such single multivalent constructs also would be preferable to alternative multivalent rMDVnpvaccines that contain multiple recombinant monovalent rMDVnpconstructs, because these alternative vaccines have, at least to date, resulted in protection against only a single viral pathogen. The failure of such alternative vaccines is presumably due to one of the monovalent rMDVnpconstructs overgrowing the other monovalent rMDVnpconstructs thereby, preventing these other monovalent rMDVnpconstructs from inducing a significant immune response. In any case, despite substantial efforts in the past to construct stable and efficacious multivalent rMDVnp vectors that express foreign genes from multiple viral pathogens indeed, such vaccines had been suggested more than twenty years ago [see e.g., U.S. 5,965,138], it has been only recently that a multivalent vaccine that comprises a recombinant herpesvirus of turkeys (abbreviated as rHVT) encoding antigens from more than one other pathogen has been shown to be both stable and efficacious.

[0007] One poultry virus disease that can be controlled through vaccination is Marek's disease. Marek's disease is a pathogenic disease that adversely affects chickens worldwide. Marek's disease occurs predominantly in young chickens between 2 and 5 months of age. Clinical signs include: progressive paralysis of one or more of the extremities, incoordination due to paralysis of legs, drooping of the limb due to wing involvement, and a lowered head position due to involvement of the neck muscles. In acute cases, severe depression may result. Bursal and thymic atrophy may also develop.

[0008] The etiological agent for Marek's disease is Marek's disease virus serotype 1 (abbreviated as MDV1 ), a cell-associated virus having a double-stranded DNA genome. MDV1 is a lymphotropic avian alphaherpesvirus that both: (i) infects B cells, which can result in cytolysis, and (ii) latently infects T cells, which can induce T-cell lymphoma. Closely related to the virulent MDV1 strain, Marek's disease virus serotype 2 (abbreviated as MDV2), previously known as Gallid herpes virus 3, is a naturally attenuated MDV strain that has been shown to have little to no pathogenicity in chickens [Petherbridge et al., J. Virological Methods 158:1 1 -17 (2009)]. SB-1 is a specific MDV2 strain that has been shown to be useful in vaccines against MDV1 [see e.g., Murthy and Calnek, Infection and Immunity 26(2) 547-553 (1979)].

[0009] Another closely related alphaherpesvirus, Marek's disease virus serotype 3 (abbreviated as MDV3), more widely known as herpesvirus of turkeys (abbreviated as HVT), is a

[0010] nonpathogenic virus of domestic turkeys [see e.g., Kingham et al., J. of General Virology 82:1 123-1 135 (2001 )]. Two commonly used strains of HVT are the PB1 strain and the FC126 strain. Whereas, HVT is also nonpathogenic in chickens, it does induce a long- lasting protective immune response in chickens against MDV1 . Accordingly, HVT has been used in poultry vaccines against virulent MDV1 for many years, generally in combination with SB-1 , which is more viraemic than HVT, but considered less safe. Alternatively, when flocks are challenged with particularly virulent MDV1 strains, HVT can be combined with the Rispen's vaccine. The Rispen's vaccine is an isolate that originated from a mildly virulent MDV1 strain that was subsequently further weakened by cell passaging. The Rispen's strain however, retains some virulence towards highly susceptible lines of chickens. The sequence of the complete genome of HVT has been disclosed [Afonso et al., J. Virology 75(2):971 -978 (2001 )], and as most alphaherpesviruses, HVT possesses a significant number of potential nonessential insertion sites [see e.g., U.S. 5,187,087; U.S. 5,830,745; U.S. 5,834,305; U.S. 5,853,733; U.S. 5,928,648; U.S. 5,961 ,982; U.S. 6,121 ,043;

[0011] U.S. 6,299,882 B1]. HVT also has been shown to be amenable to genetic modification and thus, has been used as a recombinant vector for many years [WO 87 / 04463]. Accordingly, recombinant HVT vectors have been reported to express foreign genes that encode antigens from e.g., Newcastle Disease Virus (NDV), [Sondermeijer et al., Vaccine, 1 1 :349-358 (1993); Reddy et al., Vaccine, 14:469-477 (1996)], Infectious Bursal Disease Virus (IBDV), [Darteil et al., Virology, 21 1 :481 -490 (1995); Tsukamoto et al., J. of Virology 76(1 1 ):5637-5645 (2002)], and Infectious Laryngotracheitis Virus (ILTV) [Johnson et al., Avian Disease, 54(4):1251 -

[0012] 1259 (2010); WO 92 / 03554; U.S. 6,875,856]. The entire genomic sequence of MDV2 is also known [see, GenBank acc. nr: AB049735.1 , and Petherbridge et al., supra]. The genomic organization of the MDV2 is very similar to that of HVT, with the US region in particular, being identical to that of HVT [see, Kingham et al., supra].

[0013] In addition a recombinant chimeric virus, known as the novel avian herpesvirus (NAHV), has been constructed in which specific regions of the HVT genome have been replaced by the corresponding regions of the MDV1 genome. The NAHV also has been used to express foreign genes that encode antigens from other poultry viruses [U.S. 5,965,138;

[0014] U.S. 6,913,751].

[0015] Like MDV, infectious laryngotracheitis virus (abbreviated as ILTV or ILT) is an

[0016] alphaherpesvirus that adversely affects chickens, worldwide [Fuchs et al., Veterinary

[0017] Research 38:261 -279 (2007)]. ILTV causes acute respiratory disease in chickens, which is characterized by respiratory depression, gasping, and expectoration of bloody exudate.

[0018] Viral replication is limited to cells of the respiratory tract, where in the trachea the infection gives rise to tissue erosion and hemorrhage.

[0019] Newcastle disease is another highly contagious and debilitating disease of chickens. The etiological agent for Newcastle disease is the Newcastle disease virus (NDV). NDV belongs to the order of the Mononegavirales and is in the family of Paramyxoviridae. Newcastle disease viruses have a non-segmented, negative sense, single-stranded RNA genome. NDV has been grouped into three distinct pathotypes according to their virulence. Infection of poultry by the non-pathogenic lentogenic strains of NDV is essentially asymptomatic. In direct contrast, the mesogenic (medium pathogenic) and velogenic (highly pathogenic) NDV strains cause extensive disease that can be fatal. Most types of NDV infect the respiratory system and / or the nervous system, and can result in gasping and torticollis.

[0020] Infectious bursal disease virus (abbreviated as IBDV or IBD), also called Gumboro disease virus, is the causative agent of infectious bursal disease. IBDV causes an acute, highly- contagious, viral infection of a chicken's lymphoid tissue, with its primary target being the bird's essential immunological organ: the bursa of Fabricius. The morbidity rate in susceptible flocks is high, with rapid weight loss and moderate to high mortality rates.

[0021] Chicks that recover from the disease may have immune deficiencies because of destruction of (or parts of) the bursa of Fabricius. This makes them particularly vulnerable to secondary infections.

[0022] IBDV is a member of the Birnaviridae family. The viruses in this family have a genome consisting of two segments (A and B) of double-stranded RNA. Two serotypes of IBDV exist, serotype 1 and 2, which can be differentiated by virus neutralization (VN) tests.

[0023] Serotype 1 viruses have been shown to be pathogenic to chickens, while serotype 2 viruses cause only sub-acute disease in turkeys. Historically, IBDV serotype 1 viruses consisted of only one type that is now known as "classic" IBD virus. More recently, so-called "variant" IBDV strains have emerged. Classic and variant strains of IBDV can be identified and distinguished by a virus neutralization test using a panel of monoclonal antibodies, or by RT- PCR [Wu et al., Avian Diseases, 51 :515-526(2007)]. Well-known classic IBDV strains include, D78, Faragher 52 / 70, and STC, whereas 89 / 03 is a well-known variant strain. Many live or inactivated IBDV vaccines are commercially available, e.g. a live vaccine such as NOBILISRGumboro D78 (MSD Animal Health). As indicated above, because HVT can act as both an antigen that provides significant protection against Marek's Disease and as a recombinant vector, it is presently used as a platform vector for such multivalent vaccines as lnnovax®-ILT (sold by Merck Animal Health), which protects against ILTV; lnnovax®-ND-SB (sold by Merck Animal Health) Vectormune®HVT-NDV (sold by Ceva), both of which protect against NDV; and Vaxxitek®HVT+IBD (Merial; previously named: Gallivac™ HVT-IBD), and Vectormune™ HVT-IBD (Ceva) both of which protect against IBDV. Notably, lnnovax®-ILT comprises two foreign genes, i.e., ILTV gD and ILTV gl, which has proved to be safe, effective, and stable. However, these two foreign genes are from the same pathogen and moreover, they naturally overlap and need to be co-expressed in order to allow proper immunization against ILTV. More recently, a recombinant safe, effective, and stable multivalent vaccine comprising HVT-ILTV-NDV has been disclosed [US 8,932,604 B2 and U.S. 9,409,954 B2, the contents of which are hereby incorporated by reference in their entireties]. An early HVT-NDV-IBDV also has been disclosed, though upon prolonged testing during the development of the corresponding product one of the main constructs, HVP309, was found neither to display adequate genetic stability nor sustained expression of the heterologous inserts [WO 2013 / 057,235].

[0024] Subsequently, a more stable and efficatious construct was developed [WO 2016 / 102647]. Other recombinant HVT constructs also have been described [see e.g., US 9,1 14,108, US 9,555,016, US 9,555,096, and US 2018 / 0163230 A1].

[0025] However, despite the clear advantages of stable, multivalent, recombinant MDVnpconstructs that can efficaciously express heterologous antigens from three or more different pathogens, and the substantial efforts to design them, heretofore, none have been forthcoming. Indeed, prior unsuccessful attempts to construct such recombinant MDVnpconstructs has led to the general consensus in the field that the insertion of foreign antigens from three or more different viral pathogens into an MDVnpconstruct overtaxes that construct, leading to the observed lack of stability. Accordingly, the suitability of any given multivalent recombinant MDVnp as a vaccine remains at best, unpredictable when the recombinant MDVnpcomprises a combination of heterologous antigens that are obtained from a unique set of three or more poultry viruses. Therefore, there is a clear need to overcome the collective industry failures, by constructing novel, stable, recombinant MDVnpvectors that can be used in multivalent vaccines as the sole active to protect against three or more different non-MDV1 poultry virus pathogens.

[0026] The citation of any reference herein should not be construed as an admission that such reference is available as "prior art" to the instant application.

[0027] SUMMARY OF THE INVENTION

[0028] Accordingly, the present invention provides a novel, multivalent recombinant nonpathogenic Marek's Disease virus (rMDVnp) for use as a vector to express foreign genes from multiple viral pathogens. In particular embodiments, the rMDVnpis a recombinant herpesvirus of turkeys (rHVT). In alternative embodiments, the rMDVnpis a recombinant Marek's disease virus serotype 2 (rMDV2). An rMDVnp, e.g., an rHVT or an rMDV2, of the present invention can be used in safe and efficacious multivalent vaccines against pathogenic poultry viruses. The present invention thus provides recombinant nonpathogenic Marek's Disease virus (rMDVnp) vectors (including HVT vectors) that encode and express antigens from three or more foreign chicken virus pathogens. In specific embodiments the rMDVnpencodes one or more antigens from Laryngotracheitis Virus (I LTV), one or more antigens from Infectious Bursal Disease Virus (IBDV), and one or more antigens from Newcastle Disease Virus (NDV). In more specific embodiments such rMDVnpvectors aid in the protection of the chicken vaccinate from clinical signs arising from an infection from pathogenic MDV, pathogenic IBDV, pathogenic NDV, and / or pathogenic ILTV. The vaccines are preferably effective for the vaccination of healthy animals at 18-19 day of embryonation, and for day old chicks and older.

[0029] In particular embodiments, the recombinant nonpathogenic Marek's Disease Virus (rMDVnp) comprises in one or more nonessential sites of its genome a first heterologous nucleotide sequence encoding one or more antigens from a first chicken pathogen, a second heterologous nucleotide sequence encoding one or more antigens from a second chicken pathogen, and a third heterologous nucleotide sequence encoding one or more antigens from a third chicken pathogen. In specific embodiments the first chicken pathogen, the second chicken pathogen, and the third chicken pathogen are all avian viruses. In more specific embodiments the first chicken pathogen, the second chicken pathogen, and the third chicken pathogen are all different viral species from each other and are a different viral species than Marek's Disease Virus. In certain embodiments of this type, the first chicken pathogen is Infectious Bursal Disease Virus (IBDV), the second chicken pathogen is Infectious Laryngotracheitis Virus (ILTV), and the third chicken pathogen is Newcastle Disease Virus (NDV).

[0030] In specific rMDVnpembodiments, the first heterologous nucleotide sequence encodes an Infectious Bursal Disease Virus viral protein 2 (IBDV VP2); and / or the second heterologous nucleotide sequence encodes an Infectious Laryngotracheitis Virus glycoprotein D (ILTV gD), an Infectious Laryngotracheitis Virus glycoprotein I (ILTV gl), or both an ILTV gl and an ILTV gD; and / or the third heterologous nucleotide sequence encodes a Newcastle Disease Virus fusion protein (NDV F). In more specific rMDVnpembodiments, the first heterologous nucleotide sequence encodes an Infectious Bursal Disease Virus viral protein 2 (IBDV VP2), the second heterologous nucleotide sequence encodes both an Infectious Laryngotracheitis Virus glycoprotein D (ILTV gD) and an Infectious Laryngotracheitis Virus glycoprotein I (I LTV gl), and the third heterologous nucleotide sequence encodes a Newcastle Disease Virus fusion protein (NDV F).

[0031] Accordingly, in particular rMDVnpembodiments of the present invention, the first heterologous nucleotide sequence, the second heterologous nucleotide sequence and the third

[0032] heterologous nucleotide sequence are located in three different nonessential sites in the rMDVnp genome. In particular embodiments the three different sites are individually selected from the group consisting of the US2 site, the UL54.5 site, the UL7 / 8 site, the UL40 site, the UL43 site, the UL45 / 46 site, the UL55 site, the US10 site, the region between US10 and SORF3, the region between US2 and SORF3, the IG1 site, the IG2 site, and the IG3 site. In a specific embodiment of this type the first nonessential site is the US2 site, the second nonessential site is the UL54.5 site, and the third nonessential site is the UL45 / 46 site.

[0033] In alternative embodiments, the first heterologous nucleotide sequence, the second heterologous nucleotide sequence, and the third heterologous nucleotide sequence are located in a first nonessential site in the rMDVnpgenome or in a second nonessential site in the rMDVnp genome. In specific embodiments of this type, the first nonessential site and the second nonessential site are the same (i.e., there is a lone nonessential insertion site). In particular embodiments of this type, the lone nonessential insertion site is the US2 site. In other embodiments of this type, the lone nonessential insertion site is the UL54.5 site. In still other embodiments of this type, the lone nonessential insertion site is the UL7 / 8 site. In yet other embodiments of this type, the lone nonessential insertion site is the UL40 site. In still other embodiments of this type, the lone nonessential insertion site is the UL45 / 46 site. In yet other embodiments of this type, the lone nonessential insertion site is the UL55 site. In still other embodiments of this type, the lone nonessential insertion site is the US10 site. In yet other embodiments of this type, lone nonessential insertion site is the region between US10 and SORF3. In still other embodiments of this type, the lone nonessential insertion site is the region between US2 and SORF3. In yet other embodiments of this type the lone nonessential insertion site is the IG1 site. In still other embodiments of this type, the lone nonessential insertion site is the IG2 site. In yet other embodiments of this type the lone nonessential insertion site is the IG3 site. In still other embodiments of this type, the lone nonessential insertion site is the UL43 site.

[0034] In yet other types of embodiments, the first nonessential site, and the second nonessential site are different. The two different sites are individually selected from the group consisting of the US2 site, the UL54.5 site, the UL7 / 8 site, the UL40 site, the UL43 site, the UL45 / 46 site, the UL55 site, the US10 site, the region between US10 and SORF3, the region between US2 and SORF3, the IG1 site, the IG2 site, and the IG3 site. In particular embodiments, the first heterologous nucleotide sequence and the second heterologous nucleotide sequence are located in a first nonessential site and the third heterologous nucleotide sequence is located in a second nonessential site. In other embodiments, the first heterologous nucleotide sequence and the third heterologous nucleotide sequence are located in a first nonessential site and the second heterologous nucleotide sequence is located in a second nonessential site. In still other embodiments, the second heterologous nucleotide sequence and the third heterologous nucleotide sequence are located in a first nonessential site and the first heterologous nucleotide sequence is located in a second nonessential site. In preferred embodiments of this type, the first heterologous nucleotide sequence encodes an Infectious Bursal Disease Virus viral protein 2 (IBDV VP2), the second heterologous nucleotide sequence encodes an Infectious Laryngotracheitis Virus glycoprotein D (ILTV gD), an Infectious Laryngotracheitis Virus glycoprotein I (ILTV gl), or both an ILTV gl and an ILTV gD, and the third heterologous nucleotide sequence encodes a Newcastle Disease Virus fusion protein (NDV F).

[0035] In certain embodiments of this type, an rMDVnpcomprising heterologous nucleotide sequences encoding an ILTV gD protein, an ILTV gl protein, and an IBDV VP2 protein in the first nonessential site, and a heterologous nucleotide sequence that encodes a NDV F protein in the second nonessential site is constructed so that the heterologous nucleotide sequence encoding the IBDV VP2 protein is 5' to the heterologous nucleotide sequence encoding the ILTV gD protein and the ILTV gl protein. In other embodiments of this type, the rMDVnp is constructed so that the heterologous nucleotide sequence encoding the ILTV gD protein and the ILTV gl protein are 5' to the heterologous nucleotide sequence encoding the IBDV VP2 protein.

[0036] In alternative embodiments, an rMDVnpcomprising heterologous nucleotide sequences encoding a NDV F protein and an IBDV VP2 protein in the first nonessential site and a heterologous nucleotide sequence that encodes an ILTV gD protein and an ILTV gl protein in the second nonessential site is constructed so that the heterologous nucleotide sequence encoding the NDV F protein is 5' to the heterologous nucleotide sequence encoding the IBDV VP2 protein. In other embodiments of this type, the rMDVnpis constructed so that the heterologous nucleotide sequence encoding the IBDV VP2 protein is 5' to the heterologous nucleotide sequence encoding the NDV F protein. In yet other alternative embodiments, an rMDVnpcomprising heterologous nucleotide sequences encoding a NDV F protein, an ILTV gD protein and an ILTV gl protein in the first nonessential site and a heterologous nucleotide sequence encoding an IBDV VP2 protein in the second nonessential site is constructed so that the heterologous nucleotide sequence encoding the NDV F protein is 5' to the heterologous nucleotide sequence encoding the

[0037] ILTV gD protein and the ILTV gl protein. In alternative embodiments of this type, the rMDVnpis constructed so that the heterologous nucleotide sequence encoding the ILTV gD protein and the ILTV gl protein is 5' to the heterologous nucleotide sequence encoding the NDV F protein. In specific embodiments of this type, the first nonessential site is the US2 site and the second nonessential site is the UL54.5 site. In alternative embodiments, the first

[0038] nonessential site is the UL54.5 site and the second nonessential site is the US2 site. In yet another embodiment of this type, the first nonessential site is the US2 site and the second nonessential site is the UL45 / 46 site. In still another embodiment of this type, the first nonessential site is the UL45 / 46 site and the second nonessential site is the US2 site.

[0039] In yet another embodiment of this type, the first nonessential site is the UL54.5 site and the second nonessential site is the UL45 / 46 site. In still another embodiment of this type, the first nonessential site is the UL45 / 46 site and the second nonessential site is the UL54.5 site. In yet another embodiment of this type, the first nonessential site is the US2 site and the second nonessential site is the UL55 site. In still another embodiment of this type, the first nonessential site is the UL55 site and the second nonessential site is the US2 site.

[0040] Accordingly, the rMDVnpvectors of the present invention can comprise heterologous nucleotide sequences that encode any combination of these foreign protein antigens. In specific embodiments, the ILTV gD protein comprises the amino acid sequence of SEQ ID NO: 2. In other embodiments, the ILTV gl protein comprises the amino acid sequence of SEQ ID NO: 4. In still other embodiments, the IBDV VP2 protein comprises the amino acid sequence of SEQ ID NO: 6. In yet other embodiments the NDV F protein comprises the amino acid sequence of SEQ ID NO: 8. In still other embodiments, the NDV F protein comprises the amino acid sequence of SEQ ID NO: 10. Moreover, the present invention also provides rMDVnpvectors that comprise any combination of nucleotide sequences that encode one or more of these amino acid sequences, including specific embodiments that encode all of them. In yet other embodiments of the rMDVnp, the ILTV gD protein comprises the amino acid sequence of SEQ ID NO: 2 and the ILTV gl protein comprises the amino acid sequence of SEQ ID NO: 4. In certain embodiments of this type, the ILTV gD protein comprises the amino acid sequence of SEQ ID NO: 2, the ILTV gl protein comprises the amino acid sequence of SEQ ID NO: 4, and the IBDV VP2 protein comprises the amino acid sequence of SEQ ID NO: 6. In related embodiments the ILTV gD protein comprises the amino acid sequence of SEQ ID NO: 2, the ILTV gl protein comprises the amino acid sequence of SEQ ID NO: 4, and the NDV F protein comprises the amino acid sequence of SEQ ID NO: 8. In similar embodiments the ILTV gD protein comprises the amino acid sequence of SEQ ID NO: 2, the ILTV gl protein comprises the amino acid sequence of SEQ ID NO: 4, and the NDV F protein comprises the amino acid sequence of SEQ ID NO: 10. In more specific embodiments the ILTV gD protein comprises the amino acid sequence of SEQ ID NO: 2, the ILTV gl protein comprises the amino acid sequence of SEQ ID NO: 4, the IBDV VP2 protein comprises the amino acid sequence of SEQ ID NO: 6, and the NDV F protein either comprises the amino acid sequence of SEQ ID NO: 8 or the amino acid sequence of SEQ ID NO: 10. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2.

[0041] In related embodiments, the ILTV gD protein is encoded by the nucleotide sequence of SEQ ID NO: 1 . In other embodiments, the ILTV gl protein is encoded by the nucleotide sequence of SEQ ID NO: 3. In still other embodiments, the IBDV VP2 protein is encoded by the nucleotide sequence of SEQ ID NO: 5. In yet other embodiments, the NDV F protein is encoded by the nucleotide sequence of SEQ ID NO: 7. In still other embodiments, the NDV F protein is encoded by the nucleotide sequence of SEQ ID NO: 9.

[0042] Similarly, the rMDVnpvectors of the present invention can comprise heterologous nucleic acids that comprise any combination of such heterologous nucleotide sequences. In certain embodiments, the rMDVnpcomprises a first heterologous nucleic acid located in the first nonessential site in the rMDVnpgenome and a second heterologous nucleic acid located in the second nonessential site in the rMDVnpgenome, with the first heterologous nucleic acid comprising both the first heterologous nucleotide sequence and the second heterologous nucleotide sequence, whereas the second heterologous nucleic acid comprises the third heterologous nucleotide sequence. In certain embodiments of this type, the first heterologous nucleic acid comprises heterologous nucleotide sequences encoding an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) protein, an Infectious Laryngotracheitis Virus (ILTV) glycoprotein I (gl) protein, and an Infectious Bursal Disease Virus (IBDV) viral protein 2 (VP2), whereas the second heterologous nucleic acid comprises a heterologous nucleotide sequence that encodes a Newcastle Disease Virus (NDV) F protein. In certain embodiments of this type, the first heterologous nucleic acid is constructed and / or inserted into the rMDVnpgenome so that the heterologous nucleotide sequence encoding the IBDV VP2 protein is 5' to the heterologous nucleotide sequence encoding the ILTV gD protein and the ILTV gl protein. In other embodiments of this type, the first heterologous nucleic acid is constructed and / or inserted into the rMDVnpgenome so that the heterologous nucleotide sequence encoding the ILTV gD protein and the ILTV gl protein is 5' to the heterologous nucleotide sequence encoding the IBDV VP2 protein.

[0043] In alternative embodiments, the first heterologous nucleic acid comprises heterologous nucleotide sequences that encode a NDV F protein and an IBDV VP2 protein, whereas the second heterologous nucleic acid comprises a heterologous nucleotide sequence encoding an ILTV gD protein and an ILTV gl protein. In certain embodiments of this type, the first heterologous nucleic acid is constructed and / or inserted into the rMDVnpgenome so that the heterologous nucleotide sequence encoding the NDV F protein is 5' to the heterologous nucleotide sequence encoding the IBDV VP2 protein. In alternative embodiments of this type, the first heterologous nucleic acid is constructed and / or inserted into the rMDVnpgenome so that the heterologous nucleotide sequence encoding the IBDV VP2 protein is 5' to the heterologous nucleotide sequence encoding the NDV F protein.

[0044] In yet other alternative embodiments, the first heterologous nucleic acid comprises heterologous nucleotide sequences that encode a NDV F protein, an ILTV gD protein, and an ILTV gl protein, whereas the second heterologous nucleic acid comprises a heterologous nucleotide sequence encoding an IBDV VP2 protein. In certain embodiments of this type, the first heterologous nucleic acid is constructed and / or inserted into the rMDVnpgenome so that the heterologous nucleotide sequence encoding the NDV F protein is 5' to the heterologous nucleotide sequence encoding the ILTV gD protein and the ILTV gl protein. In alternative embodiments of this type, the first heterologous nucleic acid is constructed and / or inserted into the rMDVnpgenome so that the heterologous nucleotide sequence encoding the ILTV gD protein and the ILTV gl protein is 5' to the heterologous nucleotide sequence encoding the NDV F protein. Moreover, the present invention also provides rMDVnpvectors that encode any combination of these nucleotide sequences, including specific embodiments wherein a first heterologous nucleic acid encodes the nucleotide sequence of SEQ ID NOs: 1 , 3, and 5, and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 7. In alternative embodiments, the first heterologous nucleic acid encodes the nucleotide sequence of SEQ ID NOs: 1 , 3, and 5, and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 9. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2.

[0045] In particular embodiments the two different nonessential sites of the rMDVnpare individually selected from the group consisting of the US2 site, the UL54.5 site, the UL7 / 8 site, the UL40 site, the UL 43 site, the UL45 / 46 site, the UL55 site, the US10 site, the region between US10 and SORF3, the region between US2 and SORF3, intergenic region 1 (IG1 ) site, intergenic region 2 (IG2) site and intergenic region (IG3).

[0046] In certain embodiments, the first nonessential site of the rMDVnpis the US2 site, while the second nonessential site of the rMDVnpis a nonessential site other than the US2 site. In other embodiments, the first nonessential site of the rMDVnpis the UL 54.5 site, while the second nonessential site of the rMDVnpis a nonessential site other than the UL 54.5 site. In specific embodiments of this type, the first nonessential site is the US2 site and the second nonessential site is the UL54.5 site. In alternative embodiments, the first nonessential site is the UL54.5 site and the second nonessential site is the US2 site. In yet another embodiment of this type, the first nonessential site is the US2 site and the second nonessential site is the UL45 / 46 site. In still another embodiment of this type, the first nonessential site is the

[0047] UL45 / 46 site and the second nonessential site is the US2 site. In yet another embodiment of this type, the first nonessential site is the UL54.5 site and the second nonessential site is the UL45 / 46 site. In still another embodiment of this type, the first nonessential site is the UL45 / 46 site and the second nonessential site is the UL54.5 site. In yet another

[0048] embodiment of this type, the first nonessential site is the US2 site and the second

[0049] nonessential site is the UL55 site. In still another embodiment of this type, the first nonessential site is the UL55 site and the second nonessential site is the US2 site. In related embodiments, the first nonessential site of the rMDVnpis the UL 54.5 and the second nonessential site of the rMDVnpis the UL7 / 8 site. In yet other embodiments, the first nonessential site of the rMDVnpis the UL 54.5 and the second nonessential site of the rMDVnpis the US10 site. In related embodiments, the second nonessential site of the rMDVnp is the US2 site and the first nonessential site of the rMDVnpis the UL7 / 8 site. In yet other embodiments, the second nonessential site of the rMDVnpis the US2 site and the first nonessential site of the rMDVnpis the US10 site. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2.

[0050] In specific embodiments of this type, the first nonessential site and the second nonessential site are the same (i.e., there is a lone nonessential insertion site). In particular embodiments of this type, the lone nonessential insertion site is the US2 site. In other embodiments of this type, the lone nonessential insertion site is the UL54.5 site. In still other embodiments of this type, the lone nonessential insertion site is the UL7 / 8 site. In yet other embodiments of this type, the lone nonessential insertion site is the UL40 site. In still other embodiments of this type, the lone nonessential insertion site is the UL45 / 46 site. In yet other embodiments of this type, the lone nonessential insertion site is the UL55 site. In still other embodiments of this type, the lone nonessential insertion site is the US10 site. In yet other embodiments of this type, lone nonessential insertion site is the region between US10 and SORF3. In still other embodiments of this type, the lone nonessential insertion site is the region between US2 and SORF3. In yet other embodiments of this type the lone nonessential insertion site is the IG1 site. In still other embodiments of this type, the lone nonessential insertion site is the IG2 site. In yet other embodiments of this type the lone nonessential insertion site is the IG3 site. In still other embodiments of this type, the lone nonessential insertion site is the UL43 site. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2. The nucleotide sequences encoding the ILTV gD protein, the ILTV gl protein, and the IBDV VP2 protein can be operatively under the control of exogenous promoters, i.e., promoters that are not naturally found in the MDVnp. In certain embodiments, these three nucleotide sequences are operatively under the control of different promoters, i.e., the nucleotide sequence encoding the ILTV gD protein is operatively under the control of a first promoter, the nucleotide sequence encoding the ILTV gl protein is operatively under the control of a second promoter, and the nucleotide sequence encoding the IBDV VP2 protein is operatively under the control of a third promoter, with the first promoter, the second promoter, and the third promoter all being different. In particular embodiments, the promoter for the nucleotide sequence encoding the ILTV gD protein is the endogenous ILTV gD promoter (i.e., endogenous for ILTV). In certain embodiments, the promoter for the nucleotide sequence encoding the ILTV gl protein is the endogenous ILTV gl promoter. In particular embodiments of this type, the promoter for the nucleotide sequence encoding the ILTV gD protein is the endogenous ILTV gD promoter and the promoter for the nucleotide sequence encoding the ILTV gl protein is the endogenous ILTV gl promoter. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2.

[0051] In certain embodiments, at least one of the promoters operably linked to a nucleotide sequence encoding the NDV F protein, the ILTV gD protein, the ILTV gl protein, or the IBDV VP2 protein is the murine cytomegalovirus immediate early (mCMV IE) promoter. In related embodiments, at least one of the promoters operably linked to a nucleotide sequence encoding the NDV F protein, the ILTV gD protein, the ILTV gl protein, or the IBDV VP2 protein is the human cytomegalovirus immediate early (hCMV IE) promoter or a derivative thereof (e.g., from strain AD169). In other embodiments, at least one of the promoters operably linked to a nucleotide sequence encoding the NDV F protein, the ILTV gD protein, the ILTV gl protein, or the IBDV VP2 protein is the guinea pig cytomegalovirus immediate early promoter. In other embodiments, at least one of the promoters operably linked to a nucleotide sequence encoding the NDV F protein, the ILTV gD protein, the ILTV gl protein, or the IBDV VP2 protein is the chicken β-actin promoter. In still other embodiments, at least one of the promoters operably linked to a nucleotide sequence encoding the NDV F protein, the ILTV gD protein, the ILTV gl protein or the IBDV VP2 protein is the pseudorabies virus (PRV) gpX promoter. In particular embodiments, the promoter for the nucleotide sequence encoding the IBDV VP2 protein is the mCMV IE promoter. In related embodiments, the promoter for the nucleotide sequence encoding the IBDV VP2 protein is the human cytomegalovirus immediate early (hCMV IE) promoter or a derivative thereof (e.g., from strain AD169).

[0052] In other embodiments, the promoter for the nucleotide sequence encoding the IBDV VP2 protein is the guinea pig cytomegalovirus immediate early promoter. In yet other

[0053] embodiments, the promoter for the nucleotide sequence encoding the IBDV VP2 protein is the chicken beia-actin gene promoter.

[0054] In certain embodiments, the promoter operably linked to a nucleotide sequence encoding the NDV F protein is the human cytomegalovirus immediate early (hCMV IE) promoter. In other embodiments, the promoter operably linked to a nucleotide sequence encoding the NDV F protein is the pseudorabies virus (PRV) gpX promoter. In related embodiments, the promoter operably linked to a nucleotide sequence encoding the NDV F protein is the chicken beia-actin gene promoter. In still other embodiments, the promoter operably linked to a nucleotide sequence encoding the NDV F protein is the Simian virus 40 (SV40) promoter. In more specific embodiments, the promoter for the nucleotide sequence encoding the IBDV VP2 protein is the mCMV IE promoter, the promoter for the nucleotide sequence encoding the ILTV gD protein is the endogenous ILTV gD promoter, the promoter for the nucleotide sequence encoding the ILTV gl protein is the endogenous ILTV gl promoter, and the promoter for the nucleotide sequence encoding the NDV F protein is the hCMV IE promoter. In other specific embodiments, the promoter for the nucleotide sequence encoding the IBDV VP2 protein is the hCMV IE promoter (or a derivative thereof), the promoter for the nucleotide sequence encoding the ILTV gD protein is the endogenous ILTV gD promoter, the promoter for the nucleotide sequence encoding the ILTV gl protein is the endogenous

[0055] ILTV gl promoter, and the promoter for the nucleotide sequence encoding the NDV F protein is the hCMV IE promoter. In yet other specific embodiments, the promoter for the nucleotide sequence encoding the IBDV VP2 protein is the chicken β-actin promoter, the promoter for the nucleotide sequence encoding the ILTV gD protein is the endogenous ILTV gD promoter, the promoter for the nucleotide sequence encoding the ILTV gl protein is the endogenous ILTV gl promoter, and the promoter for the nucleotide sequence encoding the NDV F protein is the hCMV IE promoter.

[0056] In certain embodiments, an rMDVnpof the present invention that includes insertions of nucleotide sequences encoding the ILTV gD protein, the ILTV gl protein, and the IBDV VP2 protein also includes one or more exogenous transcription terminator sequences. In specific embodiments of this type, a transcription terminator sequence is downstream from the nucleotide sequence encoding the IBDV VP2 protein. In particular embodiments, the nucleotide sequences encoding the ILTV gD protein and the ILTV gl protein share one transcription terminator sequence and the nucleotide sequence encoding the IBDV VP2 protein has another. In more particular embodiments, at least one of the transcription terminator sequences comprises a feline herpesvirus US-9 (FHV US-9) polyadenylation sequence. In even more particular embodiments, at least one of the transcription terminator sequences comprises a Simian virus 40 (SV40) polyadenylation sequence.

[0057] In certain embodiments, the NDV F protein also includes one or more exogenous transcription terminator sequences. In specific embodiments of this type, a transcription terminator sequence is downstream from the nucleotide sequence encoding the NDV F protein. In related embodiments at least one of the transcription terminator sequences comprises a Herpes Simplex Virus thymidine kinase (HSV TK) polyadenylation sequence.

[0058] In alternative embodiments at least one of the transcription terminator sequences comprises a human cytomegalovirus immediate early (hCMV IE) polyadenylation sequence. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2.

[0059] The present invention also provides an rMDVnpthat comprises (i) an mCMV IE promoter, a chicken beia-actin gene promoter, or an hCMV promoter (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence (iv) an ILTV gD promoter, (v) a coding sequence for the ILTV gD protein, (vi) an ILTV gl promoter, and (vii) a coding sequence for the ILTV gl protein in the UL54.5 site of the rMDVnpgenome. In particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 21 is comprised within the UL54.5 site of the rMDVnp genome. In specific embodiments, the rMDVnpfurther comprises (i) an hCMV IE promoter, (ii) a coding sequence for the NDV F protein and (iii) a hCMV IE transcription terminator sequence in the US2 site of its genome. In particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 22 is comprised within the US2 site of the rMDVnpgenome.

[0060] The present invention further provides an rMDVnpcomprising (i) an mCMV IE promoter, a chicken beia-actin gene promoter, or an hCMV promoter (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence (iv) an ILTV gD promoter, (v) a coding sequence for the ILTV gD protein, (vi) an ILTV gl promoter, and (vii) a coding sequence for the ILTV gl protein in the US2 site of the rMDVnpgenome. In certain embodiments of this type, the nucleotide sequence of SEQ ID NO: 24 is comprised within the US2 site of the rMDVnp genome. In yet other embodiments of this type, the nucleotide sequence of

[0061] SEQ ID NO: 25 is comprised within the US2 site of the rMDVnpgenome. In more particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 23 is comprised within the US2 site of the rMDVnpgenome. In specific embodiments, the rMDVnpfurther comprises (i) an hCMV IE promoter, (ii) a coding sequence for the NDV F protein and (iii) a hCMV IE transcription terminator sequence in the UL54.5 site of its genome. In particular

[0062] embodiments of this type, the nucleotide sequence of SEQ ID NO: 26 is comprised within the UL54.5 site of the rMDVnpgenome.

[0063] In addition, the present invention also provides an rMDVnpcomprising (i) an ILTV gD promoter, (ii) a coding sequence for the ILTV gD protein, (iii) an ILTV gl promoter, (iv) a coding sequence for the ILTV gl protein (v) an hCMV IE promoter, (vi) a coding sequence for the NDV F protein and (vii) a hCMV IE transcription terminator sequence in the UL54.5 site of the rMDVnPgenome. In particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 31 is comprised within the UL54.5 site of the rMDVnpgenome. In specific embodiments, the rMDVnpfurther comprises (i) a mCMV IE promoter (ii) a coding sequence for the IBDV VP2 protein, and (iii) a transcription terminator sequence within the US2 site of the rMDVnp genome. In particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 32 is comprised within the US2 site of the rMDVnpgenome.

[0064] The present invention also provides an rMDVnpcomprising (i) an I LTV gD promoter, (ii) a coding sequence for the I LTV gD protein, (iii) an I LTV gl promoter, (iv) a coding sequence for the ILTV gl protein (v) an hCMV IE promoter, (vi) a coding sequence for the NDV F protein and (vii) a hCMV IE transcription terminator sequence in the US2 site of the rMDVnpgenome. In particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 28 is comprised within the US2 site of the rMDVnpgenome. In specific embodiments, the rMDVnpfurther comprises (i) a mCMV IE promoter (ii) a coding sequence for the IBDV VP2 protein, and (iii) a transcription terminator sequence within the UL54.5 site of the rMDVnpgenome. In particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 27 is comprised within the UL54.5 site of the rMDVnpgenome.

[0065] The present invention further provides an rMDVnpcomprising (i) an mCMV IE promoter (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence (iv) an hCMV IE promoter, (v) a coding sequence for the NDV F protein and (vi) a hCMV IE transcription terminator sequence in in the US2 site of the rMDVnpgenome. In particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 30 is comprised within the US2 site of the rMDVnpgenome. In specific embodiments, the rMDVnpfurther comprises (i) an ILTV gD promoter, (ii) a coding sequence for the ILTV gD protein, (iii) an ILTV gl promoter, and (iv) a coding sequence for the ILTV gl protein is comprised within the UL54.5 site of its genome. In particular embodiments of this type, the nucleotide sequence of SEQ ID NO: 29 is comprised within the UL54.5 site of the rMDVnpgenome.

[0066] The present invention also provides an rMDVnpcomprising (i) an mCMV IE promoter (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence (iv) an hCMV IE promoter, (v) a coding sequence for the NDV F protein and (vi) a hCMV IE transcription terminator sequence in in the UL54.5 site of the rMDVnpgenome. In specific embodiments, the rMDVnpfurther comprises (i) an ILTV gD promoter, (ii) a coding sequence for the ILTV gD protein, (iii) an ILTV gl promoter, and (iv) a coding sequence for the ILTV gl protein is comprised within the US2 site of its genome. The present invention also provides an rMDVnpcomprising (i) an mCMV IE promoter (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence (iv) an hCMV IE promoter, (v) a coding sequence for the NDV F protein and (vi) a hCMV IE transcription terminator sequence in the US2 site of the rMDVnpgenome and (i) an ILTV gD promoter, (ii) a coding sequence for the ILTV gD protein, (iii) an ILTV gl promoter, and (iv) a coding sequence for the ILTV gl protein comprised within the UL7 / 8 site of its genome.

[0067] In more specific embodiments, the present invention provides an rHVT that comprises a first heterologous nucleic acid and a second heterologous nucleic acid. The first heterologous nucleic acid comprising (i) a murine cytomegalovirus immediate early (mCMV IE) promoter, (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence (iv) an ILTV gD promoter, (v) a coding sequence for the ILTV gD protein, (vi) an ILTV gl promoter, and (vii) a coding sequence for the ILTV gl protein. In particular embodiments of this type, the specific 5' to 3' order for the nucleotide sequences of this recombinant nucleic acid is (i) - (vii). In a more specific embodiment the transcription terminator sequence comprises an SV40 polyadenylation sequence. In an even more specific embodiment of this type, the first heterologous nucleic is located in the US2 site of the rHVT genome. The second heterologous nucleic acid comprises a recombinant nucleic acid that comprises in 5' to 3' direction in the following order (i) a human cytomegalovirus immediate early (hCMV IE) promoter, (ii) a coding sequence for the NDV F protein, and (iii) a transcription terminator sequence. In a more specific embodiment the transcription terminator sequence comprises a human cytomegalovirus immediate early (hCMV IE) polyadenylation sequence. In more specific embodiments of this type, the second heterologous nucleic acid is located in the UL54.5 site of the rHVT genome.

[0068] Accordingly the present invention includes recombinant HVTs (rHVTs) that comprises two heterologous nucleic acids, each inserted in separate nonessential sites of the HVT genome. In certain embodiments the first heterologous nucleic acid comprises (i) a murine

[0069] cytomegalovirus immediate early (mCMV IE) promoter, (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence (iv) an ILTV gD promoter, (v) a coding sequence for the ILTV gD protein, (vi) an ILTV gl promoter, and (vii) a coding sequence for the ILTV gl protein. In particular embodiments of this type, the specific 5' to 3' order for the nucleotide sequences of this recombinant nucleic acid is (i) - (vii). The second heterologous nucleic acid comprises the following 5' to 3' order (i) a human cytomegalovirus immediate early (hCMV IE) promoter, (ii) a coding sequence for the NDV F protein, and (iii) a

[0070] transcription terminator sequence. In particular embodiments the first heterologous nucleic acid is inserted into the US2 site and the second heterologous nucleic acid is inserted into the UL54.5 site. In particular embodiments of this type, the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 23 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 26. In alternative embodiments the second heterologous nucleic acid is inserted into the US2 site and the first heterologous nucleic acid is inserted into the UL54.5 site. In certain embodiments of this type, the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 21 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 22. In other embodiments, the first heterologous nucleic acid comprises (i) a murine

[0071] cytomegalovirus immediate early (mCMV IE) promoter, (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence (iv) a human cytomegalovirus immediate early (hCMV IE) promoter, (v) a coding sequence for the NDV F protein, and (vi) a transcription terminator sequence. In particular embodiments of this type, the specific 5' to 3' order for the nucleotide sequences of this recombinant nucleic acid is (i) - (vi). The second heterologous nucleic acid comprises the following 5' to 3' order (i) an ILTV gD promoter, (ii) a coding sequence for the ILTV gD protein, (iii) an ILTV gl promoter, and (iv) a coding sequence for the ILTV gl protein. In particular embodiments the first heterologous nucleic acid is inserted into the US2 site and the second heterologous nucleic acid is inserted into the UL54.5 site. In particular embodiments, the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 30 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 29. In alternative embodiments the second heterologous nucleic acid is inserted into the US2 site and the first heterologous nucleic acid is inserted into the UL54.5 site.

[0072] In still other embodiments, the first heterologous nucleic acid comprises (i) an ILTV gD promoter, (ii) a coding sequence for the ILTV gD protein, (iii) an ILTV gl promoter, (iv) a coding sequence for the ILTV gl protein (v) a human cytomegalovirus immediate early (hCMV IE) promoter, (vi) a coding sequence for the NDV F protein, and (vii) a transcription terminator sequence. In particular embodiments of this type, the specific 5' to 3' order for the nucleotide sequences of this recombinant nucleic acid is (i) - (vii). The second heterologous nucleic acid comprises the following 5' to 3' order (i) a murine cytomegalovirus immediate early (mCMV IE) promoter, (ii) a coding sequence for the IBDV VP2 protein, (iii) a transcription terminator sequence. In particular embodiments the first heterologous nucleic acid is inserted into the US2 site and the second heterologous nucleic acid is inserted into the UL54.5 site. In particular embodiments of this type the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 28 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 27. In alternative embodiments the second heterologous nucleic acid is inserted into the US2 site and the first heterologous nucleic acid is inserted into the UL54.5 site. In particular embodiments of this type the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 31 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 32.

[0073] The present invention further provides methods for making any rMDVnpof the present invention (e.g., a rHVT). In certain embodiments, a first heterologous nucleic acid is constructed to comprise a nucleotide sequence that encodes an ILTV gD protein, a nucleotide sequence that encodes an ILTV gl protein, and a nucleotide sequence that encodes an IBDV VP2 protein. In particular embodiments of this type, the promoters for the nucleotide sequences that encode the ILTV gD protein and the ILTV gl protein respectively, are their respective endogenous promoters. In related embodiments, the promoter for the nucleotide sequence that encodes an IBDV VP2 protein is the mCMV IE promoter, the chicken beia-actin gene promoter, or the hCMV promoter.

[0074] The first heterologous nucleic acid is then inserted into a nonessential site of an rMDVnpof the present invention. In certain embodiments, the first heterologous nucleic acid is an expression cassette. In particular embodiments of this type, the expression cassette comprises the nucleotide sequence of SEQ ID NO: 21 .

[0075] The process can further comprises a second heterologous nucleic acid being constructed that is also inserted into a nonessential site of the rMDVnp. In particular embodiments, the second heterologous nucleic acid comprises a human cytomegalovirus immediate early (hCMV IE) promoter, a coding sequence for the NDV F protein, and a transcription terminator sequence. In certain embodiments, the second heterologous nucleic acid is an expression cassette. In particular embodiments of this type, the expression cassette comprises the nucleotide sequence of SEQ ID NO: 22. In specific embodiments the first heterologous nucleic acid is inserted into a first nonessential site of the rMDVnp, and the second heterologous nucleic acid is inserted into second nonessential site of the rMDVnp. In certain embodiments, the first nonessential site of the rMDVnpis the UL 54.5 site. In related embodiments, the second nonessential site of the rMDVnpis the US2 site. In alternative embodiments, the first nonessential site of the rMDVnpis the US2 site and the second nonessential site of the rMDVnpis the UL 54.5 site. In specific embodiments of this type, the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 23 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 26. In other embodiments of this type, the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 24 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 26. In still other embodiments of this type the the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 25 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 26. In certain embodiments, the method of making an rMDVnpis a method of making an rHVT. In alternative embodiments, the method of making an rMDVnpis a method of making an rMDV2.

[0076] Accordingly in one aspect, the present invention provides immunogenic compositions and / or vaccines that comprise an rMDVnpof the present invention (e.g., a rHVT). In particular embodiments these immunogenic compositions and / or vaccines are stable, safe, and have relatively strong antigen expression and / or efficacy. Alternatively, or in addition, the immunogenic compositions and / or vaccines that comprise an rMDVnpof the present invention aid in the protection of a chicken against a disease caused by ILTV and / or IBDV and / or NDV and / or MDV1 , following the administration of the immunogenic compositions and / or vaccines to the chicken. The present invention further provides immunogenic compositions and / or vaccines that comprise any rMDVnpof the present invention (e.g., a rHVT) that are further combined with an additional IBDV, ILTV, NDV, and / or MDV antigen(s) to improve and expand the immunogenicity provided. In a particular embodiment of this type, the antigen is an attenuated or mild live variant IBDV (e.g., IBDV 89 / 03). In another particular embodiment of this type, the antigen is an attenuated (or mild live) Newcastle Disease Virus (NDV), e.g., NDV C2. In yet another particular embodiment of this type, the antigen is an attenuated Marek's disease virus e.g., SB1 . In addition, the present invention also provides

[0077] immunogenic compositions and / or vaccines that comprise any rMDVnpof the present invention that is further encodes an antigen for a pathogen other than MDV, ILTV, or NDV. The present invention also provides methods for aiding in the protection of poultry against a disease caused by ILTV and / or IBDV and / or NDV and / or MDV1 by administering such vaccines and / or immunogenic compositions to a poultry subject (e.g., to a chicken). In particular embodiments of this type, a vaccine of the present invention is administered subcutaneously. In other embodiments, a vaccine of the present invention is administered in ovo. These and other aspects of the present invention will be better appreciated by reference to the following Figures and the Detailed Description.

[0078] BRIEF DESCRIPTION OF THE DRAWING

[0079] Figure 1 is a schematic drawing of insertion fragments for generating HVT / IBDV / ILTV / NDV constructs as described in Example 2, below. In short, this is a schematic view of the HVT genome, consisting of two unique regions, each flanked by repeat regions, and the cloned fragments required to reconstruct the HVT / IBDV / ILTV / NDV 670-14 virus. The orientation of the inserted gene cassettes (mlE-IBDV-vp2 and ILTV-gD / gl or hIE-NDV-F), relative to the interrupted genes (UL54.5 or US2), and the flanking genes are shown in the blow-up regions. Legend: TRL: Terminal Repeat Long region, UL: Unique Long region; IRL: Internal Repeat Long region, IRS: Internal Repeat Short region; US: Unique Short region; TRS: Terminal Repeat Short region.

[0080] Figure 2 is a schematic drawing of insertion fragments for generating HVT / IBDV / ILT / NDV construct #2. The two HVT insertion sites are UL54.5 and US2. [See also description for Figure 1 above]. Figure 3 is a schematic drawing of insertion fragments for generating HVT / IBDV / ILT / NDV construct #3. The two HVT insertion sites are UL54.5 and US2. [See also description for Figure 1 above].

[0081] Figure 4 is a schematic drawing of insertion fragments for generating HVT / IBDV / ILT / NDV construct: #4. The two HVT insertion sites are UL54.5 and US2. [See also description for Figure 1 above].

[0082] Figure 5 is a schematic drawing of insertion fragments for generating HVT / IBDV / ILT / NDV construct #5. The two HVT insertion sites are UL54.5 and US2. [See also description for Figure 1 above].

[0083] DETAILED DESCRIPTION OF THE INVENTION

[0084] The present invention overcomes the prior failure to be able to construct a single rMDVnpvector that encodes and expresses antigens from three or more foreign pathogenic chicken viruses. In particular embodiments, an rMDVnpof the present invention encodes and expresses foreign antigen proteins from three or more of the avian viruses. In particular embodiments the avian viruses are Newcastle Disease Virus (NDV), Infectious

[0085] Laryngotraceitis virus (ILTV), and Infectious Bursal Disease (IBDV). Such rMDVnpvectors can be employed in vaccines and / or immunogenic compositions that aid in the protection against Marek's disease, Infectious Bursal Disease (Gumboro disease), Infectious

[0086] Laryngotraceitis virus, and / or Newcastle Disease Virus. In specific embodiments, the rMDVnp is an rHVT. In alternative embodiments, the rMDVnpis an rMDV2. The present invention further provides immunogenic compositions and / or vaccines that comprise any rMDVnpof the present invention combined with an additional IBDV, ILTV, NDV, and / or MDV antigen, and / or one or more antigens from a chicken pathogen other than MDV, ILTV, NDV, or IBDV. In a completely different aspect, the recombinant vector that encodes and expresses the foreign antigens from NDV, ILTV, IBDV is not an rMDVnp, but rather a chimeric Marek's Disease virus that contains specified genomic sequences from MDV1 replacing their counterparts in an HVT vector, e.g., the novel avian herpes virus (NAHV) [see e.g., U.S. 6,913,751 ].

[0087] Prior to the present invention, an HVT vector already had been constructed containing an NDV gene inserted into the US10 region. This HVT-NDV vector was shown to be stable and to express sufficient levels of the corresponding NDV gene product, the NDV F protein, to protect vaccinated chickens against a virulent NDV challenge. In addition, an HVT vector already had been constructed containing a pair of ILTV genes inserted in the HVT UL54.5 region. This HVT-ILTV vector was shown to be stable and to express sufficient levels of the corresponding ILTV gene products, the ILTV gl and gD proteins, to protect vaccinated chickens against a virulent ILTV challenge virus. More recently, other multivalent constructs also have been reported.

[0088] More particularly, a multivalent HVT construct to protect against both NDV and ILTV was designed based on the successful constructs comprising the insertion of the NDV-F gene in the US10 site and the insertion of the ILTV gD and gl genes in UL54.5 site in individual constructs [see, US 8,932,604 B2]. Unexpectedly however, following the passaging of this multivalent construct in tissue culture the recombinant virus lost its ability to express the ILTVgD, ILTVgl, and NDV F proteins. This proved to be true with a number of duplicate recombinant HVT constructs. Indeed, these recombinant viruses were unstable and unsuitable for further development as vaccines. These findings demonstrate that the design of a single multivalent rHVT vector that can stably express both the NDV F protein and the ILTVgD and ILTVgl proteins was not a simple process that can be extrapolated from existing information. Indeed, if such stable and efficacious multivalent rHVT vectors were possible at all, their design needed to be premised on an unpredictable set of complex interactions minimally involving the relationship between the insertion sites used and the foreign nucleotide sequences to be inserted. Accordingly, the design of rHVT constructs remains unpredictable from the known art. This would appear to be even a bigger issue for an rMDVnp that encodes heterologous antigens from three or more avian virus pathogens.

[0089] Despite the clear difficulties outlined above, and the general consensus in the field that the insertion of foreign antigens from three or more different viral pathogens into an MDVnpconstruct overtaxes that construct, leading to a lack of stability, the present invention surprisingly provides stable recombinant MDVnpvectors in which two genes from I LTV, one gene from IBDV, and one gene from NDV have been inserted into a single MDVnp.

[0090] Accordingly, such a single rMDVnpconstruct can be employed as the sole active in a vaccine that aids in the protection against four major pathogenic poultry viruses.

[0091] In particular embodiments of the present invention nucleotide sequences encoding four foreign antigens are inserted into one or more nonessential regions of the genome of a single HVT. Accordingly, such a recombinant HVT vector should be capable of being used to provide protection against MDV, NDV, IBDV, and ILTV infections. Previously, multiple different rHVT vectors were necessary to protect against these four viruses, which can interfer with the antigenicity of each other.

[0092] The present invention therefore, is advantageous over current methods because it should be able to provide simultaneous protection against MDV, NDV, IBDV, and ILTV infections by inoculation of poultry and / or poultry eggs with only a single recombinant MDVnp. In particular, this allows for additonal vaccines to be administered via the in ovo route, because there is a limit on how much volume can be injected into an egg, and further saves on manufacturing costs because only one rather than two vectors is needed.

[0093] Furthermore, the present invention includes embodiments that comprise different rMDVnpconstructs in the same vaccine and / or immunogenic compositions. In certain embodiments of this type, the vaccine and / or immunogenic composition comprise both an rMDV2 and an rHVT, each of which encode one or more foreign antigens. Indeed, unlike the combination of two rHVTs, which inevitably lead to one construct significantly overgrowing the other, combining an rHVT with an rMDV2 has been reported not to lead to significant overgrowth. Therefore, in specific embodiments, a vaccine of the present invention comprises an rHVT that encodes an ILTV gD protein, an ILTV gl protein, an IBDV VP2 protein, and an NDV F protein, with an rMDV2 that encodes yet another poultry viral antigen. Heretofore, no rMDVnphad been shown to encode and express foreign antigens from three different poultry viruses, and still remain stable, as well as capable of expressing sufficient levels of the corresponding antigens for protecting vaccinated chickens against a virulent challenge with the corresponding three viruses, as well as against virulent MDV.

[0094] Accordingly, the present invention provides immunogenic compositions and / or vaccines that comprise any rMDVnpof the present invention. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2. In addition, the present invention provides methods for aiding in the protection of poultry (and in certain

[0095] embodiments protects) against a disease caused by ILTV and / or IBDV and / or NDV and / or MDV1 by administering such a vaccine and / or immunogenic composition of the present invention. In specific embodiments, the poultry subject is a chicken. In particular embodiments of this type, a vaccine of the present invention is administered

[0096] subcutaneously. In other embodiments, a vaccine of the present invention is administered in ovo. In preferred embodiments, the rMDVnpvaccine of the present invention is both safe, stable, and efficacious.

[0097] In order to more fully appreciate the instant invention, the following definitions are provided.

[0098] The use of singular terms for convenience in description is in no way intended to be so limiting. Thus, for example, reference to a composition comprising "a polypeptide" includes reference to one or more of such polypeptides.

[0099] As used herein a "nonpathogenic Marek's Disease Virus" or "MDVnp" or "npMDV" is a virus in the MDV family that shows little to no pathogenicity in poultry. The term "MDVnp" includes naturally occurring MDVs that have been passaged or otherwise similarly manipulated, but does not include viral constructs in which a specific region of the genome of one MDV serotype is replaced by the corresponding region of a different MDV serotype to form a chimeric virus, such as the novel avian herpesvirus (NAHV). In certain embodiments, the MDVnpis an HVT. In other embodiments, the MDVnpis an MDV2. In particular embodiments of this type, the MDV2 is SB1 . As used herein, an MDVnpthat has been genetically modified to encode a heterologous nucleotide sequence (e.g., a foreign gene) is defined as a "recombinant MDVnp" or "rMDVnp". The term "rMDVnp" includes naturally occurring MDVnp's that have been genetically modified to encode a heterologous nucleotide sequence, but does not include viral constructs in which a specific region of the genome of one MDV serotype is replaced by the

[0100] corresponding region of a different MDV serotype to form a chimeric virus, such as the novel avian herpesvirus (NAHV).

[0101] As used herein a "novel avian herpesvirus" ("NAHV") is a recombinant chimeric virus comprising a unique long viral genomic region which naturally occurs in herpesvirus of turkeys virus (HVT) and a unique short viral genomic region which naturally occurs in Marek's disease 1 (MDV1 ) [see, U.S.5,965,138, U.S. 6,183,753, U.S. 6,913,751 B2]. In a preferred emdodiment the NAHV comprises a unique long viral genomic region which naturally occurs in herpesvirus of turkeys virus (HVT), a unique short viral genomic region which naturally occurs in Marek's disease 1 (MDV1 ), and the repeat viral regions of the HVT [see, U.S. 6,913,751 B2].

[0102] As used herein, a "nonessential site" is a site in the MDVnpgenome (or alternatively in the NAVH genome) in which an insertion of a heterologous nucleotide sequence into that site does not prevent the MDVnp(or NAVH) from replicating in a host cell. Nonessential sites are generally identified by the open reading frame in which they reside, e.g., the US2 site, or a region between two open reading frames, e.g., the UL7 / 8 site. The use of the term

[0103] "nonessential site" is in no way intended to even suggest that there is only a single unique nucleotide position in the nucleotide sequence of a given open reading frames (or in the region between two open reading frames) where an insertion of a heterologous nucleic acid must be made in order for the MDVnp(or NAVH) to maintain its ability to replicate in a host cell.

[0104] As used herein, when an rMDVnp(or NAHV) is said to comprise a given nucleic acid

[0105] "inserted" in a nonessential site in the rMDVnpgenome (or NAHV genome), it means that the given nucleic acid is a heterologous nucleic acid that is located in that nonessential site of the MDVnp(or NAHV). Accordingly, an rMDVnpcomprising a first nucleic acid inserted in a first nonessential site in the rMDVnpgenome and a second nucleic acid inserted in a second nonessential site in the rMDVnpgenome is equivalent to an rMDVnpcomprising a first heterologous nucleic acid located in a first nonessential site in the rMDVnpgenome and a second heterologous nucleic acid located in a second nonessential site in the rMDVnpgenome, and vice versa.

[0106] As used herein the term "poultry" can include chickens, turkeys, ducks, geese, quail, and pheasants.

[0107] As used herein, a "vaccine" is a composition that is suitable for application to an animal (including, in certain embodiments, humans, while in other embodiments being specifically not for humans) comprising one or more antigens typically combined with a pharmaceutically acceptable carrier such as a liquid containing water, which upon administration to the animal induces an immune response strong enough to minimally aid in the protection from a disease arising from an infection with a wild-type micro-organism, i.e., strong enough for aiding in the prevention of the disease, and / or preventing, ameliorating or curing the disease. As used herein, the term "aids in the protection" does not require complete protection from any indication of infection. For example, "aids in the protection" can mean that the protection is sufficient such that, after challenge, symptoms of the underlying infection are at least reduced, and / or that one or more of the underlying cellular, physiological, or

[0108] biochemical causes or mechanisms causing the symptoms are reduced and / or eliminated. It is understood that "reduced," as used in this context, means relative to the state of the infection, including the molecular state of the infection, not just the physiological state of the infection.

[0109] The vaccines of the present invention comprise at least one stable rMDVnpof the present invention. A rMDVnpis considered phenotypically stable when at least 90% of the viral plaques examined are positive for expression of the inserted foreign antigen, as

[0110] demonstrated by binding of antibodies specific for the expressed protein in an

[0111] immunofluorescent assay, following at least 10 tissue culture passages from the original stock, or following reisolation of the virus from vaccinated birds.

[0112] The vaccines of the present invention also are efficacious and preferably minimally provide at least 70% protection against NDV, and / or at least 70% protection against IBDV, and / or at least 70% protection against ILTV, and / or at least 60% protection against MDV from clinical signs or lesions associated with the disease. More preferably, the vaccine minimally provides at least 80% protection against NDV, at least 80% protection against IBDV, at least 80% protection against ILTV, and at least 70% protection against MDV from clinical signs or lesions associated with the disease. Even more preferably the vaccines follow the guidelines established by the USDA and codified in the Title 9 Code of Federal Regulations, part 1 13 (9CFR 1 13) «Standard requirements for Animal Products* live virus vaccines must provide at least 90% protection, in the case of NDV, IBDV and ILTV, and at least 80% in the case of MDV, from clinical signs or lesions associated with the disease to obtain a license.

[0113] As used herein, a "multivalent vaccine" is a vaccine that comprises two or more different antigens. In a particular embodiment of this type, the multivalent vaccine stimulates the immune system of the recipient against two or more different pathogens.

[0114] As used herein, an "adjuvant" is a substance that is able to favor or amplify the cascade of immunological events, ultimately leading to a better immunological response, i.e., the integrated bodily response to an antigen. An adjuvant is in general not required for the immunological response to occur, but favors or amplifies this response.

[0115] As used herein, the term "pharmaceutically acceptable" is used adjectivally to mean that the modified noun is appropriate for use in a pharmaceutical product. When it is used, for example, to describe an excipient in a pharmaceutical vaccine, it characterizes the excipient as being compatible with the other ingredients of the composition and not disadvantageously deleterious to the intended recipient.

[0116] As used herein, "systemic administration" is administration into the circulatory system of the body (comprising the cardiovascular and lymphatic system), thus affecting the body as a whole rather than a specific locus such as the gastro-intestinal tract (via e.g., oral or rectal administration) and the respiratory system (via e.g., intranasal administration). Systemic administration can be performed e.g., by administering into muscle tissue (intramuscular), into the dermis (intradermal or transdermal), underneath the skin (subcutaneous), underneath the mucosa (submucosal), in the veins (intravenous) etc. As used herein the term "parenteral administration" includes subcutaneous injections, submucosal injections, intravenous injections, intramuscular injections, intradermal injections, and infusion.

[0117] The term "approximately" is used interchangeably with the term "about" and signifies that a value is within twenty-five percent of the indicated value i.e., a peptide containing "approximately" 100 amino acid residues can contain between 75 and 125 amino acid residues.

[0118] As used herein, the term, "polypeptide" is used interchangeably with the terms "protein" and "peptide" and denotes a polymer comprising two or more amino acids connected by peptide bonds. The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids, generally at least about 12 amino acids, typically at least about 16 amino acids, preferably at least about 20 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids, e.g., 35, 40, 45, 50, etc. Such fragments may have ends which begin and / or end at virtually all positions, e.g., beginning at residues 1 , 2, 3, etc., and ending at, e.g., 155, 154, 153, etc., in all practical combinations.

[0119] Optionally, a polypeptide may lack certain amino acid residues that are encoded by a gene or by an mRNA. For example, a gene or mRNA molecule may encode a sequence of amino acid residues on the N-terminus of a polypeptide {i.e., a signal sequence) that is cleaved from, and therefore, may not be part of the final protein.

[0120] As used herein the term "antigenic fragment" in regard to a particular protein (e.g., a protein antigen) is a fragment of that protein (including large fragments that are missing as little as a single amino acid from the full-length protein) that is antigenic, i.e., capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. For example, an antigenic fragment of an IBDV VP2 protein is a fragment of the VP2 protein that is antigenic. Preferably, an antigenic fragment of the present invention is immunodominant for antibody and / or T cell receptor recognition. In particular embodiments, an antigenic fragment with respect to a given protein antigen is a fragment of that protein that retains at least 25% of the antigenicity of the full length protein. In preferred embodiments an antigenic fragment retains at least 50% of the antigenicity of the full length protein. More preferred embodiments it retains at least 75% of the antigenicity of the full length protein. Antigenic fragments can be as small as 5-10 amino acids or at the other extreme, be large fragments that are missing as little as a single amino acid from the full-length protein. In particular embodiments the antigenic fragment comprises 25 to 100 amino acid residues. As used herein an amino acid sequence is 100% "homologous" to a second amino acid sequence if the two amino acid sequences are identical, and / or differ only by neutral or conservative substitutions as defined below. Accordingly, an amino acid sequence is about 80% "homologous" to a second amino acid sequence if about 80% of the two amino acid sequences are identical, and / or differ only by neutral or conservative substitutions. Functionally equivalent amino acid residues often can be substituted for residues within the sequence resulting in a conservative amino acid substitution. Such alterations define the term "a conservative substitution" as used herein. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutions for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.

[0121] Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point. Particularly preferred conservative substitutions are: Lys for Arg and vice versa such that a positive charge may be maintained; Glu for Asp and vice versa such that a negative charge may be maintained; Ser for Thr such that a free -OH can be maintained; and Gin for Asn such that a free NH2can be maintained. The amino acids also can be placed in the following similarity groups: (1 ) proline, alanine, glycine, serine, and threonine; (2) glutamine, asparagine, glutamic acid, and aspartic acid; (3) histidine, lysine, and arginine; (4) cysteine; (5) valine, leucine, isoleucine, methionine; and (6) phenylalanine, tyrosine, and tryptophan.

[0122] In a related embodiment, two highly homologous DNA sequences can be identified by their own homology, or the homology of the amino acids they encode. Such comparison of the sequences can be performed using standard software available in sequence data banks. In a particular embodiment two highly homologous DNA sequences encode amino acid sequences having about 80% identity, more preferably about 90% identity and even more preferably about 95% identity. More particularly, two highly homologous amino acid sequences have about 80% identity, even more preferably about 90% identity and even more preferably about 95% identity. As used herein, protein and DNA sequence percent identity can be determined using software such as MacVector v9, commercially available from Accelrys (Burlington,

[0123] Massachusetts) and the Clustal W algorithm with the alignment default parameters, and default parameters for identity. See, e.g., Thompson, et al,. 1994. Nucleic Acids Res.

[0124] 22:4673-4680. ClustalW is freely downloadable for Dos, Macintosh and Unix platforms from, e.g., EMBLI, the European Bioinformatics Institute. The present download link is found at http: / / www.ebi.ac.uk / clustalw / . These and other available programs can also be used to determine sequence similarity using the same or analogous default parameters. As used herein the terms "polynucleotide", or a "nucleic acid" or a "nucleic acid molecule" are used interchangeably and denote a molecule comprising nucleotides including, but is not limited to, RNA, cDNA, genomic DNA and even synthetic DNA sequences. The terms are also contemplated to encompass nucleic acid molecules that include any of the art-known base analogs of DNA and RNA.

[0125] A nucleic acid "coding sequence" or a "sequence encoding" a particular protein or peptide, is a nucleotide sequence which is transcribed and translated into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory elements. The boundaries of the coding sequence are determined by a start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., avian) DNA, and even synthetic DNA sequences. A transcription termination sequence can be located 3' to the coding sequence.

[0126] "Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening

[0127] untranslated yet transcribed sequences can be present between a promoter and the coding sequence and the promoter can still be considered "operably linked" to the coding sequence.

[0128] As used herein, the term "transcription terminator sequence" is used interchangeably with the term "polyadenylation regulatory element" and is a sequence that is generally

[0129] downstream from a DNA coding region and that may be required for the complete termination of the transcription of that DNA coding sequence. A transcription terminator is a regulatory DNA element involved in the termination of the transcription of a coding region into RNA. Generally, such an element encodes a section, e.g. a hairpin structure, which has a secondary structure that can cause the RNA polymerase complex to stop transcription. A transcription terminator is therefore always situated downstream of the stop codon from the region to be translated, the 3' untranslated region.

[0130] As used herein an "expression cassette" is a recombinant nucleic acid that minimally comprises a promoter and a heterologous coding sequence operably linked to that promoter. In many such embodiments, the expression cassette further comprises a transcription terminator sequence. Accordingly, the insertion of an expression cassette into a

[0131] nonessential site of the rMDVnpgenome can lead to the expression of the heterologous coding sequence by the rMDVnp. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2.

[0132] A "heterologous nucleotide sequence" as used herein is a nucleotide sequence that is added to a nucleotide sequence of the present invention by recombinant methods to form a nucleic acid that is not naturally formed in nature. In specific embodiments, a "heterologous nucleotide sequence" of the present invention can encode a protein antigen, (e.g., encoded by a "foreign gene" relative to the rMDVnpvectors of the present invention) such as an IBDV VP2 protein, an ILTV gl protein, an ILTV gD protein, and / or an NDV F protein. In this case, such protein antigens can be termed "foreign antigens" or more specifically "foreign protein antigens". Heterologous nucleotide sequences can also encode fusion (e.g., chimeric) proteins. In addition, a heterologous nucleotide sequence can encode peptides and / or proteins that contain regulatory and / or structural properties. In other such embodiments, a heterologous nucleotide sequence can encode a protein or peptide that functions as a means of detecting the protein or peptide encoded by the nucleotide sequence of the present invention after the recombinant nucleic acid is expressed. In still another embodiment, the heterologous nucleotide sequence can function as a means of detecting a nucleotide sequence of the present invention. A heterologous nucleotide sequence can comprise non-coding sequences including restriction sites, regulatory sites, promoters and the like. A

[0133] "heterologous nucleic acid" comprises a heterologous nucleotide sequence. Insertion of a nucleic acid encoding an antigen of the present invention into an rMDVnpvector is easily accomplished when the termini of both the nucleic acid and the vector comprise compatible restriction sites. If this cannot be done, it may be necessary to modify the termini of the nucleotide sequence and / or vector by digesting back single-stranded nucleic acid overhangs (e.g., DNA overhangs) generated by restriction endonuclease cleavage to produce blunt ends, or to achieve the same result by filling in the single-stranded termini with an appropriate polymerase. Alternatively, desired sites may be produced, e.g., by ligating nucleotide sequences (linkers) onto the termini. Such linkers may comprise specific oligonucleotide sequences that define desired restriction sites. Restriction sites can also be generated through the use of the polymerase chain reaction (PCR). [See, e.g., Saiki et al., Science 239:487-491 (1988)]. The cleaved vector and the DNA fragments may also be modified, if required, by homopolymeric tailing. Alternatively, a recombinant nucleotide sequence can be synthesized de novo. Protein Antigens and Nucleic Acids Encoding the Protein Antigens

[0134] The ILTV gD gene appears to encode a glycoprotein of 434 amino acids in length having a molecular weight of 48,477 daltons, although others have suggested that a downstream start codon, which leads to an ILTV gD protein comprising only 377 amino acid residues, is the actual start codon [Wild et al., Virus Genes 12:104 - 1 16 (1996)]. The ILTV gl gene encodes a glycoprotein of 362 amino acids in length having a molecular weight of 39,753 daltons [U.S. 6,875,856, hereby incorporated by reference]. Nucleic acids encoding natural and / or laboratory derived variants of the ILTV gD and ILTV gl may be substituted for those presently exemplified. In particular embodiments of the present invention, an rMDVnpcomprises a recombinant nucleic acid (e.g., an expression cassette) that encodes an ILTV gD protein comprising the amino acid sequence of SEQ ID NO: 2 or an antigenic fragment thereof. In related embodiments the rMDVnpcomprises a recombinant nucleic acid that encodes an ILTV gD protein comprising an amino acid sequence that has greater than 90%, and / or greater than 95%, and / or greater than 98%, and / or greater than 99% identity to the amino acid sequence of SEQ ID NO: 2. In particular embodiments, the ILTV gD protein is encoded by the nucleotide sequence of SEQ ID NO: 1 . In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2. In certain embodiments of the present invention, an rMDVnpcomprises a recombinant nucleic acid (e.g., an expression cassette) that encodes an ILTV gl protein comprising the amino acid sequence of SEQ ID NO: 4 or an antigenic fragment thereof. In related embodiments, the rMDVnpcomprises a recombinant nucleic acid that encodes an I LTV gl protein comprising an amino acid sequence that has greater than 90%, and / or greater than 95%, and / or greater than 98%, and / or greater than 99% identity to the amino acid sequence of SEQ ID NO: 4. In particular embodiments, the ILTV gl protein is encoded by the nucleotide sequence of SEQ ID NO: 3. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2.

[0135] As mentioned earlier, IBDV is a member of the Birnaviridae family, which has a genome consisting of two segments (A and B) of double-stranded RNA. The larger segment A encodes a polyprotein of 1 10 kDa, which is subsequently cleaved by autoproteolysis to form mature viral proteins VP2, VP3 and VP4. Of these, VP2 and VP3 are the structural capsid proteins for the virion, with VP2 protein being the major host-protective immunogen. In the case of IBDV, two serotypes exist, serotype 1 and 2 which can be distinguished by virus neutralization (VN) tests. Serotype 1 viruses have been shown to be pathogenic to chickens, while serotype 2 IBDV only causes sub-acute disease in turkeys. Historically, IBDV serotype 1 viruses consisted of only one type that is known as "classic" IBD virus, but subsequently, so-called "variant" IBDV strains have emerged. In particular embodiments of the present invention the IBDV VP2 gene encodes a VP2 protein from an IBDV that is of the classic type. Such genes are well known and their sequence information is readily available, [see e.g., GenBank acc.nr: D00869 (F52 / 70), D00499 (STC), or AF499929 (D78)].

[0136] Alternatively, this gene can be obtained from the genome of a classic IBDV isolated from nature, using routine techniques for manipulating a Birnavirus. Classic type IBDV's can be readily identified using serology, or molecular biology.

[0137] In particular embodiments of the present invention, an rMDVnpcomprises a recombinant nucleic acid (e.g., an expression cassette) that encodes an IBDV VP2 protein comprising the amino acid sequence of SEQ ID NO: 6 or an antigenic fragment thereof. In related embodiments, the rMDVnpcomprises a recombinant nucleic acid that encodes an IBDV VP2 protein comprising an amino acid sequence that has greater than 90%, and / or greater than 95%, and / or greater than 98%, and / or greater than 99% identity to the amino acid sequence of SEQ ID NO: 6. In specific embodiments, the IBDV VP2 protein is encoded by the nucleotide sequence of SEQ ID NO: 5. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2. Routine vaccinations against IBDV are performed as early as possible in the life of poultry using attenuated IBDV strains, but these can only be applied when the level of MDA against IBDV has decreased enough, which commonly is somewhere between 15 and 20 days post hatch. Many 'live' or inactivated IBDV vaccines are commercially available, e.g., a 'live' vaccine such as Nobilis™ Gumboro D78 (Merck Animal Health).

[0138] NDV has a non-segmented, negative sense, single stranded RNA genome, which is about 15 kb in size, and contains six genes, amongst which is the NDV F protein gene which encodes the so-called "fusion" glycoprotein (F protein). The F protein is involved in NDV's attachment of and entry into host cells, and as the immunodominant protein it can be the basis of an effective immune response against NDV. The NDV F protein is expressed as a native F0 protein, which is activated upon cleavage by extra-cellular peptidases.

[0139] An NDV F protein gene, for example, can be derived from NDV Clone 30, a common lentogenic NDV vaccine strain. In certain embodiments of the present invention, an rMDVnpcomprises a recombinant nucleic acid (e.g., an expression cassette) that encodes an NDV F protein comprising the amino acid sequence of SEQ ID NO: 8 or an antigenic fragment thereof. In related embodiments, the rMDVnpcomprises a recombinant nucleic acid that encodes an NDV F protein comprising an amino acid sequence that has greater than 90%, and / or greater than 95%, and / or greater than 98%, and / or greater than 99% identity to the amino acid sequence of SEQ ID NO: 8. In particular embodiments, the NDV F protein is encoded by the nucleotide sequence of SEQ ID NO: 7. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2. In related embodiments of the present invention, an rMDVnpcomprises a recombinant nucleic acid (e.g., an expression cassette) that encodes an NDV F protein comprising the amino acid sequence of SEQ ID NO: 10 or an antigenic fragment thereof. In other embodiments, the rMDVnpcomprises a recombinant nucleic acid that encodes an NDV F protein comprising an amino acid sequence that has greater than 90%, and / or greater than 95%, and / or greater than 98%, and / or greater than 99% identity to the amino acid sequence of SEQ ID NO: 10. In particular embodiments, the NDV F protein is encoded by the nucleotide sequence of SEQ ID NO: 9. In specific embodiments, the rMDVnpis an rHVT. In alternative embodiments, the rMDVnpis an rMDV2. Nucleic acids encoding natural and / or laboratory derived variants of the F protein gene would equally be applicable, either from lentogenic, mesogenic or velogenic NDV, as the F protein gene sequence itself is highly conserved in these different NDV pathotypes.

[0140] Nucleotide and / or protein sequences for the chicken pathogen protein antigens encoded by the rMDVnp's of the present invention also can be found in publically available databases such as GenBank or the Protein Information Resource.

[0141] Promoters and Polvadenylation Regulatory Elements

[0142] A promoter is a functional region on the genome of an organism that directs the transcription of a downstream coding region. A promoter is therefore situated upstream of the coding region of a gene. The mRNA synthesis directed by the promoter starts from the

[0143] 'transcription start site' (TSS). The mRNA produced is in turn translated into protein starting from the gene's start codon, which is the first ATG sequence in the open reading frame (the first AUG in the mRNA). Typically the TSS is located at 30-40 nucleotides upstream of the start codon. A TSS can be determined by sequencing the 5' end of the mRNA of a gene, e.g. by the RACE technique. In general promoters are comprised within about 1000 nucleotides upstream of the position of the A of the start codon, which is generally denoted as A+1 , and most promoters are situated between nucleotides -500 and A+1.

[0144] The nomenclature for a promoter is commonly based on the name of gene that it controls the expression of. For example, the murine cytomegalovirus immediate early 1 gene (mCMV-IE1 ) promoter "mCMV-IE1 gene promoter", refers to the promoter that naturally drives the expression of the early 1 gene (IE1 gene) for mCMV and accordingly, is situated immediately upstream of that gene. Because the IE1 - gene is such a well-documented and clearly recognizable gene, and because the genomes of several mCMVs have been sequenced (in whole or in part), such a promoter readily can be identified by routine techniques. For example, in a basic protocol a promoter can be obtained by roughly sub- cloning the region in between two consecutive genes, e.g. from the poly A signal of an upstream gene to the TSS of a downstream gene. The promoter then can be identified by standard tests, e.g., by the expression of a marker gene by progressively smaller sections of a suspected promoter.

[0145] Generally, promoters contain a number of recognizable regulatory regions, such as an enhancer region, which is involved in binding regulatory factors that influence the time, the duration, the conditions, and the level of transcription. Whereas the enhancer region is normally situated upstream, a promoter also contains a region more downstream that is involved in the binding of transcription factors and directing RNA polymerase itself. This downstream region generally contains a number of conserved promoter sequence elements such as the TATA box, the CAAT box, and the GC box.

[0146] A promoter comprising both the enhancer- and the downstream region is termed a

[0147] "complete" promoter, whereas a promoter comprising only the downstream region, is termed a "core" promoter. A promoter for the expression of a (heterologous) gene in a (virus) vector needs to be able to effectively drive the transcription of that downstream coding sequence. This is generally referred to as the promoter being "operatively linked" to the coding sequence, such that the gene is 'under the control' of the promoter, or is 'driven by' the promoter. This generally means that in an expression cassette the promoter and the coding sequence of the gene are found on the same nucleic acid, in effective proximity, and with no signals or sequences between them that would intervene with effective transcription of the coding sequence.

[0148] The mCMV-IE1 gene promoter is well known in the art, and can be readily obtained from a variety of commercial sources, such as from suppliers of commercial plasmids for cloning and expression. The IE1 gene is also called the 'major IE gene'. The mCMV-IE1 protein has also been referred to as pp89. Dorsch-Hasler et al. [Proc. Nat. Acad. Sci., 82:8325- 8329 (1985)] described the mCMV IE1 gene promoter in 1985, and the use of this promoter in heterologous expression is also described in WO 87 / 03.905 and EP 728,842. The nucleotide sequence of the complete mCMV IE locus is available from GenBank under acc. nr. L06816.1 (from March 2004). The mCMV itself is available from the ATCC: initially under acc. nr. VR-194, and more recently this has been continued under acc. nr. VR-1399.

[0149] In one embodiment of the invention, the mCMV-IE1 gene promoter is a complete promoter, comprising both the core promoter region, as well as the enhancer region for the mCMV-IE1 gene. The complete mCMV-IE1 gene promoter is about 1 .4 kb in size. However, the present invention also allows for some variance in length of not only the mCMV IE1 -gene promoter, but also of the other elements that make up the recombinant DNA expression cassette employed in the present invention. This can result from differences in the exact conditions that are used for cloning and construction. For example, this variance may arise from using different restriction enzyme sites, PCR cloning primers, or different conditions for adapting the ends of the cloning molecules used. Consequently, some variation in length - smaller or larger- of the constituting elements may occur, without affecting the stability, and relatively strong antigen expression and / or efficacy of the overall expression cassette. In that case these length differences are immaterial, and are within the scope of the invention. Therefore, an mCMV-IE1 gene promoter of "about 1.4 kb" is: 1 .4 kb ± about 25 %. In particular embodiments the promoter is 1.4 kb ± about 20%. In still other embodiments the variance can be 1 .4 kb ± about 15%, 1.4 kb ± about 12%, 1.4 kb ± about 10%, 1 .4 kb ± about 8%, 1 .4 kb ± about 6%, 1.4 kb ± about 5%, 1 .4 kb ± about 4%, 1.4 kb ± about 3%, 1 .4 kb ± about 2%, or even 1.4 kb ± about 1 %. Similarly, homologs or variants of the promoter element may be used that are equally effective and stable. Therefore, in certain embodiments the mCMV-IE1 gene promoter of the present invention can be a DNA molecule of about 1 .4 kb that comprises a nucleotide sequence with at least 95%, 96%, 97%, 98%, or even 99 % nucleotide sequence identity to the nucleotide sequence of SEQ ID NO: 13. In a particular embodiment the mCMV-IE1 gene promoter consists of nucleotide sequence of SEQ ID NO: 13.

[0150] Many alternative promoters can be used to drive the expression of a heterologous gene encoding a protein antigen or antigenic fragment thereof in an rMDVnpof the present invention. Examples include the pseudorabies virus (PRV) gpX promoter [see, WO

[0151] 87 / 04463], the Rous sarcoma virus LTR promoter, the SV40 early gene promoter, the chicken befa-actin gene promoter comprising the nucleotide sequence of SEQ ID NO: 17, the Towne Strain hCMV IE promoter SEQ ID NO: 16, a derivative of the hCMV IE promoter (from strain AD169) comprising the nucleotide sequence of SEQ ID NO: 14, an I LTV gD promoter comprising the nucleotide sequence of SEQ ID NO: 1 1 , and an ILTV gl promoter comprising the nucleotide sequence of SEQ ID NO: 12, [see e.g., U.S. 6,183,753 B1], the human cytomegalovirus immediate earlyl (hCMV IE1 ) gene promoter [U.S. 5,830,745; U.S. 5,980,906], and the chicken befa-actin gene promoter [EP 1 298 139 B1]. A particular heterologous promoter for the IBDV VP2 gene is the murine (mCMV IE1 ) cytomegalovirus promoter. In a particular embodiment of this type the mCMV IE1 comprises the nucleotide sequence of SEQ ID NO: 13 [see e.g., EP 728,842; PCT / EP2015 / 081 121 ].

[0152] The inclusion of a polyadenylation regulatory element downstream from a DNA coding region is oftentimes required to terminate the transcription of the coding DNA sequence. Accordingly, many genes comprise a polyadenylation regulatory element at the downstream end of their coding sequence. Many such regulatory elements have been identified and can be used in an rMDVnpof the present invention. Specific examples of polyadenylation regulatory elements as exemplified herein, include a Feline Herpesvirus (FHV) US-9 polyadenylation signal comprising the nucleotide sequence of SEQ ID NO: 18, and the human Herpes Simplex Virus (HSV) thymidine kinase polyadenylation signal comprising the nucleotide sequence of SEQ ID NO: 19. The terminator and polyadenylation sequence also may come from the glycoprotein B (gB) gene of Feline Herpesvirus (FHV), from the immediate early (IE) gene of human cytomegalovirus (hCMV), strain AD 169, or from simian virus 40 (SV40).

[0153] Vaccines and Immunogenic Compositions

[0154] The present invention relates to the use of the recombinant MDVnp, the nucleic acid molecules used to construct the MDVnp, or the host cells to grow them, or any combination thereof, all according to the present invention for the manufacture of a vaccine for poultry. Accordingly, the present invention provides vaccines and / or immunogenic compositions that include a multivalent recombinant MDVnpof the present invention. Such vaccines can be used to aid in the prevention and / or prevent Infectious Bursal Disease (Gumboro disease), and / or Marek's disease, and / or maladies associated with I LTV infections and / or maladies associated with NDV infections. A vaccine according to the present invention can be used for prophylactic and / or for therapeutic treatment, and thus can interfere with the

[0155] establishment and / or with the progression of an infection and / or its clinical signs of disease.

[0156] A recombinant MDVnpof the present invention can be grown by any number of means currently practiced in the field. For example, a recombinant MDVnpof the present invention can be grown through the use of in vitro cultures of primary chicken cells, see e.g., the Examples below where chicken embryo fibroblast cells (CEFs) were used. The CEFs can be prepared by trypsinization of chicken embryos. The CEFs also can be plated in monolayers and then infected with the MDVnp. This particular process can be readily scaled up to industrial-sized production.

[0157] Therefore, a further aspect of the invention relates to a method for the preparation of the vaccine according to the invention comprising the steps of infecting host cells with a recombinant MDVnpof the present invention, harvesting the infected host cells, and then mixing the harvested infected host cells with a pharmaceutically acceptable carrier. Suitable methods for infection, culture and harvesting are well known in the art and are described and exemplified herein. Typically, the infected host cells are harvested while still intact to obtain the recombinant MDVnp in its cell-associated form. These cells can be taken up in an appropriate carrier composition to provide stabilization for storage and freezing. The infected cells can be filled into glass ampoules, which are sealed, frozen and stored in liquid nitrogen. Accordingly, in certain embodiments of the present invention, the vaccines and / or immunogenic

[0158] compositions of the present invention are stored frozen and accordingly, comprise a cryropreservative, such as dimethyl sulfoxide (DMSO), to preserve the frozen infected cells.

[0159] Alternatively, when the recombinant MDVnpis a recombinant HVT, it can be isolated from its host cell, for instance through sonication at the end of culturing, and then taken up into a stabilizer, and freeze-dried (lyophilized) for stable storage or otherwise reduced in liquid volume, for storage, and then reconstituted in a liquid diluent before or at the time of administration. Such reconstitution may be achieved using, for example, vaccine-grade water. In certain embodiments, a lyophilized portion of a multivalent vaccine can comprise one or more antigens and the diluent can comprise one or more other antigens.

[0160] In particular embodiments a vaccine of the present invention (or a portion thereof) can be in a freeze-dried form, e.g., as tablets and / or spheres that are produced by a method described in WO 2010 / 125084, hereby incorporated by reference in its entirety. In particular, reference is made to the examples, from page 15, line 28 to page 27, line 9 of WO 2010 / 125084, describing a method to produce such fast disintegrating tablets / spheres. Such freeze-dried forms can be readily dissolved in a diluent, to enable systemic administration of the vaccine.

[0161] Vaccines and immunogenic compositions can, but do not necessarily include, physiologically compatible buffers and saline and the like, as well as pharmaceutically acceptable adjuvants. Adjuvants can be useful for improving the immune response and / or increasing the stability of vaccine preparations. Adjuvants are typically described as non-specific stimulators of the immune system, but also can be useful for targeting specific arms of the immune system. One or more compounds which have this activity may be added to the vaccine. Therefore, particular vaccines of the present invention can further comprise an adjuvant. Examples of chemical compounds that can be used as adjuvants include, but are not limited to aluminum compounds (e.g., aluminum hydroxide), metabolizable and non- metabolizable oils, mineral oils including mannide oleate derivatives in mineral oil solution (e.g., MONTANIDE ISA 70 from Seppic SA, France), and light mineral oils such as

[0162] DRAKEOL 6VR, block polymers, ISCOM's (immune stimulating complexes), vitamins and minerals (including but not limited to: vitamin E, vitamin A, selenium, and vitamin B12) and CARBOPOL®

[0163] Other suitable adjuvants, which sometimes have been referred to as immune stimulants, include, but are not limited to: cytokines, growth factors, chemokines, supernatants from cell cultures of lymphocytes, monocytes, cells from lymphoid organs, cell preparations and / or extracts from plants, bacteria or parasites {Staphylococcus aureus or lipopolysaccharide preparations) or mitogens. Generally, an adjuvant is administered at the same time as an antigen of the present invention. However, adjuvants can also or alternatively be

[0164] administered within a two-week period prior to the vaccination, and / or for a period of time after vaccination, i.e., so long as the antigen, e.g., a recombinant MDVnpof the present invention persists in the tissues.

[0165] The vaccines and / or immunogenic compositions of the present invention may be

[0166] administered by any route such as in ovo, by parenteral administration, including

[0167] intramuscular injection, subcutaneous injection, intravenous injection, intradermal injection, by scarification, by oral administration, or by any combination thereof.

[0168] Furthermore, the multivalent recombinant MDVnpof the present invention can be used and / or combined with additional IBDV, ILTV, NDV, and / or MDV antigens to improve and expand the immunogenicity provided, and / or antigens for other pathogens in order to provide immune protection against such other pathogens. These additional antigens can be either live or killed whole microorganisms, other recombinant vectors, cell homogenates, extracts, proteins, or any other such derivative, provided that they do not negatively interfere with the safety, and stability with relatively strong antigen expression and / or efficacy of the vaccine according to the present invention.

[0169] The combination of a multivalent recombinant MDVnpof the present invention with an additional MDV, IBDV, NDV, and / or ILTV antigen can be advantageous in those cases in which very virulent field strains of MDV, IBDV, NDV, or ILTV are prevalent, e.g., in a particular geographic region. In this regard, the combination of a multivalent recombinant MDVnp of the present invention with an MDV1 , MDV2, or HVT includes the Rispens (MDV1 ) strain, the SB1 (MDV2) strain, the FC-126 (HVT) strain and / or PB1 (HVT) strain. To improve the response against IBDV, multivalent recombinant MDVnpmay be combined with an IBDV vaccine strain, such as a mild live IBDV vaccine strain, e.g., D78 (cloned intermediate strain), PBG98, Cu-1 , ST-12 (an intermediate strain), or 89 / 03 (a live Delaware variant strain) in a multivalent vaccine.

[0170] Examples of other microorganisms that can be used as antigens together with the multivalent recombinant MDVnpof the present invention include: (i) viruses such as infectious bronchitis virus, avian influenza virus, adenovirus, egg drop syndrome virus, infectious bursal disease virus, chicken anaemia virus, avian encephalo-myelitis virus, fowl pox virus, turkey rhinotracheitis virus, duck plague virus (duck viral enteritis), pigeon pox virus, avian leucosis virus, avian pneumovirus, and reovirus, (ii) bacteria, such as

[0171] Escherichia coli, Salmonella spec, Ornitobacterium rhinotracheale, Haemophilis

[0172] paragallinarum, Pasteurella multocida, Erysipelothrix rhusiopathiae, Erysipelas spec, Mycoplasma spec, and Clostridium spec, (iii) parasites such as Eimeria spec, and (iv) fungi, such as Aspergillus spec. In particular embodiments of the present invention, a recombinant MDVnpof the present invention can be combined with a mild live NDV vaccine strain such as vaccine strain C2. Many of such strains are used in commercial vaccines.

[0173] The combination vaccine can be made in a variety of ways including by combining the recombinant MDVnpof the present invention with preparations of virus, or bacteria, or fungi, or parasites, or host cells, or a mixture of any and / or all of these. In particular embodiments, the components for such a combination vaccine are conveniently produced separately and then combined and filled into the same vaccine container.

[0174] As described above, a vaccine according to the invention can be used advantageously to provide safe and effective immune protection to a chicken, for example, from one or more poultry diseases by a single inoculation at very young age or in ovo. Alternatively, as would be apparent to anyone skilled in the art of poultry vaccines, the combinations described above also could include vaccination schedules in which the multivalent recombinant MDVnpof the present invention and an additional antigen are not applied simultaneously; e.g., the recombinant MDVnpmay be applied in ovo, and the NDV C2 and / or the IBDV strain (e.g., 89 / 03) could be applied at a subsequent time / date.

[0175] Accordingly, the vaccines of the present invention can be administered to the avian subject in a single dose or in multiple doses. For example, a vaccine of the present invention may be applied at the day of hatch and / or in ovo at day 16-18 (Embryonation Day) ED. When multiple doses are administered, they may be given either at the same time or sequentially, in a manner and time compatible with the formulation of the vaccine, and in such an amount as will be immunologically effective. Therefore, a vaccine of the present invention may effectively serve as a priming vaccination, which later can be followed and amplified by a booster vaccination of the identical vaccine, or with a different vaccine preparation e.g., a classical inactivated, adjuvanted whole-virus vaccine. Alternatively, a vaccine of the present invention can be administered to the avian subject solely as a booster vaccination.

[0176] The volume per dose of a vaccine of the present invention can be optimized according to the intended route of application: in ovo inoculation is commonly applied with a volume between 0.05 and 0.5 ml / egg, and parenteral injection is commonly done with a volume between 0.1 and 1 ml / avian. In any case, optimization of the vaccine dose volume is well within the capabilities of the skilled artisan.

[0177] SEQUENCE TABLE

[0178] SEQ ID Description Type NO:

[0179] 1 I LTV gD Glycoprotein nucleic acid

[0180] 2 I LTV gD Glycoprotein amino acid

[0181] 3 I LTV gl Glycoprotein nucleic acid

[0182] 4 I LTV gl Glycoprotein amino acid

[0183] 5 IBDV VP2 nucleic acid

[0184] 6 IBDV VP2 amino acid

[0185] 7 NDV F Protein (Clone 30) nucleic acid

[0186] 8 NDV F Protein (Clone 30) amino acid

[0187] 9 NDV F Protein (B1 Hitchner) nucleic acid

[0188] 10 NDV F Protein (B1 Hitchner) amino acid

[0189] 1 1 I LTV gD promoter nucleic acid

[0190] 12 I LTV gl promoter nucleic acid

[0191] 13 mCMV IE promoter nucleic acid

[0192] 14 hCMV IE promoter (from strain AD169) nucleic acid

[0193] 15 hCMV IE promoter (Truncated) nucleic acid

[0194] 16 hCMV IE promoter (Towne Strain) nucleic acid

[0195] 17 chicken β-actin promoter nucleic acid

[0196] 18 FHV US-9 polyadenylation signal nucleic acid

[0197] 19 HSV TK polyadenylation signal nucleic acid

[0198] 20 SV40 polyadenylation signal nucleic acid

[0199] 21 484-1050-2641 -10859 (HVT / IBDV / ILTV / NDV 670-14) nucleic acid mCMV IEpro-VP2-SV40pA / ILTV / HVT UL54.5

[0200] 22 (HVT / IBDV / ILTV / NDV 670-14) nucleic acid hCMV IEpro-F-IE(term) / HVT US2 1322-48.1

[0201] 23 (HVT / IBDV / ILTV / NDV #2) nucleic acid 228509-1 LT-435Vec6 (mCMV IEpro-VP2-SV40pA / ILTV / HVT)

[0202] 24 1333-85.B6 (ILTV / Chicken β-actin pro-VP2-FHV US9pA / HVT) nucleic acid

[0203] 25 1386-04.4#1 (ILTV / hCMV IEpro-VP2-HSV TKpA / HVT) nucleic acid

[0204] 26 654-45:325341 IE-F / 1 C1 (HVT / IBDV / ILT / NDV # 2) nucleic acid hCMV IEpro-F-IE(term) / HVT UL54.5

[0205] VP2 / 1 C1#8 nucleic acid

[0206] 27 (HVT / IBDV / ILT / NDV # 3)

[0207] mCMV IEpro-VP2-SV40pA / HVT UL54.5

[0208] 1332-47.A2 nucleic acid

[0209] 28 (HVT / IBDV / ILT / NDV # 3)

[0210] ILT / hCMV IEpro-F-IE(term) / HVT US2 1332-23.7 nucleic acid

[0211] 29 (HVT / IBDV / ILT / NDV # 4)

[0212] ILT / HVT UL54.5

[0213] 435Vec60 nucleic acid

[0214] 30 (HVT / IBDV / ILT / NDV # 4)

[0215] mCMV IEpro-VP2-SV40pA /

[0216] hCMV IEpro-F-IE(term) / HVT US2

[0217] 1332-29.4 nucleic acid

[0218] 31 (HVT / IBDV / ILT / NDV # 5)

[0219] ILT / hCMV IEpro-F-IE(term) / HVT UL54.5

[0220] 435Vec6 nucleic acid

[0221] 32 (HVT / IBDV / ILT / NDV # 5)

[0222] mCMV IEpro-VP2-SV40pA / HVT US2

[0223] The present invention may be better understood by reference to the following non-limiting examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate embodiments of the invention and should in no way be construed as limiting the broad scope of the invention.

[0224] EXAMPLES EXAMPLE 1

[0225] CONSTRUCTION OF RECOMBINANT HVT / ILTV / IBDV / NDV VIRAL VECTORS

[0226] Recombinant multivalent non-pathogenic Marek's Disease virus constructs were prepared that encode and express (i) two Infectious Laryngotracheitis Virus protein antigens, (ii) an Infectious Bursal Disease Virus protein antigen, and (iii) a Newcastle Disease Virus protein antigen. The present invention overcomes the problem of vaccine interference encountered when two recombinant HVT vaccines, such as lnnovax®-ILT (sold by Merck Animal Health) and Vaxxitek®(sold by Merial) are given to the same animal. Moreover, the present invention uniquely provides the first recombinant nonpathogenic Marek's Disease Virus (rMDVnp) that encodes antigens from three different viral pathogens other than MDV.

[0227] Recombinant Herpesvirus of Turkey (HVT) constructs were created in which antigenic donor material from three poultry pathogens, Infectious Laryngotracheitis Virus (ILTV), Newcastle Disease Virus (NDV) and Infectious Bursal Disease virus (IBDV) were inserted into the HVT vector [see also, US 8,932,604 B2, WO 2013 / 057,235, WO 2016 / 102647, and U.S. Serial No. 62 / 351 ,471 filed June 17, 2016, the contents of all of which are hereby incorporated by reference in its entireties]. The donor materials include a 3.563 kb Sal\-Hind\\\ fragment from ILTV, NVSL Challenge Strain, Lot # 83-2 [nucleotide positions 10532-14094; Wild et al., Virus Genes 12:104-1 16 (1996): Acc.#U28832], encoding the full length genes for glycoprotein D (gD) and glycoprotein I (gl), plus partial coding regions from glycoprotein E (amino acids 1 -101 ), and ORF5 (amino acids 734-985); an expression cassette consisting of the coding region for NDV, Clone 30 strain, fusion protein (F) gene (nucleotide positions 4544 - 6205; Romer-Oberdorfer et al., (1999); Acc.# Y18898), driven by a viral promoter and followed by a terminator sequence; and an expression cassette consisting of the coding region for IBDV, Faragher, type F52 / 70 strain, viral protein 2 (vp2) gene, driven by a viral promoter and followed by a terminator sequence. In the exemplified embodiment, the promoter driving IBDV VP2 expression comes from the immediate early (IE) of mouse cytomegalovirus (mCMV) strain ATCC VR-194, whereas that for NDV F expression comes from the immediate early (IE) gene of human cytomegalovirus (hCMV), strain AD 169. The terminator and polyadenylation sequence for IBDV VP2 comes from Simian virus 40 (SV40), whereas the terminator and polyadenylation sequence for NDV F comes from the immediate early (IE) gene of human cytomegalovirus (hCMV). The donor material for the first heterologous nucleic acid was inserted into the UL54.5 site (pos. 1 1 1240 / 1 1 1241 , Afonso et al., J. Virology 75{2):971 -978 (2001 ),; Acc. #AF291866, between amino acids residues 21 and 22), whereas the donor material for the second heterologous nucleic acid was inserted into the US2 site (position 140540 / 140541 , Afonso et al., (2001 )st / pra; Acc. #AF291866, between amino acids residues 124 and 125) [see, Figure 1 ]. Genetic and phenotypic stability is a major component of the safety and relatively strong antigen expression and / or efficacy profile of any new recombinant viral vaccine candidate. The IBDV / ILTV and NDV expression cassettes inserted into the HVT backbone are not intrinsically required for viral replication and therefore may be lost due to mutation during amplification of the virus stock in tissue culture passages. A satisfactory vaccine candidate must not easily mutate to lose expression of the foreign gene insert. A vaccine candidate is considered stable if it can be demonstrated that at least 90% of the viral plaques express the inserted foreign antigenic protein following greater than or equal to 10 passages in tissue culture. The ability to generate herpesviruses by the cosmid reconstruction method previously had been demonstrated for pseudorabies virus [van Zijl et al., J. Virology 62:2191 -2195 (1988)]. This procedure subsequently was employed to construct recombinant HVT vectors [see, U.S. 5,853,733, hereby incorporated by references with respect to the methodology disclosed regarding the construction of recombinant HVT vectors] and was used to construct the recombinant HVT / IBDV / ILTV / NDV vectors of the present invention. In this method, the entire HVT genome is cloned into bacterial vectors as several large overlapping subgenomic fragments constructed utilizing standard recombinant DNA techniques [Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York (1982); and Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York (1989)]. An HVT strain FC126 cosmid library was derived from sheared viral DNA cloned into the cosmid vector pWE15 (Stratagene, now Agilent

[0228] Technologies of Santa Clara, Calif.). In addition, several large genomic DNA fragments were isolated by restriction digestion with the enzyme, BamHI, and cloned into either pWE15 or the plasmid vector pSP64 (Promega, Madison Wis.). As described in U.S. 5,853,733, cotransfection of these fragments into chicken embryo fibroblast (CEF) cells results in the regeneration of the HVT genome mediated by homologous recombination across the overlapping regions of the fragments. If an insertion is engineered directly into one or more of the subgenomic fragments prior to the cotransfection, this procedure results in a high frequency of viruses containing the insertion. Five overlapping subgenomic clones are required to generate the complete genome of FC126 HVT, and served as the basis for creating all HVT / IBDV / ILTV / NDV recombinant viruses.

[0229] Construction of HVT / IBDV / ILTV / NDV 670-14.1-1 A1 or A2

[0230] The triple recombinant HVT vector virus, HVT / IBDV / ILTV / NDV 670-14.1 -1 contains an IBDV / ILTV expression cassette inserted into the HVT UL54.5 site, and an NDV expression cassette inserted into the HVT US2 site. The cosmid regeneration of HVT / IBDV / ILTV / NDV 670-14.1 -1 was performed essentially as described in U.S. 5,853,733 [e.g., FIG. 8 of U.S. 5,853,733]. To allow integration into the UL54.5 region of the FC126 HVT genome, the region covered by the cosmid nr. 407-31 .1 C1 in U.S. 5,853,733, was now provided from three smaller plasmids: 672-01 . A40 and 672-07. C40, and one transfer plasmid (484-1050- 2641 -10859), overlapping these two, and containing the IBDV / ILTV expression cassettes in the UL54.5 gene locus. To allow integration into the US region of the FC126 HVT genome, the region covered by the cosmid nr. 378-50 in U.S. 5,853,733, was now provided from three smaller plasmids: pSY640 and 556-60.6, and one transfer plasmid (1322-48.1 ), overlapping these two, and containing the NDV expression cassettes in the US2 gene locus.

[0231] The set of nine linearized constructs: 2 cosmids and 7 plasmids are transfected all together into chicken embryo fibroblasts (CEFs), using a standard CaCI2transfection protocol and the resulting virus stock was plaque purified two times. Description of Subgenomic Fragments for Generating FC126 HVT

[0232] Subgenomic Clone 407-32.2C3 Cosmid 407-32.2C3 contains an approximately 40,170 base pair region of genomic HVT DNA [Left terminus - pos. 39,754; Afonso et al., (2001 ), supra; Acc. #AF291866]. This region includes HVT BamHI fragments F', L, P, N 1 , E, D, and 2,092 base pairs of fragment B.

[0233] Subgenomic Clone 172-07.BA2

[0234] Plasmid 172-07. BA2 contains a 25,931 base pair region of genomic HVT DNA. It was constructed by cloning the HVT BamHI B fragment [pos. 37,663 to 63,593; Afonso et al., 2001 , supra; Acc. #AF291866], into the plasmid pSP64 (Promega, Madison Wis.).

[0235] Subgenomic Clone 407-32.5G6

[0236] Cosmid 407-32.5G6 contains a 39,404 base pair region of genomic HVT DNA [pos. 61 ,852 - 101 ,255; Afonso et al., (2001 ), supra; Acc. #AF291866]. This region includes HVT BamHI fragments H, C, Q, K1 , M, K2, plus 1 ,742 base pairs of fragment B, and 3,880 base pairs of fragment J.

[0237] Subgenomic Clone 407-31.1C1

[0238] Cosmid 407-31.1 C1 contains a 37,444 base pair region of genomic HVT DNA [pos. 96,095 - 133,538; Afonso et al., (2001 ), supra; Acc. #AF291866]. This region includes HVT BamHI fragments J, G, I, F, O, plus 1 ,281 base pairs of fragment K2, and 6,691 base pairs of fragment A.

[0239] Subgenomic Clone 378-50

[0240] Cosmid 378-50 contains a 28,897 base pair region of genomic HVT DNA [see, FIG. 8 of U.S. 5,853,733]. This region includes the HVT BamHI fragment A. It was constructed by cloning the HVT BamHI A fragment [position 126,848 - 155,744; Afonso et al., (2001 ), supra; Acc. #AF291866] into cosmid pWE15.

[0241] Additional Insertion Fragments for Generating

[0242] HVT / IBDV / ILTV / NDV 670-14.1-1 A 1 or A2 {see, Figure 1 )

[0243] Subgenomic Clone 484-1050-2641-10859

[0244] The insertion plasmid 484-1050-2641 -10859 contains an 8636 base pair region of genomic HVT unique long region [pos. 109489-1 18124; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into a derivative of plasmid pNEB193 (deleted Aatll-Pvull). It is flanked by Ascl sites and includes HVT BamHI fragments I, S, plus 1337 base pairs of fragment G and 1 177 base pairs of fragment F. Inserted into an Xhol site within the HVT UL54.5 open reading frame [pos. 1 1 1240 / 1 1 1241 ; Afonso et al., 2001 , supra; Acc. #AF291866, between amino acid residues 21 and 22] are 2 elements: an expression cassette consisting of the MCMV IE promoter, the IBDV classic type F52 / 70, Faragher strain, virus protein 2 gene (VP2), and the SV40 polyadenylation signal, followed by a 3563 base pair Sall-Hindlll fragment from ILTV, NVSL Challenge Strain, Lot#83-2 [pos. 10532-14094; Wild et al., Virus Genes 12:104- 1 16 (1996); Acc.#U28832], encoding the full length genes for glycoprotein D (gD) and glycoprotein I (gl), plus partial coding regions from glycoprotein E (amino acids 1 -101 ), and ORF5 (amino acids 734-985). The IBDV VP2, ILTV gD and ILTV gl genes are transcribed in the opposite direction relative to the HVT UL54.5 gene.

[0245] Subgenomic Clone 672-01.A40

[0246] Plasmid 672-01.A40 contains a 14,731 base pair region of genomic HVT DNA derived from the unique long region [pos. 96095-1 10825; Afonso et al., 2001 , supra; Acc.#AF291866], cloned into a derivative of plasmid pNEB193. This region includes HVT BamHI fragments G, J and 1281 base pairs of K2.

[0247] Subgenomic clone 672-07.C40

[0248] Plasmid 672-07. C40 contains a 12,520 base pair region of genomic HVT DNA derived from the unique long region [pos. 1 16948-129467; Afonso et al., 2001 , supra; Acc.#AF291866], cloned into a derivative of plasmid pNEB193. This region includes HVT BamHI fragments F, O and 2620 base pairs of A.

[0249] Subgenomic Clone 1322-48.1

[0250] The insertion plasmid 1322-48.1 contains a 731 1 base pair EcoRI fragment of the HVT unique short regions [pos. 126880-144190; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into the plasmid pSP64 (Promega, Madison, Wl.). Inserted into a unique Stul site within the HVT US2 gene [pos. 140540 / 140541 ; Afonso et al., 2001 , supra; Acc.

[0251] #AF291866, between amino acid residues 124 and 125] is an expression cassette consisting of the HCMV IE promoter, the NDV, Clone 30 strain, fusion gene (F), and the transcription terminator from the HCMV IE gene. The NDV F gene is transcribed in the opposite direction relative to the HVT US2 gene.

[0252] Subgenomic Clone pSY640

[0253] Plasmid pSY640 contains an approximately 13,600 base pair region of genomic HVT DNA (pos. 126848 -140540; Afonso et al., 2001 , supra; Acc. #AF291866] derived from BamHI fragment A. To generate this plasmid the region of DNA located upstream of the US2 gene, beginning at the StuI site located in the US2 gene and continuing to the end of the BamHI A fragment, was cloned into the plasmid pSP64 (Promega, Madison Wl.).

[0254] Subgenomic Clone 556-60.6

[0255] Plasmid 556-60.6 contains an approximately 12,500 base pair region of genomic HVT DNA derived from BamHI fragment A (approximate pos. 143300-155744; Afonso et al., 2001 , supra; Acc. #AF291866]. To generate this plasmid, the region of DNA located downstream of the US2 gene (beginning at the StuI site located in the US2 gene and continuing to the end of the BamHI A fragment) was cloned into pSP64 (Promega, Madison Wl.), and then treated with exonuclease to "chewed back" from StuI site -150 bp, and re-cloned into pBR322 plasmid vector.

[0256] Standard CaCI2Transfection Protocol

[0257] Secondary CEF's are seeded on 6 well culture plates and incubated at 38°C with 5% C02for 24 hours and confluent monolayers form. For each well a total amount of 0.5 μg DNA of cosmids and plasmids were mixed in Hepes buffer and 125 mM CaCI2was added dropwise until precipitation was imminent. This mixture was added to the CEF cell monolayer, and incubated for 2 to 3 hours. The supernatant was removed and an overlay of 15% glycerol was added, and kept on the cells for one minute. Then this was removed, washed with phosphate buffered saline (PBS), and fresh culture medium was added and the cells were incubated for two days. Next, the infection was expanded twice by harvesting cells by trypsinization and seeding onto larger plates, 6 cm plates first, then 10 cm plates 3 days later, until 50-90% CPE was achieved. Next, the amplified transfected cells were harvested by trypsinization, and dilutions of 10"3to 10"4were plated on 6 cm plates with CEF monolayers and incubated. The following day, the plates were covered with agar, and a number of individual plaques of HVT / IBDV / ILTV / NDV were isolated and amplified on CEFs. Each virus stock was plaque purified a second time by infecting confluent monolayers of CEFs on 6 cm plates with first round purified stocks diluted to 10"4to 10"5and incubating cells. The following day, the plates were covered with agar, and a number of individual plaques of HVT / IBDV / ILTV / NDV were isolated and amplified on CEFs.

[0258] EXAMPLE 2

[0259] RECOMBINANT HVT / IBDV / ILTV / NDV VIRUS STOCKS ARE PHENOTYPICALLY

[0260] STABLE FOR EXPRESSION OF THE IBDV, ILTV, AND NDV PROTEINS

[0261] FOLLOWING SERIAL PASSAGE IN TISSUE CULTURE Two plaque purified isolates of HVT / IBDV / ILTV / NDV, each from a separate cotransfection stock were serial passaged 15 times on secondary CEF cells and evaluated for expression of the inserted ILTV, NDV and IBDV genes in an Immunofluorescence Assay.

[0262] GENERATION OF TISSUE CULTURE PASSAGE STOCKS

[0263] For each tissue culture passage, confluent secondary CEF monolayers were inoculated with

[0264] 50 - 100 μΙ_ of virus stock, and incubated at 38°C, 5% C02for 2 - 5 days until CPE was evident. Next, cells were harvested by trypsinization, passage 1 (P1 ). The process was repeated to prepare further passage stocks (P2 - P15).

[0265] PHENOTYPIC STABILITY ANALYSIS

[0266] Six well plates were planted with secondary CEF monolayers. The cells were inoculated with virus stocks harvested at various passage levels: P0 - P15, or diluent alone. The plates were inoculated at multiple dilutions to achieve a countable number of plaques per well, and incubated at 38°C, 5% C02. After a five-day incubation, the supernatant was decanted and CEF monolayers were fixed with 70% acetone for approximately 20 minutes at 15-30°C. The acetone solution was decanted and the cells were allowed to air dry prior to staining with ILTV gD (polyclonal Rabbit anti-ILTV gD), ILTV gl (polyclonal rabbit anti-ILTV gl), NDV F (Mab #57), and IBDV VP2 (MCA GDV-R63) primary antibodies. Following an

[0267] approximately 1 .5 hour blocking step, 5% goat sera in PBS + 0.5% Triton-X 100, 2 mL per well, is added to the dishes, and then incubated at 36°-39°C in a humidified incubator. The primary antibodies were diluted as appropriate, added at 2 mL per well, and then incubated at 36°-39°C for 1 .3 hours in a humidified incubator. Following the antibody incubation, the plates were washed three times with PBS + 0.5%

[0268] Triton-X 100. The FITC-labeled secondary antibody solution (rabbit anti-mouse or goat anti- rabbit) was prepared at 1 :50 and 2 mL was added to each well. Following incubation, plates were washed three times with PBS + 0.5% Triton-X 100, and examined under a fluorescent scope, and the plaques were scored as positive or negative for fluorescent staining. Plates were then examined under a white light microscope and the plaques were re-counted. The percentage of fluorescing plaques at each passage level is described in the Table 1 below. Both isolates maintain an acceptable expression level for all four antigens (greater than 90%) at passage level 15. TABLE 1

[0269] STABILITY OF EXPRESSION FOLLOWING PASSAGE IN TISSUE CULTURE

[0270] EXAMPLE 3

[0271] RECOMBINANT HVT / IBDV / ILTV / NDV VIRUS STOCKS ARE PHENOTYPICALLY STABLE FOR EXPRESSION OF THE ILTV, NDV, AND IBDV PROTEINS FOLLOWING VACCINATION AND RECOVERY FROM BIRDS Vaccines were prepared from the two isolates of HVT / IBDV / ILTV / NDV 670-14.1 -1 , isolate A1 and isolate A2, and used to inoculate two groups of twenty-one (21 ) day-of-age chickens by the subcutaneous route. A third group of birds were vaccinated with diluent alone to serve as a negative control group. Pooled spleen samples from three birds were collected twice weekly for four weeks post vaccination, and processed for virus isolation on chicken embryo fibroblast cells (CEFs). When a cytopathic effect was clearly visible, monolayers were fixed, and the plaques were analyzed for the expression of the IBDV VP2, ILTV gD, and ILTV gl, and NDV F proteins by immunofluorescence assay (IFA), with antibodies that are specific for each protein. PHENOTYPIC STABILITY ANALYSIS

[0272] Six well plates were planted with secondary CEF monolayers. The cells were inoculated with 5 x 106spleen cells, and incubated at 38°C, 5% C02. After five days of incubation, the supernatant was decanted and the CEF monolayers were fixed with 70% acetone for approximately 20 minutes at 15-30°C. The acetone solution was decanted and the cells were allowed to air dry prior to staining with ILTV gD (polyclonal rabbit anti-ILTV gD), ILTV gl (polyclonal rabbit anti-ILTV gl), NDV F (Mab #57) and IBDV VP2 (MCA GDV-R63) primary antibodies. Following an approximately 0.5 hour blocking step, 5% goat sera in PBS + 0.5% Triton-X 100, 2 mL per well, is added to the dishes, and then incubated at 36°-39°C in a humidified incubator. The primary antibodies were diluted as appropriate, added at 2 mL per well, and then incubated at 36°-39°C for 1 hour in a humidified incubator. After the antibody incubation, the plates were washed three times with PBS + 0.5% Triton-X 100. The FITC- labeled secondary antibody solution (rabbit anti-mouse or goat anti-rabbit) was prepared at 1 :50, and 2 mL was added to each well. The plates were incubated for 1 hour at 36°-39°C in a humidified incubator. Following incubation, the plates were washed three times with PBS + 0.5% Triton-X 100, and examined under a fluorescent scope and the plaques were scored for positive (+) or negative (-) fluorescence staining. The plates were then examined under a white light microscope and the plaques were re-counted. The percentage of fluorescing plaques at each passage level is provided in Table 2 below.

[0273] EXAMPLE 4

[0274] HVT / IBDV / ILTV / NDV

[0275] EFFICACY DATA FOR TWO ISOLATES OF A PARTICULAR CONSTRUCT

[0276] The following four studies were conducted to demonstrate the effectiveness of a single construct HVT / IBDV / ILTV / NDV 670-14 as a vaccine candidate for protecting against a challenge with virulent Infectious Laryngotracheitis virus (ILTV), or virulent Infectious Bursal Disease Virus (IBDV), or virulent Marek's disease virus (MDV).

[0277] In the first study, one-day-old specific pathogen free (SPF) chicks were vaccinated with an HVT / IBDV / ILTV / NDV 670-14.1 -1A2 vaccine candidate. Controls included a second group that remained unvaccinated. At 28 days post-vaccination, the vaccinated chicks and the non-vaccinated control chicks were challenged with virulent ILTV / USDA lot LT 96-3 via the intracheal (IT) route. Birds were then observed for clinical signs of disease for 10 days. In Table 3, the results show the 670-14.1 -1A2 vaccine provided partial protection from challenge. A second study was conducted using a second clone of the vaccine, 670-14.1 - 1 A1 . In Table 4, the results show a marked improvement in protection. Accordingly, the next two studies were performed with the 670-14.1 -1A1 vaccine candidate. These results provide evidence that an HVT / IBDV / ILTV / NDV can be both stable and efficacious.

[0278] TABLE 3

[0279] ILTV Challen e Followin Vaccination with Isolate 670-14.1 -1A2

[0280]

[0281] TABLE 4

[0282] ILTV CHALLENGE FOLLOWING VACCINATION WITH ISOLATE 670-14.1 -1A1

[0283]

[0284] In the third study, one-day-old specific pathogen free (SPF) chicks were vaccinated with the HVT / IBDV / ILTV / NDV 670-14.1 -1A1 vaccine. Controls included a second unvaccinated group. At 28 days post-vaccination, vaccinated chicks and non-vaccinated control chicks were challenged with virulent IBDV / CS89 strain via the intraocular (IO) route. Birds were then observed for clinical signs of disease for 10 days, and bursa collected and examined histologically for gross lesions consistent with IBDV and scored as per the European Pharmacopoeia 9.0 (04 / 2013:0587). The results, in Table 5, show the 670-14.1 - 1A1 vaccine provided 100% protection from challenge. TABLE 5

[0285] IBDV CHALLENGE FOLLOWING VACCINATION WITH ISOLATE 670-14.1 -1A1

[0286]

[0287] In a fourth study, one-day-old specific pathogen free (SPF) chicks were vaccinated with the HVT / IBD / ILTV / NDV 670-14.1 -1A1 vaccine. Controls included a second group of unvaccinated chicks. At 5 days post-vaccination, the vaccinated chicks and the non- vaccinated control chicks were challenged with virulent MDV / GA strain via the intra- abdominal (IA) route. Birds were then observed for clinical signs of disease for 50 days, and following death or euthanasia examined for gross lesions consistent with MDV. The results, in Table 6, show that the 670-14.1 -1A1 vaccine provided 95% protection from challenge. In sum, these results indicate that an HVT / IBD / ILTV / NDV vaccine can be both stable and efficacious. It also leads credence for the upper limit of foreign antigens encoded in a multivalent HVT construct has not been reached for stable and efficacious multivalent HVT vaccines.

[0288] TABLE 6

[0289] MDV CHALLENGE FOLLOWING VACCINATION WITH ISOLATE 670-14.1 -1A1

[0290] Vaccination Challenge Results

[0291] Vaccine SC MDV GA5 Day 50 Necropsy

[0292] Group Identification Age at # Affected / % %

[0293] Age Dose

[0294] Challenge Total Affected Protection

[0295] 3 HVT / IBDV / ILTV / NDV 1 day 3328 Day 5 1 / 22 5% 95%

[0296] 4 HVT 1 day 2372 Day 5 0 / 22 0% 100%

[0297] 5 Diluent 1 day NA Day 5 15 / 22 68% NA

[0298] 6 Diluent 1 day NA - 0 / 12 0% NA EXAMPLE 5

[0299] ADDITIONAL HVT / IBDV / ILTV / NDV CONSTRUCTS Construction of HVT / IBDV / ILTV / NDV #2

[0300] The triple recombinant HVT vector virus, HVT / IBDV / ILTV / NDV #2 contains an NDV expression cassette inserted into the HVT UL54.5 site, and an IBDV / ILTV expression cassette inserted into the HVT US2 site. The cosmid regeneration of HVT / IBDV / ILTV / NDV #2 was performed essentially as described in U.S. 5,853,733 [e.g., FIG. 8 of

[0301] U.S. 5,853,733]. To allow integration into the UL54.5 region of the FC126 HVT genome, the region covered by the cosmid nr. 407-32.1 C1 in U.S. 5,853,733, was now provided from three smaller plasmids: 672-01 .A40 and 672-07. C40, and one transfer plasmid (654- 45:325341_IE-F / 1 C1 ), overlapping these two, and containing the NDV expression cassette in the UL54.5 gene locus. To allow integration into the US region of the FC126 HVT genome, the region covered by the cosmid nr. 378-50 in U.S. 5,853,733, was now provided from three smaller plasmids: pSY640 and 556-60.6, and one transfer plasmid (228509-1 LT- 435Vec6), overlapping these two, and containing the IBDV / ILTV expression cassettes in the US2 gene locus. The set of nine linearized constructs: 2 cosmids and 7 plasmids are transfected all together into chicken embryo fibroblasts (CEFs), using a standard CaCI2transfection protocol and the resulting virus stock was plaque purified two times.

[0302] Construction of HVT / IBDV / ILTV / NDV #3

[0303] The triple recombinant HVT vector virus, HVT / IBDV / ILTV / NDV #3 contains an IBDV expression cassette inserted into the HVT UL54.5 site, and an ILTV / NDV expression cassette inserted into the HVT US2 site. The cosmid regeneration of HVT / IBDV / ILTV / NDV #3 was performed essentially as described in U.S. 5,853,733 [e.g., FIG. 8 of

[0304] U.S. 5,853,733]. To allow integration into the UL54.5 region of the FC126 HVT genome, the region covered by the cosmid nr. 407-32.1 C1 in U.S. 5,853,733, was now provided from three smaller plasmids: 672-01 .A40 and 672-07. C40, and one transfer plasmid

[0305] (VP2 / 1 C1#8), overlapping these two, and containing the IBDV expression cassette in the UL54.5 gene locus. To allow integration into the US region of the FC126 HVT genome, the region covered by the cosmid nr. 378-50 in U.S. 5,853,733, was now provided from three smaller plasmids: pSY640 and 556-60.6, and one transfer plasmid (1332-47.A2), overlapping these two, and containing the ILTV / NDV expression cassettes in the US2 gene locus.

[0306] The set of nine linearized constructs: 2 cosmids and 7 plasmids are transfected all together into chicken embryo fibroblasts (CEFs), using a standard CaCI2transfection protocol and the resulting virus stock was plaque purified two times.

[0307] Construction of HVT / IBDV / ILTV / NDV #4

[0308] The triple recombinant HVT vector virus, HVT / IBDV / ILTV / NDV #4 contains an ILTV expression cassette inserted into the HVT UL54.5 site, and an IBDV / NDV expression cassette inserted into the HVT US2 site. The cosmid regeneration of HVT / IBDV / ILTV / NDV #4 was performed essentially as described in U.S. 5,853,733 [e.g., FIG. 8 of

[0309] U.S. 5,853,733]. To allow integration into the UL54.5 region of the FC126 HVT genome, the region covered by the cosmid nr. 407-32.1 C1 in U.S. 5,853,733, was now provided from three smaller plasmids: 672-01 . A40 and 672-07. C40, and one transfer plasmid (1332-23.7), overlapping these two, and containing the ILTV expression cassette in the UL54.5 gene locus. To allow integration into the US region of the FC126 HVT genome, the region covered by the cosmid nr. 378-50 in U.S. 5,853,733, was now provided from three smaller plasmids: pSY640 and 556-60.6, and one transfer plasmid (435Vec60), overlapping these two, and containing the IBDV / NDV expression cassettes in the US2 gene locus.

[0310] The set of nine linearized constructs: 2 cosmids and 7 plasmids are transfected all together into chicken embryo fibroblasts (CEFs), using a standard CaCI2transfection protocol and the resulting virus stock was plaque purified two times.

[0311] Construction of HVT / IBDV / ILTV / NDV #5

[0312] The triple recombinant HVT vector virus, HVT / IBDV / ILTV / NDV #5 contains an ILTV / NDV expression cassettes inserted into the HVT UL54.5 site, and an IBDV expression cassette inserted into the HVT US2 site. The cosmid regeneration of HVT / IBDV / ILTV / NDV #5 was performed essentially as described in U.S. 5,853,733 [e.g., FIG. 8 of U.S. 5,853,733]. To allow integration into the UL54.5 region of the FC126 HVT genome, the region covered by the cosmid nr. 407-32.1 C1 in U.S. 5,853,733, was now provided from three smaller plasmids: 672-01. A40 and 672-07. C40, and one transfer plasmid (1332-29.4), overlapping these two, and containing the ILTV / NDV expression cassettes in the UL54.5 gene locus. To allow integration into the US region of the FC126 HVT genome, the region covered by the cosmid nr. 378-50 in U.S. 5,853,733, was now provided from three smaller plasmids:

[0313] pSY640 and 556-60.6, and one transfer plasmid (435Vec6), overlapping these two, and containing the IBDV expression cassette in the US2 gene locus. The set of nine linearized constructs: 2 cosmids and 7 plasmids are transfected all together into chicken embryo fibroblasts (CEFs), using a standard CaCI2transfection protocol and the resulting virus stock was plaque purified two times. Additional Insertion Fragments for Generating

[0314] HVT / IBDV / ILTV / NDV# 2 (see, Figure 2)

[0315] Subgenomic Clone 654-45: 325341 J E-F / 1C1

[0316] The insertion plasmid 654-45:325341 E-F / 1C1 contains an 8636 base pair region of genomic HVT unique long region [pos. 109489-1 18124; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into a derivative of plasmid pNEB193 (deleted Aatll-Pvull). It is flanked by Ascl sites and includes HVT BamHI fragments I, S, plus 1337 base pairs of fragment G and 1 177 base pairs of fragment F. Inserted into an Xhol site within the HVT UL54.5 open reading frame [pos. 1 1 1240 / 1 1 1241 ; Afonso et al., 2001 , supra; Acc. #AF291866, between amino acid residues 21 and 22] is an expression cassette consisting of the HCMV IE promoter, the NDV, Clone 30 strain, fusion gene (F), and the transcription terminator from the HCMV IE gene. The NDV F gene is transcribed in the opposite direction relative to the HVT UL54.5 gene.

[0317] Subgenomic Clone 228509-1 LT-435Vec6 [see, International Application

[0318] PCT / EP2017 / 064662]

[0319] The insertion plasmid 228509-1 LT-435Vec6 contains a 731 1 base pair EcoRI fragment of the HVT unique short regions [pos. 126880-144190; Afonso et al., 2001 , supra; Acc.

[0320] #AF291866], cloned into the plasmid pSP64 (Promega, Madison, Wl.). Inserted into a unique Stul site within the HVT US2 gene [pos. 140540 / 140541 ; Afonso et al., 2001 , supra; Acc. #AF291866, between amino acid residues 124 and 125] are two elements: an expression cassette consisting of the MCMV IE promoter, the IBDV classic type F52 / 70, Faragher strain, virus protein 2 gene (VP2), and the SV40 polyadenylation signal; followed by a 3563 base pair Sall-Hindlll fragment from ILTV, NVSL Challenge Strain, Lot#83-2 [pos. 10532-14094; Wild et al., Virus Genes 12:104-1 16 (1996); Acc.#U28832], encoding the full length genes for glycoprotein D (gD) and glycoprotein I (gl), plus partial coding regions from glycoprotein E (amino acids 1 -101 ), and ORF5 (amino acids 734-985). The IBDV VP2, ILTV gD and ILTV gl genes are transcribed in the opposite direction relative to the HVT US2 gene. Additional Insertion Fragments for Generating

[0321] HVT / IBDV / ILTV / NDV# 3 (see, Figure 3) Subgenomic Clone VP2 / 1C1#8

[0322] The insertion plasmid VP2 / 1C1#8 contains an 8636 base pair region of genomic HVT unique long region [pos. 109489-1 18124; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into a derivative of plasmid pNEB193 (deleted Aatll-Pvull). It is flanked by Ascl sites and includes HVT BamHI fragments I, S, plus 1337 base pairs of fragment G and 1 177 base pairs of fragment F. Inserted into an Xhol site within the HVT UL54.5 open reading frame [pos. 1 1 1240 / 1 1 1241 ; Afonso et al., 2001 , supra; Acc. #AF291866, between amino acid residues 21 and 22] is an expression cassette consisting of the MCMV IE promoter, the IBDV classic type F52 / 70, Faragher strain, virus protein 2 gene (VP2), and the SV40 polyadenylation signal. The IBDV VP2 gene is transcribed in the opposite direction relative to the HVT UL54.5 gene.

[0323] Subgenomic Clone 1332-47. A2

[0324] The insertion plasmid 1332-47 A2 contains a 731 1 base pair EcoRI fragment of the HVT unique short regions [pos. 126880-144190; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into the plasmid pSP64 (Promega, Madison, Wl.). Inserted into a unique Stul site within the HVT US2 gene [pos. 140540 / 140541 ; Afonso et al., 2001 , supra; Acc.

[0325] #AF291866, between amino acid residues 124 and 125] are two elements: a 3563 base pair Sall-Hindlll fragment from ILTV, NVSL Challenge Strain, Lot#83-2 [pos. 10532-14094; Wild et al., Virus Genes 12:104-1 16 (1996); Acc.#U28832], encoding the full length genes for glycoprotein D (gD) and glycoprotein I (gl), plus partial coding regions from glycoprotein E (amino acids 1 -101 ), and ORF5 (amino acids 734-985); followed by an expression cassette consisting of the HCMV IE promoter, the NDV, Clone 30 strain, fusion gene (F), and the transcription terminator from the HCMV IE gene. The ILTV gD, the ILTV gl, and the NDV F genes are transcribed in the opposite direction relative to the HVT US2 gene.

[0326] Additional Insertion Fragments for Generating

[0327] HVT / IBDV / ILTV / NDV# 4 (see, Figure 4)

[0328] Subgenomic Clone 1332-23.7

[0329] The insertion plasmid 1332-23.7 contains an 8636 base pair region of genomic HVT unique long region [pos. 109489-1 18124; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into a derivative of plasmid pNEB193 (deleted Aatll-Pvull). It is flanked by Ascl sites and includes HVT BamHI fragments I, S, plus 1337 base pairs of fragment G and 1 177 base pairs of fragment F. Inserted into an Xhol site within the HVT UL54.5 open reading frame [pos. 1 1 1240 / 1 1 1241 ; Afonso et al., 2001 , supra; Acc. #AF291866, between amino acid residues 21 and 22] is a 3563 base pair Sall-Hindlll fragment from ILTV, NVSL Challenge Strain, Lot#83-2 [pos. 10532-14094; Wild et al., Virus Genes 12:104-1 16 (1996);

[0330] Acc.#U28832], encoding the full length genes for glycoprotein D (gD) and glycoprotein I (gl), plus partial coding regions from glycoprotein E (amino acids 1 -101 ), and ORF5 (amino acids 734-985). The ILTV gD and the ILTV gl genes are transcribed in the opposite direction relative to the HVT UL54.5 gene.

[0331] Subgenomic Clone 435Vec60

[0332] The insertion plasmid 435Vec60 contains a 731 1 base pair EcoRI fragment of the HVT unique short regions [pos. 126880-144190; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into the plasmid pSP64 (Promega, Madison, Wl.). Inserted into a unique Stul site within the HVT US2 gene [pos. 140540 / 140541 ; Afonso et al., 2001 , supra; Acc.

[0333] #AF291866, between amino acid residues 124 and 125] are two elements: an expression cassette consisting of the MCMV IE promoter, the IBDV classic type F52 / 70, Faragher strain, virus protein 2 gene (VP2), and the SV40 polyadenylation signal; followed by an expression cassette consisting of the HCMV IE promoter, the NDV, Clone 30 strain, fusion gene (F), and the transcription terminator from the HCMV IE gene. Both the IBDV VP2 and NDV F genes are transcribed in in the opposite direction relative to the HVT US2 gene. Additional Insertion Fragments for Generating

[0334] HVT / IBDV / ILTV / NDV# 5 (see, Figure 5)

[0335] Subgenomic Clone 1332-29.4 [see, U.S. 9,409,954 B2]

[0336] The insertion plasmid 1332-29.4 contains an 8636 base pair region of genomic HVT unique long region [pos. 109489-1 18124; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into a derivative of plasmid pNEB193 (deleted Aatll-Pvull). It is flanked by Ascl sites and includes HVT BamHI fragments I, S, plus 1337 base pairs of fragment G and 1 177 base pairs of fragment F. Inserted into an Xhol site within the HVT UL54.5 open reading frame [pos. 1 1 1240 / 1 1 1241 ; Afonso et al., 2001 , supra; Acc. #AF291866, between amino acid residues 21 and 22] are two elements: a 3563 base pair Sall-Hindlll fragment from ILTV, NVSL Challenge Strain, Lot#83-2 [pos. 10532-14094; Wild et al., Virus Genes 12:104-1 16 (1996); Acc.#U28832], encoding the full length genes for glycoprotein D (gD) and glycoprotein I (gl), plus partial coding regions from glycoprotein E (amino acids 1 -101 ), and ORF5 (amino acids 734-985); followed by an expression cassette consisting of the HCMV IE promoter, the NDV, Clone 30 strain, fusion gene (F), and the transcription terminator from the HCMV IE gene. The ILTV gD, the ILTV gl, and the NDV F genes are transcribed in the opposite direction relative to the HVT UL54.5 gene.

[0337] Subgenomic Clone 435Vec6

[0338] The insertion plasmid 435Vec6 contains a 731 1 base pair EcoRI fragment of the HVT unique short regions [pos. 126880-144190; Afonso et al., 2001 , supra; Acc. #AF291866], cloned into the plasmid pSP64 (Promega, Madison, Wl.). Inserted into a unique Stul site within the HVT US2 gene [pos. 140540 / 140541 ; Afonso et al., 2001 , supra; Acc. #AF291866, between amino acid residues 124 and 125] is an expression cassette consisting of the MCMV IE promoter, the IBDV classic type F52 / 70, Faragher strain, virus protein 2 gene (VP2), and the SV40 polyadenylation signal. The IBDV VP2 gene is transcribed in in the opposite direction relative to the HVT US2 gene.

[0339] The sequences used in the HVT / ILTV / IBDV / NDV viral vectors disclosed in this example are provided in Example 7 below as SEQ ID NOs: 23 and 26-32.

[0340] EXAMPLE 6

[0341] UNSUCCESSFUL CONSTRUCTS The recombinant vector vaccine viruses, by definition are engineered to carry and express foreign genes. Should transcription and expression of these foreign genes provide a growth disadvantage to the recombinant virus relative to the parental virus, it is possible for these genes to be lost during production of the vaccine. For this reason, vaccine candidates must be tested for both genetic and phenotypic stability.

[0342] In addition, the protection criteria used is that which has been established by the USDA and codified in the Title 9 Code of Federal Regulations, part 1 13 (9CFR 1 13) «Standard requirements for Animal Products*. Live virus vaccines must provide at least 90% protection, in the case of NDV, IBDV and ILTV, and at least 80% in the case of MDV, from clinical signs or lesions associated with the disease to obtain a license.

[0343] Genetic stability of the viral constructs was determined by Southern blot analysis after a defined number of passages in tissue culture, the highest anticipated vaccine production level, and compared with DNA from the original isolate. DNA extracted from viral stocks would be digested with restriction enzymes, transfered to a membrane and hybridized with probes designed to detect the presence of the inserted foriegn genes. Genetic stability may also be determined by PCR analysis. PCR primers designed to anneal to DNA within or flanking the foreign DNA could be used to amplify fragments of a known size from the viral DNA templates both before and after passage in tissue culture.

[0344] Phenotypic stability of the viral constructs was determined by immunological staining of individual viral plaques with antibodies directed against the protein products of these inserted foreign genes. Protection provided by these recombinant vaccines relies on expression of these protein products in order to stimulate the animals immune system. In most cases, if the percent of viruses staining positive for the foreign protein expression dropped below 90%, it was likely detrimental to the viruses ability to be grown in tissue culture, and therefore unsuitable as a vaccine candidate.

[0345] As is readily apparent from Tables 7A and 7B below, most rMDVnp constructs do not meet these two criteria, namely stabilty with relatively strong antigen expression and / or efficacy. Table 7A provides a series of recombinant HVT constructs with multiple heterologous inserts in which one of the heterologous inserts encodes an IBDV antigen. As the results show, all of the constructs in Table 7A failed to meet the stability with relatively strong antigen expression and / or efficacy criteria.

[0346] TABLE 7A

[0347] DOUBLE RECOMBINANT HVT AND IBDV VIRUS CONSTRUCTS:

[0348]

[0349] Table 7B below, provides a series of eleven recombinant HVT constructs and one lone NAHV construct each of which comprise multiple heterologous inserts in which at least one of the heterologous inserts encodes either an NDV or an ILTV antigen.1As the results show, all of the constructs in Table 7B failed to meet the stability with relatively strong antigen expression and / or efficacy criteria.

[0350] 1The data in Table 7B was submitted to the U.S. Patent Ofice during the prosecution of U.S. 8,932,604 B2 in a Declaration signed by one of the co-Inventors of the present application. TABLE 7B

[0351] DOUBLE RECOMBINANT HVT AND NAHV VIRUS CONSTRUCTS:

[0352] * Protective, but subsequently failed in field studies**Only 75% birds seroconverted to NDV F

[0353] EXAMPLE 7

[0354] SEQUENCES

[0355] The following sequences have been used in the exemplary rHVT constructs. The coding sequences provided below include individual stop codons, which can be readily replaced with alternative stop codons without modifying the properties of the protein antigens that the coding sequences encode.

[0356] SEQ ID NO 1 : I LTV gD Glycoprotein (1 134 bp)

[0357] atggaccgccatttatttttgaggaatgctttttggactatcgtactgctttcttccttcgctagcca gagcaccgccgccgtcacgtacgactacattttaggccgtcgcgcgctcgacgcgctaaccataccgg cggttggcccgtataacagatacctcactagggtatcaagaggctgcgacgttgtcgagctcaacccg atttctaacgtggacgacatgatatcggcggccaaagaaaaagagaaggggggccctttcgaggcctc cgtcgtctggttctacgtgattaagggcgacgacggcgaggacaagtactgtccaatctatagaaaag agtacagggaatgtggcgacgtacaactgctatctgaatgcgccgttcaatctgcacagatgtgggca gtggactatgttcctagcacccttgtatcgcgaaatggcgcgggactgactatattctcccccactgc tgcgctctctggccaatacttgctgaccctgaaaatcgggagatttgcgcaaacagctctcgtaactc tagaagttaacgatcgctgtttaaagatcgggtcgcagcttaactttttaccgtcgaaatgctggaca acagaacagtatcagactggatttcaaggcgaacacctttatccgatcgcagacaccaatacacgaca cgcggacgacgtatatcggggatacgaagatattctgcagcgctggaataatttgctgaggaaaaaga atcctagcgcgccagaccctcgtccagatagcgtcccgcaagaaattcccgctgtaaccaagaaagcg gaagggcgcaccccggacgcagaaagcagcgaaaagaaggcccctccagaagactcggaggacgacat gcaggcagaggcttctggagaaaatcctgccgccctccccgaagacgacgaagtccccgaggacaccg agcacgatgatccaaactcggatcctgactattacaatgacatgcccgccgtgatcccggtggaggag actactaaaagttctaatgccgtctccatgcccatattcgcggcgttcgtagcctgcgcggtcgcgct cgtggggctactggtttggagcatcgtaaaatgcgcgcgtagctaa

[0358] SEQ ID NO 2: ILTV gD Glycoprotein (377 amino acids)

[0359] MDRHLFLRNAFWTIVLLSSFASQSTAAVTYDYILGRRALDALTIPAVGPYNRYLTRVSRGCDVVELNP ISNVDDMISAAKEKEKGGPFEASVVWFYVIKGDDGEDKYCPIYRKEYRECGDVQLLSECAVQSAQMWA VDYVPSTLVSRNGAGLTIFSPTAALSGQYLLTLKIGRFAQTALVTLEVNDRCLKIGSQLNFLPSKCWT

[0360] TEQYQTGFQGEHLYPIADTNTRHADDVYRGYEDILQRWNNLLRKKNPSAPDPRPDSVPQEIPAVTKKA EGRTPDAESSEKKAPPEDSEDDMQAEASGENPAALPEDDEVPEDTEHDDPNSDPDYYNDMPAVIPVEE TTKSSNAVSMPIFAAFVACAVALVGLLVWSIVKCARS SEQ ID NO 3: ILTV gl Glycoprotein (1089 bp)

[0361] atggcatcgctacttggaactctggctctccttgccgcgacgctcgcacccttcggcgcgatgggaat cgtgatcactggaaatcacgtctccgccaggattgacgacgatcacatcgtgatcgtcgcgcctcgcc ccgaagctacaattcaactgcagctatttttcatgcctggccagagaccccacaaaccctactcagga accgtccgcgtcgcgtttcggtctgatataacaaaccagtgctaccaggaacttagcgaggagcgctt tgaaaattgcactcatcgatcgtcttctgtttttgtcggctgtaaagtgaccgagtacacgttctccg cctcgaacagactaaccggacctccacacccgtttaagctcactatacgaaatcctcgtccgaacgac agcgggatgttctacgtaattgttcggctagacgacaccaaagaacccattgacgtcttcgcgatcca actatcggtgtatcaattcgcgaacaccgccgcgactcgcggactctattccaaggcttcgtgtcgca ccttcggattacctaccgtccaacttgaggcctatctcaggaccgaggaaagttggcgcaactggcaa gcgtacgttgccacggaggccacgacgaccagcgccgaggcgacaaccccgacgcccgtcactgcaac cagcgcctccgaacttgaagcggaacactttacctttccctggctagaaaatggcgtggatcattacg aaccgacacccgcaaacgaaaattcaaacgttactgtccgtctcgggacaatgagccctacgctaatt ggggtaaccgtggctgccgtcgtgagcgcaacgatcggcctcgtcattgtaatttccatcgtcaccag aaacatgtgcaccccgcaccgaaaattagacacggtctcgcaagacgacgaagaacgttcccaaacta gaagggaatcgcgaaaatttggacccatggttgcgtgcgaaataaacaagggggctgaccaggatagt gaacttgtggaactggttgcgattgttaacccgtctgcgctaagctcgcccgactcaataaaaatgtg a SEQ ID NO 4: ILTV gl Glycoprotein (362 amino acids)

[0362] MASLLGTLALLAATLAPFGAMGIVITGNHVSARIDDDHIVIVAPRPEATIQLQLFFMPGQRPHKPYSG TVRVAFRSDITNQCYQELSEERFENCTHRSSSVFVGCKVTEYTFSASNRLTGPPHPFKLTIRNPRPND SGMFYVIVRLDDTKEPIDVFAIQLSVYQFANTAATRGLYSKASCRTFGLPTVQLEAYLRTEESWRNWQ AYVATEATTTSAEATTPTPVTATSASELEAEHFTFPWLENGVDHYEPTPANENSNVTVRLGTMSPTLI GVTVAAWSATIGLVIVISIVTRNMCTPHRKLDTVSQDDEERSQTRRESRKFGPMVACEINKGADQDS ELVELVAIVNPSALSSPDSIKM SEQ ID NO 5: IBDV VP2 (1362 bp)

[0363] atgacaaacctgcaagatcaaacccaacagattgttccgttcatacggagccttctgatgccaacaac cggaccggcgtccattccggacgacaccctggagaagcacactctcaggtcagagacctcgacctaca atttgactgtgggggacacagggtcagggctaattgtctttttccctggattccctggctcaattgtg ggtgctcactacacactgcagagcaatgggaactacaagttcgatcagatgctcctgactgcccagaa cctaccggccagctacaactactgcagactagtgagtcggagtctcacagtgaggtcaagcacactcc ctggtggcgtttatgcactaaacggcaccataaacgccgtgaccttccaaggaagcctgagtgaactg acagatgttagctacaatgggttgatgtctgcaacagccaacatcaacgacaaaattgggaatgtcct ggtaggggaaggggtcactgtcctcagcctacccacatcatatgatcttgggtatgtgaggcttggtg accccattcccgctatagggcttgacccaaaaatggtagctacatgcgacagcagtgacaggcccaga gtctacaccataactgcagccgatgattaccaattctcatcacagtaccaaccaggtggggtaacaat cacactgttctcagccaacattgatgctatcacaagcctcagcattgggggagagctcgtgtttcaaa caagcgtccaaggccttgtactgggcgccaccatctaccttataggctttgatgggactgcggtaatc accagagctgtggccgcagataatgggctgacggccggcaccgacaatcttatgccattcaatcttgt cattccaaccaatgagataacccagccaatcacatccatcaaactggagatagtgacctccaaaagtg gtggtcaggcaggggatcagatgtcatggtcggcaagtgggagcctagcagtgacgatccatggtggc aactatccaggggccctccgtcccgtcacactagtagcctacgaaagagtggcaacaggatccgtcgt tacggtcgctggggtgagtaacttcgagctgattccaaatcctgaactagcaaagaacctggttacag aatacggccgatttgacccaggagccatgaactacacaaaattgatactgagtgagagggaccgtctt ggcatcaagaccgtctggccaacaagggagtacactgattttcgtgagtacttcatggaggtggccga cctcaactctcccctgaagattgcaggagcatttggcttcaaagacataatccgggctataaggaggt aa

[0364] SEQ ID NO 6: IBDV VP2 (453 amino acids)

[0365] MTNLQDQTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFFPGFPGSIV GAHYTLQSNGNYKFDQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYALNGTINAVTFQGSLSEL TDVSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLGYVRLGDPIPAIGLDPKMVATCDSSDRPR VYTITAADDYQFSSQYQPGGVTITLFSANIDAITSLSIGGELVFQTSVQGLVLGATIYLIGFDGTAVI TRAVAADNGLTAGTDNLMPFNLVIPTNEITQPITSIKLEIVTSKSGGQAGDQMSWSASGSLAVTIHGG NYPGALRPVTLVAYERVATGSVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERDRL GIKTVWPTREYTDFREYFMEVADLNSPLKIAGAFGFKDIIRAIRR

[0366] SEQ ID NO: 7: NDV F Protein, coding sequence (Clone 30; 1662 bp)

[0367] atgggccccagaccttctaccaagaacccagtacctatgatgctgactgtccgagtcgcgctggtact gagttgcatctgtccggcaaactccattgatggcaggcctcttgcggctgcaggaattgtggttacag gagacaaagccgtcaacatatacacctcatcccagacaggatcaatcatagttaagctcctcccgaat ctgcccaaggataaggaggcatgtgcgaaagcccccttggatgcatacaacaggacattgaccacttt gctcaccccccttggtgactctatccgtaggatacaagagtctgtgactacatctggaggggggagac aggggcgccttataggcgccattattggcggtgtggctcttggggttgcaactgccgcacaaataaca gcggccgcagctctgatacaagccaaacaaaatgctgccaacatcctccgacttaaagagagcattgc cgcaaccaatgaggctgtgcatgaggtcactgacggattatcgcaactagcagtggcagttgggaaga tgcagcagtttgttaatgaccaatttaataaaacagctcaggaattagactgcatcaaaattgcacag caagttggtgtagagctcaacctgtacctaaccgaattgactacagtattcggaccacaaatcacttc acctgctttaaacaagctgactattcaggcactttacaatctagctggtggaaatatggattacttat tgactaagttaggtgtagggaacaatcaactcagctcattaatcggtagcggcttaatcaccggtaac cctattctatacgactcacagactcaactcttgggtatacaggtaactctaccttcagtcgggaagct aaataatatgcgtgccacctacttggaaaccttatccgtaagcacaaccaggggatttgcctcggcac ttgtcccaaaagtggtgacacaggtcggttctgtgatagaagaacttgacacctcatactgtatagaa actgacttacatttatattgtacaagaatagtaacgttccctatgtcccctggtatttattcctgctt gagcggcaatacgtcggcctgtatgtactcaaagaccgaaggcgcacttactacaccatacatgacta tcaaaggttcagtcatcgccaactgcaagatgacaacatgtagatgtgtaaaccccccgggtatcata tcgcaaaactatggagaagccgtgtctctaatagataaacaatcatgcaatgttttatccttaggcgg gataactttaaggctcagtggggaattcgatgtaacttatcagaagaatatctcaatacaagattctc aagtaataataacaggcaatcttgatatctcaactgagcttgggaatgtcaacaactcgatcagtaat gctttgaataagttagaggaaagcaacagaaaactagacaaagtcaatgtcaaactgactagcacatc tgctctcattacctatatcgtgttgactatcatatctcttgtttttggtatacttagcctgattctag catgctacctaatgtacaagcaaaaggcgcaacaaaagaccttattatggcttgggaataatactcta gatcagatgagagccactacaaaaatgtga

[0368] SEQ ID NO: 8: NDV F Protein (Clone 30; 553 amino acids)

[0369] MGPRPSTKNPVPMMLTVRVALVLSCICPANSIDGRPLAAAGIWTGDKAV IYTSSQTGSI IVKLLPN

[0370] LPKDKEACAKAPLDAYNRTLTTLLTPLGDSIRRIQESVTTSGGGRQGRLIGAI IGGVALGVATAAQIT AAAALIQAKQNAANILRLKESIAATNEAVHEVTDGLSQLAVAVGKMQQFVNDQFNKTAQELDCIKIAQ QVGVELNLYLTELTTVFGPQITSPALNKLTIQALYNLAGGNMDYLLTKLGVGNNQLSSLIGSGLITGN PILYDSQTQLLGIQVTLPSVGKLNNMRATYLETLSVSTTRGFASALVPKWTQVGSVIEELDTSYCIE TDLHLYCTRIVTFPMSPGIYSCLSGNTSACMYSKTEGALTTPYMTIKGSVIANCKMTTCRCVNPPGII SQNYGEAVSLIDKQSCNVLSLGGITLRLSGEFDVTYQKNISIQDSQVIITGNLDISTELGNVNNSISN ALNKLEESNRKLDKVNVKLTSTSALITYIVLTIISLVFGILSLILACYLMYKQKAQQKTLLWLGNNTL DQMRATTKM SEQ ID NO: 9: NDV F Protein, coding sequence: (B1 Hitchner; 1698bp)

[0371] atggatcgatcccggttggcgccctccaggtgcaggatgggctccagaccttctaccaagaacccagc acctatgatgctgactatccgggtcgcgctggtactgagttgcatctgtccggcaaactccattgatg gcaggcctcttgcagctgcaggaattgtggttacaggagacaaagcagtcaacatatacacctcatcc cagacaggatcaatcatagttaagctcctcccgaatctgccaaaggataaggaggcatgtgcgaaagc ccccttggatgcatacaacaggacattgaccactttgctcaccccccttggtgactctatccgtagga tacaagagtctgtgactacatctggaggggggagacaggggcgccttataggcgccattattggcggt gtggctcttggggttgcaactgccgcacaaataacagcggccgcagctctgatacaagccaaacaaaa tgctgccaacatcctccgacttaaagagagcattgccgcaaccaatgaggctgtgcatgaggtcactg acggattatcgcaactagcagtggcagttgggaagatgcagcagttcgttaatgaccaatttaataaa acagctcaggaattagactgcatcaaaattgcacagcaagttggtgtagagctcaacctgtacctaac cgaatcgactacagtattcggaccacaaatcacttcacctgccttaaacaagctgactattcaggcac tttacaatctagctggtgggaatatggattacttattgactaagttaggtatagggaacaatcaactc agctcattaatcggtagcggcttaatcaccggtaaccctattctatacgactcacagactcaactctt gggtatacaggtaactctaccttcagtcgggaacctaaataatatgcgtgccacctacttggaaacct tatccgtaagcacaaccaggggatttgcctcggcacttgtcccaaaagtggtgacacgggtcggttct gtgatagaagaacttgacacctcatactgtatagaaactgacttagatttatattgtacaagaatagt aacgttccctatgtcccctggtatttactcctgcttgagcggcaatacatcggcctgtatgtactcaa agaccgaaggcgcacttactacaccatatatgactatcaaaggctcagtcatcgctaactgcaagatg acaacatgtagatgtgtaaaccccccgggtatcatatcgcaaaactatggagaagccgtgtctctaat agataaacaatcatgcaatgttttatccttaggcgggataactttaaggctcagtggggaattcgatg taacttatcagaagaatatctcaatacaagattctcaagtaataataacaggcaatcttgatatctca actgagcttgggaatgtcaacaactcgatcagtaatgccttgaataagttagaggaaagcaacagaaa actagacaaagtcaatgtcaaactgaccagcacatctgctctcattacctatatcgttttgactatca tatctcttgtttttggtatacttagcctgattctagcatgctacctaatgtacaagcaaaaggcgcaa caaaagaccttattatggcttgggaataataccctagatcagatgagagccactacaaaaatgtga

[0372] SEQ ID NO: 10: NDV F Protein (B1 Hitchner; 565 amino acids)

[0373] MDRSRLAPSRCRMGSRPSTKNPAPMMLTIRVALVLSCICPANSIDGRPLAAAGIWTGDKAVNIYTSS QTGSIIVKLLPNLPKDKEACAKAPLDAYNRTLTTLLTPLGDSIRRIQESVTTSGGGRQGRLIGAI IGG VALGVATAAQITAAAALIQAKQNAA ILRLKESIAATNEAVHEVTDGLSQLAVAVGKMQQFVNDQFNK TAQELDCIKIAQQVGVELNLYLTESTTVFGPQITSPALNKLTIQALYNLAGGNMDYLLTKLGIGNNQL SSLIGSGLITGNPILYDSQTQLLGIQVTLPSVGNLNNMRATYLETLSVSTTRGFASALVPKWTRVGS VIEELDTSYCIETDLDLYCTRIVTFPMSPGIYSCLSGNTSACMYSKTEGALTTPYMTIKGSVIANCKM TTCRCVNPPGIISQNYGEAVSLIDKQSCNVLSLGGITLRLSGEFDVTYQKNISIQDSQVIITGNLDIS TELGNVNNSISNALNKLEESNRKLDKVNVKLTSTSALITYIVLTI ISLVFGILSLILACYLMYKQKAQ QKTLLWLGNNTLDQMRATTKM

[0374] SEQ ID NO 1 1 : ILTV gD promoter (527 bp)

[0375] aaacagctgtactacagagtaaccgatggaagaacatcggtccagctaatgtgcctgtcgtgcacgag ccattctccggaaccttactgtcttttcgacacgtctcttatagcgagggaaaaagatatcgcgccag agttatactttacctctgatccgcaaacggcatactgcacaataactctgccgtccggcgttgttccg agattcgaatggagccttaataatgtttcactgccggaatatttgacggccacgaccgttgtttcgca taccgctggccaaagtacagtgtggaagagcagcgcgagagcaggcgaggcgtggatttctggccggg gaggcaatatatacgaatgcaccgtcctcatctcagacggcactcgcgttactacgcgaaaggagagg tgcttaacaaacacatggattgcggtggaaaacggtgctgctcaggcgcagctgtattcactcttttc tggacttgtgtcaggattatgcgggagcatatctgctttgtacgcaacgct

[0376] SEQ ID NO 12: I LTV gl promoter (264 bp)

[0377] tgactattacaatgacatgcccgccgtgatcccggtggaggagactactaaaagttctaatgccgtct ccatgcccatattcgcggcgttcgtagcctgcgcggtcgcgctcgtggggctactggtttggagcatc gtaaaatgcgcgcgtagctaatcgagcctagaataggtggtttcttcctacatgccacgcctcacgct cataatataaatcacatggaatagcataccaatgcctattcattgggacgttcgaaaagc

[0378] SEQ ID NO 13: mCMV IE promoter (1391 bp)

[0379] aactccgcccgttttatgactagaaccaatagtttttaatgccaaatgcactgaaatcccctaatttg caaagccaaacgccccctatgtgagtaatacggggactttttacccaatttcccacgcggaaagcccc ctaatacactcatatggcatatgaatcagcacggtcatgcactctaatggcggcccatagggactttc cacatagggggcgttcaccatttcccagcataggggtggtgactcaatggcctttacccaagtacatt gggtcaatgggaggtaagccaatgggtttttcccattactggcaagcacactgagtcaaatgggactt tccactgggttttgcccaagtacattgggtcaatgggaggtgagccaatgggaaaaacccattgctgc caagtacactgactcaatagggactttccaatgggtttttccattgttggcaagcatataaggtcaat gtgggtgagtcaatagggactttccattgtattctgcccagtacataaggtcaatagggggtgaatca acaggaaagtcccattggagccaagtacactgcgtcaatagggactttccattgggttttgcccagta cataaggtcaataggggatgagtcaatgggaaaaacccattggagccaagtacactgactcaataggg actttccattgggttttgcccagtacataaggtcaatagggggtgagtcaacaggaaagttccattgg agccaagtacattgagtcaatagggactttccaatgggttttgcccagtacataaggtcaatgggagg taagccaatgggtttttcccattactggcacgtatactgagtcattagggactttccaatgggttttg cccagtacataaggtcaataggggtgaatcaacaggaaagtcccattggagccaagtacactgagtca atagggactttccattgggttttgcccagtacaaaaggtcaatagggggtgagtcaatgggtttttcc cattattggcacgtacataaggtcaataggggtgagtcattgggtttttccagccaatttaattaaaa cgccatgtactttcccaccattgacgtcaatgggctattgaaactaatgcaacgtgacctttaaacgg tactttcccatagctgattaatgggaaagtaccgttctcgagccaatacacgtcaatgggaagtgaaa gggcagccaaaacgtaacaccgccccggttttcccctggaaattccatattggcacgcattctattgg ctgagctgcgttctacgtgggtataagaggcgcgaccagcgtcggtaccgtcgcagtcttcggtctga ccaccgtagaacgcagagctcctcgctgcag SEQ ID NO 14: hCMV IE promoter, from strain AD169 (301 bp)

[0380] ggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatggg cgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgtt ttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcg gtaggcgtgtacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcgcctggaga cgccatccacgctgttttgacctccatag

[0381] SEQ ID NO: 15: hCMV IE Promoter (Truncated; 360 bp)

[0382] cgcgccaggtcaattccctggcattatgcccagtacatgaccttatgggactttcctacttggcagta catctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggat agcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcac caaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtagcgt gtacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcgcctggagacgccatcc acgctgttttgacctccata

[0383] SEQ ID NO: 16: hCMV IE Promoter (Towne Strain; 1 191 bp)

[0384] gtgaataataaaatgtgtgtttgtccgaaatacgcgtttgagatttctgtcccgactaaattcatgtc gcgcgatagtggtgtttatcgccgatagagatggcgatattggaaaaatcgatatttgaaaatatggc atattgaaaatgtcgccgatgtgagtttctgtgtaactgatatcgccatttttccaaaagttgatttt tgggcatacgcgatatctggcgatacgcttatatcgtttacgggggatggcgatagacgcctttggtg acttgggcgattctgtgtgtcgcaaatatcgcagtttcgatataggtgacagacgatatgaggctata tcgccgatagaggcgacatcaagctggcacatggccaatgcatatcgatctatacattgaatcaatat tggccattagccatattattcattggttatatagcataaatcaatattggctattggccattgcatac gttgtatccatatcataatatgtacatttatattggctcatgtccaacattaccgccatgttgacatt gattattgactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttc cgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtc aataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatt tacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtc aatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggca gtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtg gatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttgg caccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtag gcgtgtacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcgcctggagacgcc atccacgctgttttgacctccatagaagacaccgg

[0385] SEQ ID NO 17: chicken β-actin promoter (692 bp)

[0386] (Note: "nnn" denotes an ambiguous sequence in highly GC-rich region. Could be 3 - 5 "g's") cgcgccggatcagatctccatggtcgaggtgagccccacgttctgcttcactctccccatctcccccc cctccccacccccaattttgtatttatttattttttaattattttgtgcagcgatgggggcggggggg ggggnnncgcgcgccaggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcgg cggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggcggcggcggcggcggccc tataaaaagcgaagcgcgcggcgggcgggagtcgctgcgcgctgccttcgccccgtgccccgctccgc cgccgcctcgcgccgcccgccccggctctgactgaccgcgttactcccacaggtgagcgggcgggacg gcccttctcctccgggctgtaattagcggcaggaaggaaatgggcggggagggccttcgtgcgtcgcc gcgccgccgtccccttctccctctccagcctcggggctgtccgcggggggacggctgccttcgggggg gacggggcagggcggggttcggcttctggcgtgtgaccggcggctctagagcctctgctaaccatgtt catgccttcttctttttcctacagctcctgggcaacgtgctggttattgtgctgtctcatcattttgg caaagaattgca

[0387] SEQ ID NO 18: FHV US-9 polyadenylation signal (55 bp)

[0388] caataaacatagcatacgttatgacatggtctaccgcgtcttatatggggacgac SEQ ID NO 19: HSV TK polyadenylation signal (370 bp)

[0389] gatccataattgattgacgggagatgggggaggctaactgaaacacggaaggagacaataccggaagg aacccgcgctatgacggcaataaaaagacagaataaaacgcacgggtgttgggtcgtttgttcataaa cgcggggttcggtcccagggctggcactctgtcgataccccaccgagaccccattggggccaatacgc ccgcgtttcttccttttccccaccccaccccccaagttcgggtgaaggcccagggctcgcagccaacg tcggggcggcaggccctgccatagccactggccccgtgggttagggacggggtcccccatggggaatg gtttatggttcgtgggggttattattttga

[0390] SEQ ID NO 20: SV40 polyadenylation signal (199 bp)

[0391] agcttcagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaat gctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagtt aacaacaacaattgcattcattttatgtttcaggttcagggggaggtgtgggaggttttttcg SEQ ID NO 21 : 484-1050-2641 -10859(mCMV IEpro-VP2-SV40pA / ILTV / HVT UL54.5 region (15,252 bp) (HVT / IBDV / ILTV / NDV 670-14 Virus)

[0392] ggcgcgccactggagaacggcatgaccgcaaaaggcgttgtagagatcgatcccacgaactctcaggc gatcgtgtcagtcgccataaacagcgacgatcgtctccaggatctgaacggttttcttctcaacgatc atcagtatatgaggaactgaacctgatatttagccgagggaaacgcaggttaaaaaccctatcaagcg attgcgattttcgcgtatctagtaaaaatagatgggcttcggtactagccttcgccgccaactctgaa tatgcccttcgtggacctcatataacatggcattgtttgttggatgcggggccggaattaagaagaac attcgaaatacgagcaaaaatttcggccctggcatgtgctgcgcgagaatcggtacttcggggagaaa gttttatcggagctttgggtagtgcagaggaaactctatcttggttgaaaatgcatgcgaccctgcac ttgattctggttaaccacgatccaatttttaagacggctggcgcggtcctagataacctccgcttaaa actagccccaatattgatgtgcagatataacacagaaaaacgatcaatggaagacatgctacggcggt catctcccgaagacatcaccgattccctaacaatgtgcctgattatgttatcgcgcattcgtcgtacc atgcgcaccgcaggaaataaatatagctatatgatagatccaatgaatcgtatgtctaattacactcc aggcgaatgtatgacaggtatattgcgatatattgacgaacatgctagaaggtgtcctgatcacatat gtaatttgtatatcacatgtacacttatgccgatgtatgtgcacgggcgatatttctattgtaattca tttttttgttagtaaactaccacaggctgtccggaaatctaagttaatgaataaagtagatggttaat actcattgcttagaattggactacttttaattctctttaatgttcgtattaaataaaaacatctttaa taaacttcagcctcttcgcttattgtagaaattgagtattcaaaatcatgttcaaagccgtcttcgga gagtgtactcgccacggtggttggaacatcactatgtctacacgtcaaatttaagcacgtcaggtctg tcgaggacaagaaatggttaactagtgtttcaattattcttataaacgttaagcattgtaagcccccc ggccgtccgcagcaacaatttactagtatgccgtgggctccgggactatcacggatgtccaattcgca catgcatataatttttctagggtctctcatttcgagaaatcttcggggatccatcagcaatgcgggct gtagtcccgattcccgtttcaaatgaaggtgctccaacacggtcttcaaagcaaccggcataccagca aacacagactgcaactccccgctgcaatgattggttataaacagtaatctgtcttctggaagtatatt tcgcccgacaatccacggcgcccccaaagttaaaaaccatccatgtgtatttgcgtcttctctgttaa aagaatattgactggcattttcccgttgaccgccagatatccaaagtacagcacgatgttgcacggac gactttgcagtcaccagccttcctttccacccccccaccaacaaaatgtttatcgtaggacccatatc cgtaataaggatgggtctggcagcaaccccataggcgcctcggcgtggtagttctcgaggccttaagc ttaaggatcccccaactccgcccgttttatgactagaaccaatagtttttaatgccaaatgcactgaa atcccctaatttgcaaagccaaacgccccctatgtgagtaatacggggactttttacccaatttccca cgcggaaagccccctaatacactcatatggcatatgaatcagcacggtcatgcactctaatggcggcc catagggactttccacatagggggcgttcaccatttcccagcataggggtggtgactcaatggccttt acccaagtacattgggtcaatgggaggtaagccaatgggtttttcccattactggcaagcacactgag tcaaatgggactttccactgggttttgcccaagtacattgggtcaatgggaggtgagccaatgggaaa aacccattgctgccaagtacactgactcaatagggactttccaatgggtttttccattgttggcaagc atataaggtcaatgtgggtgagtcaatagggactttccattgtattctgcccagtacataaggtcaat agggggtgaatcaacaggaaagtcccattggagccaagtacactgcgtcaatagggactttccattgg gttttgcccagtacataaggtcaataggggatgagtcaatgggaaaaacccattggagccaagtacac tgactcaatagggactttccattgggttttgcccagtacataaggtcaatagggggtgagtcaacagg aaagttccattggagccaagtacattgagtcaatagggactttccaatgggttttgcccagtacataa ggtcaatgggaggtaagccaatgggtttttcccattactggcacgtatactgagtcattagggacttt ccaatgggttttgcccagtacataaggtcaataggggtgaatcaacaggaaagtcccattggagccaa gtacactgagtcaatagggactttccattgggttttgcccagtacaaaaggtcaatagggggtgagtc aatgggtttttcccattattggcacgtacataaggtcaataggggtgagtcattgggtttttccagcc aatttaattaaaacgccatgtactttcccaccattgacgtcaatgggctattgaaactaatgcaacgt gacctttaaacggtactttcccatagctgattaatgggaaagtaccgttctcgagccaatacacgtca atgggaagtgaaagggcagccaaaacgtaacaccgccccggttttcccctggaaattccatattggca cgcattctattggctgagctgcgttctacgtgggtataagaggcgcgaccagcgtcggtaccgtcgca gtcttcggtctgaccaccgtagaacgcagagctcctcgctgcaggcggccgctctagaactcgtcgat cgcagcgatgacaaacctgcaagatcaaacccaacagattgttccgttcatacggagccttctgatgc caacaaccggaccggcgtccattccggacgacaccctggagaagcacactctcaggtcagagacctcg acctacaatttgactgtgggggacacagggtcagggctaattgtctttttccctggattccctggctc aattgtgggtgctcactacacactgcagagcaatgggaactacaagttcgatcagatgctcctgactg cccagaacctaccggccagctacaactactgcagactagtgagtcggagtctcacagtgaggtcaagc acactccctggtggcgtttatgcactaaacggcaccataaacgccgtgaccttccaaggaagcctgag tgaactgacagatgttagctacaatgggttgatgtctgcaacagccaacatcaacgacaaaattggga atgtcctggtaggggaaggggtcactgtcctcagcctacccacatcatatgatcttgggtatgtgagg cttggtgaccccattcccgctatagggcttgacccaaaaatggtagctacatgcgacagcagtgacag gcccagagtctacaccataactgcagccgatgattaccaattctcatcacagtaccaaccaggtgggg taacaatcacactgttctcagccaacattgatgctatcacaagcctcagcattgggggagagctcgtg tttcaaacaagcgtccaaggccttgtactgggcgccaccatctaccttataggctttgatgggactgc ggtaatcaccagagctgtggccgcagataatgggctgacggccggcaccgacaatcttatgccattca atcttgtcattccaaccaatgagataacccagccaatcacatccatcaaactggagatagtgacctcc aaaagtggtggtcaggcaggggatcagatgtcatggtcggcaagtgggagcctagcagtgacgatcca tggtggcaactatccaggggccctccgtcccgtcacactagtagcctacgaaagagtggcaacaggat ccgtcgttacggtcgctggggtgagtaacttcgagctgattccaaatcctgaactagcaaagaacctg gttacagaatacggccgatttgacccaggagccatgaactacacaaaattgatactgagtgagaggga ccgtcttggcatcaagaccgtctggccaacaagggagtacactgattttcgtgagtacttcatggagg tggccgacctcaactctcccctgaagattgcaggagcatttggcttcaaagacataatccgggctata aggaggtagatccagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtga aaaaaatgctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataa acaagttaacaacaacaattgcattcattttatgtttcaggttcagggggaggtgtgggaggtttttt cggatcctctagagtcgacggcagagtcgcagacgcccctattggacgtcaaaattgtagaggtgaag ttttcaaacgatggcgaagtaacggcgacttgcgtttccaccgtcaaatctccctatagggtagaaac taattggaaagtagacctcgtagatgtaatggatgaaatttctgggaacagtcccgccggggttttta acagtaatgagaaatggcagaaacagctgtactacagagtaaccgatggaagaacatcggtccagcta atgtgcctgtcgtgcacgagccattctccggaaccttactgtcttttcgacacgtctcttatagcgag ggaaaaagatatcgcgccagagttatactttacctctgatccgcaaacggcatactgcacaataactc tgccgtccggcgttgttccgagattcgaatggagccttaataatgtttcactgccggaatatttgacg gccacgaccgttgtttcgcataccgctggccaaagtacagtgtggaagagcagcgcgagagcaggcga ggcgtggatttctggccggggaggcaatatatacgaatgcaccgtcctcatctcagacggcactcgcg ttactacgcgaaaggagaggtgcttaacaaacacatggattgcggtggaaaacggtgctgctcaggcg cagctgtattcactcttttctggacttgtgtcaggattatgcgggagcatatctgctttgtacgcaac gctatggaccgccatttatttttgaggaatgctttttggactatcgtactgctttcttccttcgctag ccagagcaccgccgccgtcacgtacgactacattttaggccgtcgcgcgctcgacgcgctaaccatac cggcggttggcccgtataacagatacctcactagggtatcaagaggctgcgacgttgtcgagctcaac ccgatttctaacgtggacgacatgatatcggcggccaaagaaaaagagaaggggggccctttcgaggc ctccgtcgtctggttctacgtgattaagggcgacgacggcgaggacaagtactgtccaatctatagaa aagagtacagggaatgtggcgacgtacaactgctatctgaatgcgccgttcaatctgcacagatgtgg gcagtggactatgttcctagcacccttgtatcgcgaaatggcgcgggactgactatattctcccccac tgctgcgctctctggccaatacttgctgaccctgaaaatcgggagatttgcgcaaacagctctcgtaa ctctagaagttaacgatcgctgtttaaagatcgggtcgcagcttaactttttaccgtcgaaatgctgg acaacagaacagtatcagactggatttcaaggcgaacacctttatccgatcgcagacaccaatacacg acacgcggacgacgtatatcggggatacgaagatattctgcagcgctggaataatttgctgaggaaaa agaatcctagcgcgccagaccctcgtccagatagcgtcccgcaagaaattcccgctgtaaccaagaaa gcggaagggcgcaccccggacgcagaaagcagcgaaaagaaggcccctccagaagactcggaggacga catgcaggcagaggcttctggagaaaatcctgccgccctccccgaagacgacgaagtccccgaggaca ccgagcacgatgatccaaactcggatcctgactattacaatgacatgcccgccgtgatcccggtggag gagactactaaaagttctaatgccgtctccatgcccatattcgcggcgttcgtagcctgcgcggtcgc gctcgtggggctactggtttggagcatcgtaaaatgcgcgcgtagctaatcgagcctagaataggtgg tttcttcctacatgccacgcctcacgctcataatataaatcacatggaatagcataccaatgcctatt cattgggacgttcgaaaagcatggcatcgctacttggaactctggctctccttgccgcgacgctcgca cccttcggcgcgatgggaatcgtgatcactggaaatcacgtctccgccaggattgacgacgatcacat cgtgatcgtcgcgcctcgccccgaagctacaattcaactgcagctatttttcatgcctggccagagac cccacaaaccctactcaggaaccgtccgcgtcgcgtttcggtctgatataacaaaccagtgctaccag gaacttagcgaggagcgctttgaaaattgcactcatcgatcgtcttctgtttttgtcggctgtaaagt gaccgagtacacgttctccgcctcgaacagactaaccggacctccacacccgtttaagctcactatac gaaatcctcgtccgaacgacagcgggatgttctacgtaattgttcggctagacgacaccaaagaaccc attgacgtcttcgcgatccaactatcggtgtatcaattcgcgaacaccgccgcgactcgcggactcta ttccaaggcttcgtgtcgcaccttcggattacctaccgtccaacttgaggcctatctcaggaccgagg aaagttggcgcaactggcaagcgtacgttgccacggaggccacgacgaccagcgccgaggcgacaacc ccgacgcccgtcactgcaaccagcgcctccgaacttgaagcggaacactttacctttccctggctaga aaatggcgtggatcattacgaaccgacacccgcaaacgaaaattcaaacgttactgtccgtctcggga caatgagccctacgctaattggggtaaccgtggctgccgtcgtgagcgcaacgatcggcctcgtcatt gtaatttccatcgtcaccagaaacatgtgcaccccgcaccgaaaattagacacggtctcgcaagacga cgaagaacgttcccaaactagaagggaatcgcgaaaatttggacccatggttgcgtgcgaaataaaca agggggctgaccaggatagtgaacttgtggaactggttgcgattgttaacccgtctgcgctaagctcg cccgactcaataaaaatgtgattaagtctgaatgtggctctccaatcatttcgattctctaatctccc aatcctctcaaaaggggcagtatcggacacggactgggaggggcgtacacgatagttatatggtacag cagaggcctctgaacacttaggaggagaattcagccggggagagcccctgttgagtaggcttgggagc atattgcaggatgaacatgttagtgatagttctcgcctcttgtcttgcgcgcctaacttttgcgacgc gacacgtcctctttttggaaggcactcaggctgtcctcggggaagatgatcccagaaacgttccggaa gggactgtaatcaaatggacaaaagtcctgcggaacgcgtgcaagatgaaggcggccgatgtctgctc ttcgcctaactattgctttcatgatttaatttacgacggaggaaagaaagactgcccgcccgcgggac ccctgtctgcaaacctggtaattttactaaagcgcggcgaaagcttcccgggttaattaaggccctcg aggatacatccaaagaggttgagtattctctctacacttcttgttaaatggaaagtgcatttgcttgt tcttacaatcggcccgagtctcgttcacagcgcctcgttcacacttaaaccacaaatagtctacaggc tatatgggagccagactgaaactcacatatgactaatattcgggggtgttagtcacgtgtagcccatt gtgtgcatataacgatgttggacgcgtccttattcgcggtgtacttgatactatggcagcgagcatgg gatattcatcctcgtcatcgttaacatctctacgggttcagaatgtttggcatgtcgtcgatcctttg cccatcgttgcaaattacaagtccgatcgccatgaccgcgataagcctgtaccatgtggcattagggt gacatctcgatcatacattataagaccaacgtgcgagtcttccaaagacctgcacgccttcttcttcg gattgtcaacgggttcttcagaatctatgcccatatctggcgttgagaccattgtgcgtttaatgaac aataaagcggcatgccatggaaaggagggctgcagatctccattttctcacgccactatcctggacgc tgtagacgataattataccatgaatatagagggggtatgtttccactgccactgtgatgataagtttt ctccagattgttggatatctgcattttctgctgccgaacaaacttcatcgctatgcaaagagatgcgt gtgtacacgcgccggtggagtatacgggaaactaaatgttcatagaggtctttgggctatatgttatt aaataaaataattgaccagtgaacaatttgtttaatgttagtttattcaatgcattggttgcaaatat teattacttctccaatcccaggtcattctttagcgagatgatgttatgacattgctgtgaaaattact acaggatatatttttaagatgcaggagtaacaatgtgcatagtaggcgtagttatcgcagacgtgcaa cgcttcgcatttgagttaccgaagtgcccaacagtgctgcggttatggtttatgcgcacagaatccat gcatgtcctaattgaaccatccgatttttcttttaatcgcgatcgatgtttgggcaactgcgttattt cagatctaaaaaatttaccctttatgaccatcacatctctctggctcataccccgcttggataagata tcatgtagattccgccctaagaaatgcaaactaacattattgtcggttccatatacacttccatcttg tccttcgaaaataacaaactcgcgcaatagaccgtccgtacatgcatggccgatgtgtgtcaacatca ttggtctgctagatcccgatgggacgaatcgtacagtcgtcgctccagcattggcaaaaatccccaga taccctccatgcggcaaatctaaattgcgaccccgaagagactgcaccaaagtcttatcgacgcacgc tgatttttttgaacagcgggagcccattatcttcagtggagcgtagacgggcgaggctaattatgtga catagcaacactgcatgtatgtttttataaatcaataagagtacataatttattacgtatcatttccg tttgtaatatactgtatacatcatccacactattagtcagcactagcgcgcgggcgcacgttacaata gcagcgtgcccgttatctatattgtccgatatttacacataacatttcatcgacatgattaaatacct aagtactgcacacagatgtttaatgtatatcgtcatataaattatatcgctaggacagacccaaacga cctttatcccaaacagtcagatcctcttctcaagtgtcgatttctgttatggaatatgcataccctgg cccagaaattgcacgcacgagcgtagtgaatgcgtcattggttttacatttaaaggctaaatgcacaa attctttagacgacagcacatcgttaaatagcatctctagcgttcttatgaatgctaagcattggagt cctcctggtcggccacaataacagctgagtatcataccctgagctccggggttgtcgcacatagcgga ttcgtataaacataggattttccgcgaatccatcagttgcaaaaatctgttaggctccatcaacaacg ctggatttacttcagatccacgcgtaaagtaatggtgctcgaataccgtttttagagttgtcggcatt tcaaggaacaaagaattcatttcttcattgcaacgacgcgccagaaatcccaagacctctttgggtag tatgttcttgcctataaaacacggcgttccaagtgccaggaaccacgcatgtgttactgttggggcgt attcagaaataaagcggggtttatgcggcttttgaagctcggatatccaaagtatcgcttgctgatga acgagcgatgtagctgttacaaaacctcctttccatcctccagtcaacataatatttatcggcctacc tatgtccgtaataagtattggtcgggcaattattccgtatgaggtcttgcaggaataagctcttaggg acagccagcttggatatggtgcgaaacagaccttctcggcttcagaatgtcgctccgcagtctcttcg tgtcggtgcatcttagatccaccatcaatgtgtgcagcattgactcccgcccgtcgaatattcctttt gttacgatgcagtaatgagcacgatcatgggcggggcgatgacgttctatttgcatgtctgcgaacaa tttgcgtcagtcatacagctatggagtgggccatttctggccgtcaacttaaaaacgcgaaccgcaga catatgtatttgcatgcaaagacgtatcttcgtatttctgggcatcttcaaatgctctggccaatatg gcaatgaatttggattcgtttgacgccgatggtatgcagtgcaaatgtgccaatagcccacatccgaa aaagttatttgtcatacaagcaggtgttaagtagcaatcacataaaggcaccagacgcctcatggcat cataatgaatagctccttctccccactggaaccactgacaaaatctgcgagtatattccgcaaaccac attttatttctcatagaaactaccctaaatccttttaacgggaagaagaatcctagatagtgcttgaa gtcatgactgttactgctgcaataacactgtatattatttataaattccgtttgtctaggtatctgat gtaggcattccgatccctttactattgcgtcttcacgaccaaatgggaatgcgccaaaatccccacac ctcatcaccctggaggcagattgtgtattattaatatccgccgattgaagcacaaaacggtacggtac tgttcctaattctggtatagattctatggtcaaaagtctgcatatccccgacattgccatgagatcac acagtccaagtagcatgtttattgagtcactcagactgtcaacgtccctcgccgcaccaccaatcgaa aataaagtatctacgcaagttatagctccgcattttctatcgctagcagcaatcgcgacgcaaaacat aaaggccatgttgggatttgaactctctggggggcttgttatcttctgcaccgtcgcagtcgcagttt tccgaaatttatgtctaatatattttccggccgtgctccaatcggccgaaaagaatctgcgtattacc agactcattgacgggccgataaagaccataaaacaaaattcctgtgcactccctcctccagttttgcc atcgtccaagtcccgtaactttttttgcgtttcgaggagcaagcgttcgttatccctacccacacttg ttttccaccgttttcttattataagcggttgtatcgccaacgcgtcaccgcaggttgtcacatacagt gatggcatacttgaacgtgcaacaacgcgctcgctttgcaaatctaagtcattgaccatcaaatcgcg ttgagaggatagccaggcatcttttttcctagtatggtgacggtgcagccaccccaactcagttcttg taaaaaaagctattggcgggaatttatgttctgaggtgcattctatatttatgagtccatcaaatgcc attaaccagattcgtattttttcgctcgacccggcatcactatggatacaatacctttctatggccca tttcagctctcgaaccaaccacacggacaattgactaacataagtatgatctttatcacagtcgcacc catctgagttatatttatggcatccgagcgctcttactgtacggtcggatacacccatggtttttcct ttatatagtcgggttatagtctgtcgggtttggcggtagcacggagtagtttgatttttaagaatcga aaaccggcttggagagaccactgtcgaatatttgtccgtatactctacacgtgagtgttgtccattcc taggtatattcatctgttcggataccttcaattgctgttcaggcataaccttaaagcatatgttatgt tgtacatcaaaacttggtgagttatgttcgattgccgcgcataaagaatcgtacatgagcgtttctgc taacatactatctatattctcacacgcccctgcatatactgttcctattccaaattcacgttttgccc catcggctatctgctcccaaaaagttgtaatataggtgccgctgggtgcgaaattttcatcagttgta ttcctgataaactgaatcactttacataatttttgccacatatctgcgtgcagccatagtatcgaacc cgtgggctcggagacgacagtgcgtacaatgggtattttacctttccccaacaaaataatggtataca agttaggtccgtacctagaccttaatgtttccaattcttctgaatcactgcactctcgtaggggagta acggtaataatttcgtctctgagccccgttttgcgttgaaaactaatcacattagataatgtgcaatc ggtttcttttatccggatacatctaagtattatgacatcggtggtcattgtttccatcaacgaccatc ttttacgatcgcccatactactcatggacgttgtcggtgttgaaaaatcaccagaattgcaacggatc tctgggtaccatgctgctgatggaattggcggttttaattgttgtttcagtctattattgctatcttt ggcggggttgaataatgtggggggagagtgattgcaggaatccgaatgggtcaataaaacgaccgtgc tccgttctgccggcgccgatccgattgaagctatatacttcgcttctctccccacttttccaatttga tccggaaataaaacggccccggacaacagtatcgtacgatccggatccggatcctgcttgcctacaga agaatcaacatctcgccccaatattctggtcaaaactggctcgctcatggcaacgcggacgtttcccc cggtggccagtcttaatggttaatgttcttttcggcaatcttatacatcagcgggttgcgtgaatact ggtcacagttcagtcatttactacacaccagcaatacgacgacggacagtaccgtcccgacgaacgcg acgcccaaaattgctatcgcgaccgcgtccgaggcgatgtcgtacgggcggtgcggggttggatcctc ggcaaagagatcctcgtaattcggcggtgggagcggagggtaaagacgcgggtggggatctccctccg gaccgcgcgccgggcgcggttcgaaaatgctttccgcctcgctcagtgtcaacgccaagtattcgggc gggctgggggccggaatatctcccgcgacttcttctatcggcgcggaattggagtcgcggtcgtggcg cgcttctagcgtcgtcaacggaagtccattttcggggtctcccggtgggcgttcagcgtccatcgtcg tatatgctctaacacacgtctcgctatattaaaaaaaagaagagtatcggtcagtgtcgagtgtcgcc gacaatgtcgcgagttctcggcgatttaatttttggaactgctccctatgaatcccgtaactgtagcg cccgcgcagaaagccgccatcagaccaactacgtgtctgttcgatgtttgcccgccgatcgctttacc gattaaggttccggcgagaaatgacatgctcgatccaagaacaaagtttttcgcggtaaacaacaaca tagttaccgtgcgagatggagaaaccacatctcccgaattagtagaggaaagcccgcgctgtcggttt ggggacatatcgatcttttttgtgtttttcctaggacccttttgccagatcgtacaaagtcgcgtctt atgagcggacgttcttactgcagctcggtaggagtggggcagggttagatttcgtcggcgtttcggcc cccgtatgcgccgcgccaccctcttcgccgagctctttatgcgcggtgggggtgagcgcttccggagt tgcgatctccgatctcgagccgcagcccggcggtgtctctttcagtggagcgttagcgccatcatgtg gttcgtggcggtggaaaggctattatgtgttaggggagagaccacgtgatcggcatgcaaatgagcaa ggcgaacgcgtcagcgttcgcactgcgaaccaataatatatatattatactattggctttaggtgcga acgtccggctagtccaatagcggggtcgcgtttcgtaccacgtgttatagaccgccctaaactcgcac tcgggggtccggccgcgcccagacagggcggagacgtgccacaggggctttaaaacaccgcttcgggc accgttcatctcggcgcgcc

[0393] SEQ ID NO 22: 1322-48.1 hCMV IEpro-F-IE(term) / HVT US2 region (12,692 bp)

[0394] (HVT / IBDV / ILTV / NDV 670-14 Virus)

[0395] ctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgcagctcccggagacggtcacagcttg tctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcggg gctggcttaactatgcggcatcagagcagattgtactgagagtgcaccatatcgacgctctcccttat gcgactcctgcattaggaagcagcccagtagtaggttgaggccgttgagcaccgccgccgcaaggaat ggtgcatgcaaggagatggcgcccaacagtcccccggccacggggcctgccaccatacccacgccgaa acaagcgctcatgagcccgaagtggcgagcccgatcttccccatcggtgatgtcggcgatataggcgc cagcaaccgcacctgtggcgccggtgatgccggccacgatgcgtccggcgtagaggatctggctagcg atgaccctgctgattggttcgctgaccatttccggggtgcggaacggcgttaccagaaactcagaagg ttcgtccaaccaaaccgactctgacggcagtttacgagagagatgatagggtctgcttcagtaagcca gatgctacacaattaggcttgtacatattgtcgttagaacgcggctacaattaatacataaccttatg tatcatacacatacgatttaggtgacactatagaatacaagctagcttgggctgcaggtcgactctag aggatcgttaattaacgatccccgggcgagctcgaattccagactaaatgccccggcccaatttgtca agtgtgcagtcacggaggcgtcgaccgtgtccccggcattaaacaggaaagcgttaaagtttttgaat gttaggtcacaggtacaaacataaatgtttgtacaaacaggtaacaggtacaaacataaatgccccgg cataaatgtcccttacggcggatcgaaacgacattaggcatactcgggtaccattttgcattccgatc agcacggatgaaattaggcaggaatgcggtttatattatgcggcattggacaaacgatatggcattga ttggcagtttatgaatgtcttcatgttgggcgtaaacggattcctattggttcagaagacaacgacga tatatttagagagaaaaagctacccagcataggataaacacacattgagcattgagagacataggtat cggtatggatgggaaaactacacacgtgaacaccaaacgacttatatactcgagcggtgatactactg agcaagaatgcactgcatctgagccactgaatgaagactgtgatgaaaatgtgaccatcgatggaatt ggagaagaatatgcgcagttcttcatgtccccgcaatgggtcccaaatctacatcgcttgagcgagga taccaaaaaggtataccgatgtatggtttccaacagactcaattattttccctattatgaggcgttca ggcggtctttgtttgatatgtatatgctaggtcggttggggcgtcgacttaagcgatctgactgggag actattatgcatctgtcaccaacgcaaagtcggcgtctacatagaactttaagatttgtggagcgtag aattatcccatctaacagttatatacgcacatcgggccacgttccgccttcgagggcacttccgacag atacgaatttaaagatggatgaataattaaattggaaagagtaactacattaatcgagcgtcatgacg gcgtcccgtgaaaatgggaattttctactcgaaacaccgtgacatttgacagacctggaattgttatt ctgatatatagtgggtgtgtctggccggcaacatacataatgtgcatgcgaaaccactttttcagtgt acgctgacattgtgcaacacggaggggtagcatctacatacaatatatgttgattaatgattggagaa aaaactatgcagctcgccgatcatatggctaactcgccttcgtctatatggcggaccccgcgggaaaa atcgacgtaccatctgatttacaacaccagtaatgaacatgtcgcatccctgcccagatctgtgcgcc cattggcgcggatcgttgtgaatgccgccgaaacacttcaggtcggtatgagagccgggaggccgcca tcagcaggagtttggcgagaggtgtttgatagaatgatgacagccttccgtgaccacgagcctactgc gacatttaatgctgcaaatcccattagaaaaatggtcgagacagttctacagaataatgaagagcccc cgcggacgcatgctgaaatgggtaatcgccttatgaacattatgtactggtgttgcttgggacacgca ggacaatgctcgatatggcagttgtacgagacgaatcaggccattttaagtttattagatgaagtggt tatcggcacaacaaatcccttttgcaccctcgagcaatactggaagccattatgcaccgcaatcgcca acaaggggacctcatcgcttgttgaggatgccaaagtggccgagtacctggttagcatgcgcaaattg atataacataggcacgctctgatgttacagaccacaataccgcatacatttattgtaaggttgttaat aaaggtttattctatgtaagactacaatactttcgacattgcttgtatacatattaaatactttctca agttcctattacataaaatgggatctatcattacattcgttaagagtctggataattttactgtttgc cagcttcgatcttggaacgtactgtggatagtgccttacttggaatcgtgaaaatttgaaacgtccat tatttggatatcttccggttgtcccatatcccgccctggtaccgctcggataccttgcccgtatggat tcgtattgacagtcgcgcaatcggggaccaacaacgcgtgggtccacactcattcggaaattttccga tgattctgaatatttattgccgctcgttacgagtcgttggacatatctgtaatacatttcttcttctg aaggatcgctgcacatttgatctatacattggccaggatgttcaagtctcagatgttgcattctggca cagcacaactttatggcatttccgatgtaatcgtccggcagccctgggggagttctatattcgcatat tgggatggtaaggacaatagcagatctcgcaacctccagggaggctataataacgtttttaaaggatg gatttctcataaaaatctgtcgcaaattacactgagaatatcctttactagcgccgattgagagcatc gtcgtccaattttctaaatggaaagaaaacaaggcgggcaagagtgttccaaacattttcattttcgg cgaatctctcaaatcccatggcgtgcaattgattgcaaaattggcacttccgttcacgtttgtatctc caaactctaagacacttttaattgaaaaactacgttctagtgtggaaagaaacctataggcagaccat agaactatttgacaccacatatctttttgtatgtcaaactgaccatgatcgtatgttgctgaatgcac tagggcaattcgctcgcgcgactccatacattgaataattccacacgtcagctcatcggttagcaagg tccagtagttgaagtcatttatttttccccgcggctggccaaatctacctctgggaatatccaagttg tcgaatatgatcgcaccggctctggtcatggtgaaggaactgtagcataaagacgcaggtatcatagg ggtaatatttttttattcactcacatactaaaagtaacgcatattagcaccatgtatgggctatcaat tgacatttgcgtagcactacatcacgattatgtacaacataatgggacaacatatggcaagtagatgc aatttcctcacactagttgggtttatctactattgaattttcccctatctgtgatacacttgggagcc tctacaagcatattgccatcatgtacgtttttatctactgtcttaacgcccatgggaacggaggcgtc gtcgtcatgtattggacggcaacataggcagcaacacaaattgcgtttaggtggggtgcatgtggact cgataccaagcccctgcagctggggaacgtctggtggagagccgataatttgatatacgcacgccata ttactgtcgttgaagtacgccttatcttctatgttttcaaatttaggttcccaagtggacgtgagaag tgtttgtatctcacatggaatggcccaaggcattccagcccaggtgcctggtactttaatggcaaaca aacgttttggtagaggtattgattctattgcagttctgcagatatctgcagccccgagtatccacagg ctatacgatacgttatcggaggcaagcttcgcgccaggtcaattccctggcattatgcccagtacatg accttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcg gttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccacccca ttgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactcc gccccattgacgcaaatgggcggtagcgtgtacggtgggaggtctatataagcagagctcgtttagtg aaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacaccggttgcgccg ccaccatgggccccagaccttctaccaagaacccagtacctatgatgctgactgtccgagtcgcgctg gtactgagttgcatctgtccggcaaactccattgatggcaggcctcttgcggctgcaggaattgtggt tacaggagacaaagccgtcaacatatacacctcatcccagacaggatcaatcatagttaagctcctcc cgaatctgcccaaggataaggaggcatgtgcgaaagcccccttggatgcatacaacaggacattgacc actttgctcaccccccttggtgactctatccgtaggatacaagagtctgtgactacatctggaggggg gagacaggggcgccttataggcgccattattggcggtgtggctcttggggttgcaactgccgcacaaa taacagcggccgcagctctgatacaagccaaacaaaatgctgccaacatcctccgacttaaagagagc attgccgcaaccaatgaggctgtgcatgaggtcactgacggattatcgcaactagcagtggcagttgg gaagatgcagcagtttgttaatgaccaatttaataaaacagctcaggaattagactgcatcaaaattg cacagcaagttggtgtagagctcaacctgtacctaaccgaattgactacagtattcggaccacaaatc acttcacctgctttaaacaagctgactattcaggcactttacaatctagctggtggaaatatggatta cttattgactaagttaggtgtagggaacaatcaactcagctcattaatcggtagcggcttaatcaccg gtaaccctattctatacgactcacagactcaactcttgggtatacaggtaactctaccttcagtcggg aagctaaataatatgcgtgccacctacttggaaaccttatccgtaagcacaaccaggggatttgcctc ggcacttgtcccaaaagtggtgacacaggtcggttctgtgatagaagaacttgacacctcatactgta tagaaactgacttacatttatattgtacaagaatagtaacgttccctatgtcccctggtatttattcc tgcttgagcggcaatacgtcggcctgtatgtactcaaagaccgaaggcgcacttactacaccatacat gactatcaaaggttcagtcatcgccaactgcaagatgacaacatgtagatgtgtaaaccccccgggta tcatatcgcaaaactatggagaagccgtgtctctaatagataaacaatcatgcaatgttttatcctta ggcgggataactttaaggctcagtggggaattcgatgtaacttatcagaagaatatctcaatacaaga ttctcaagtaataataacaggcaatcttgatatctcaactgagcttgggaatgtcaacaactcgatca gtaatgctttgaataagttagaggaaagcaacagaaaactagacaaagtcaatgtcaaactgactagc acatctgctctcattacctatatcgtgttgactatcatatctcttgtttttggtatacttagcctgat tctagcatgctacctaatgtacaagcaaaaggcgcaacaaaagaccttattatggcttgggaataata ctctagatcagatgagagccactacaaaaatgtgaggatctctcgaggaattctagatcccacgtcac tattgtatactctatattatactctatgttatactctgtaatcctactcaataaacgtgtcacgcctg tgaaaccgtactaagtctcccgtgtcttcttatcaccatcaggtgacatcctcgcccaggctgtcaat catgccggtatcgattccagtagcaccggccccacgctgacaacccactcttgcagcgttagcagcgc ccctcttaacaagccgacccccaccagcgtcgcggttactaacactcctctccccgacctgcaactag taagcttgcctccgattctagcattacatagccggtcagtagatcctgccattcggtagcgcaaccgg ctacatcttcaaacagtctcacaataaatgcatctctcgttcctgccaatccggaaccgggcatacca ctcccgcctgccgatttaattctcacaattgggcgatgccggcggggcaaaacgaatgtggatttggc aaaccgacacaggtctgctgtacggactaatatgggcacacccacatcattcttcagatgctccatgc attgttctatgagaaagatccatagggtggaggcagcgtcacgagatcgcccaggcaatcgatcgcat tcgtctagtaaagtgacgagagttatcatgcacacacccatgcccacgccttccgaataactggagct gtggaagatcggaaacgtctttttgactgccggtctcgtactactttcgcacaggtgtatacccggac gcgtactatatattttatatcatccaacgtccgaaattacatacgtggcggcgatggaagtagatgtt gagtcttcgaaagtaagtgcctcgaatatgggtattgtctgtgaaaatatcgaaagcggtacgacggt tgcagaaccgtcgatgtcgccagatactagtaacaatagcttcgataacgaagacttccgtgggcctg aatacgatgtggagataaataccagaaaatctgctaatcttgatcgtatggaatcttcgtgccgtgaa caacgagcggcgtgcgaacttcgaaagtgttcgtgtcctacgtctgccgtgcgcatgcaatacagtat tctttcatctctcgctccgggttcagagggtcatgtatatatatgtactagatacggggacgcggacc aaaaaaaatgcatagtgaaggcagtcgttggaggaaagaatcccgggagggaagtggatattttaaaa accatctcacataaatcaattataaaattaatccatgcctataaatggaaaaatgttgtgtgtatggc aatgcgtgtatatcgttatgatcttttcacatatattgacggagtcggccctatgccccttcaacaga tgatctatattcaacgtggactactagaggcgctagcatacatacatgaaaggggcatcattcaccga gacgtaaagacggagaatatattcttggataatcacgaaaatgcagttttgggtgacttcggtgctgc atgccaactaggagattgtatagatacgccccaatgttacggttggagcggaactgtggaaacaaatt cgccggaattatctgcacttgatccgtattgcacaaaaacagatatttggagtgccggattggttcta tatgagatggcaattaaaaatgtaccattgtttagtaagcaggtgaaaagttcgggatctcagctgag atccataatacggtgcatgcaagtgcatgaactggagtttccccgcaacgattctaccaacctctgta aacatttcaaacaatatgcggttcgtgtacgaccgccttataccattcctcgagttataagaaatggg gggatgccaatggatgttgaatatgtcatttctaaaatgcttacgtttgaccaggagttcagaccttc tgctaaggaaatattgaatatgcccctatttactaaggcgccgattaacctgcttaatatcacaccct ctgacagtgtctaacggtatacaggcgggagcgggtcgtggcgtcatcatcaccacttgagaatttat attttgaattgttgattgataaattaacctgattcattgagaactgaaacgccatattggtttcttgg atatgtctacaacaattagttaaattgctatgttctactgcgagtaacatttgataagttgtaagaga cgggcgactcatgtcgaagttgacgaatataaagtacataacgtgtttagaatacccagaatccgaat agtccgcgggggcgtcttctcgcgtgagtaccaaatactgagttgaacttgaaaatgctaaatctgtg acactctttgtgtgatgattattgtcaccacttcgaagatggcttcgacattcatgatgttctggtgt ttgtttggaatcgtaatagcgcttgtttcgtccaagtctgacaacaaagaaaatctgaagaattatat cacggataagtcaaccaatattagaatacccacgccattatttgtatcaacggaaaactcttatccca caaaacatgtaatctacgatgaaaactgtggcttcgctgtactcaatcctataagtgaccccaaatat gtccttttgagccagcttctaatgggaaggcgcaaatatgatgcgacggtcgcgtggtttgttctcgg taaaatgtgtgccagattaatatatttgcgcgaattttataactgctcgacaaatgagccttttggca catgttctatgagctctcctggatggtgggacaggcgctacgtctcaaccagtttcatttctcgcgac gaattacagctggtttttgcagcgccgtcccgagaattagatggtttatatacgcgcgtagtagttgt caacggggactttactacggccgatataatgtttaatgttaaagtggcatgtgccttttcaaagactg gaatagaagatgatacattatgcaaaccctttcatttctttgccaatgcaacattgcacaatttaacc atgattagatcggtaactcttcgagcgcacgaaagccatttaaaggaatgggtggcacggagaggtgg taacgtccctgcagtgctacttgagtctaccatgtatcatgcatccaatctgcctagaaatttcaggg atttctacataaagtctccagatgattataagtataatcacctagatgggccatctgtaatgctcatc actgacagacctagtgaagatttggatgggaggctcgttcaccaaagtgacatttttactactacaag tcctataaaacaggtccggtatgaagagcatcagtcacatacaaagcagtatcctgtaaacaaaatac aagctataatttttttgatagggttaggctcgttcattggaagcatattcgtagttttggtagtatgg attatacgcagatattgcaatggagcgcggagtgggggaacgccccccagtcctcgccggtatgtgta taccaggctatgatcacgtgtgaaacttgggcggacctgtatcatatgtacaccgtccctattcgttt atagccagtacgtgttatctgcacatagaggaacatgtgtcatactgggatcgcatgcatggtatgtg tgactctaatattattctgtatcataataaaaacacagtgcatggtatatagaggatcgctggtaagc actacggtagaccaatcggctcagattgcattctttggcatcgataccgttgttaatttatatggcaa agtcttgttcatgggagatcagtatttggaggaaatatactctggaacgatggaaatactcaaatgga atcaagctaaccgctgctattctattgcgcatgcaacatattacgccgactgtcctataatcagttct acggtattcagaggatgccgggacgccgttgtttatactaggccccacagcagaattcgtaatcatgg tcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcat aaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccg ctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggt ttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcg agcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaaga acatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccat aggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacagg actataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgc ttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcaatgctcacgctgtagg tatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccga ccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactgg cagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtgg tggcctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttacctt cggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgttt gcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtct gacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcac ctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctg acagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagtt gcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaat gataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccg agcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctaga gtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacg ctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatccccca tgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtg ttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttc tgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcc cggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgt tcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgc acccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaa atgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatat tattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataa acaaataggggttccgcgcacatttccccgaaaagtgccacctgacgtctaagaaaccattattatca tgacattaacctataaaaataggcgtatcacgaggccctttcgt

[0396] SEQ ID NO 23: 228509-1 LT-435Vec6 (mCMV IEpro-VP2-SV40pA / ILTV / HVT US2 region) (141 13 bp)(HVT / IBDV / ILTV / NDV #2 Virus)

[0397] gaattccagactaaatgccccggcccaatttgtcaagtgtgcagtcacggaggcgtcgaccgtgtccc cggcattaaacaggaaagcgttaaagtttttgaatgttaggtcacaggtacaaacataaatgtttgta caaacaggtaacaggtacaaacataaatgccccggcataaatgtcccttacggcggatcgaaacgaca ttaggcatactcgggtaccattttgcattccgatcagcacggatgaaattaggcaggaatgcggttta tattatgcggcattggacaaacgatatggcattgattggcagtttatgaatgtcttcatgttgggcgt aaacggattcctattggttcagaagacaacgacgatatatttagagagaaaaagctacccagcatagg ataaacacacattgagcattgagagacataggtatcggtatggatgggaaaactacacacgtgaacac caaacgacttatatactcgagcggtgatactactgagcaagaatgcactgcatctgagccactgaatg aagactgtgatgaaaatgtgaccatcgatggaattggagaagaatatgcgcagttcttcatgtccccg caatgggtcccaaatctacatcgcttgagcgaggataccaaaaaggtataccgatgtatggtttccaa cagactcaattattttccctattatgaggcgttcaggcggtctttgtttgatatgtatatgctaggtc ggttggggcgtcgacttaagcgatctgactgggagactattatgcatctgtcaccaacgcaaagtcgg cgtctacatagaactttaagatttgtggagcgtagaattatcccatctaacagttatatacgcacatc gggccacgttccgccttcgagggcacttccgacagatacgaatttaaagatggatgaataattaaatt ggaaagagtaactacattaatcgagcgtcatgacggcgtcccgtgaaaatgggaattttctactcgaa acaccgtgacatttgacagacctggaattgttattctgatatatagtgggtgtgtctggccggcaaca tacataatgtgcatgcgaaaccactttttcagtgtacgctgacattgtgcaacacggaggggtagcat ctacatacaatatatgttgattaatgattggagaaaaaactatgcagctcgccgatcatatggctaac tcgccttcgtctatatggcggaccccgcgggaaaaatcgacgtaccatctgatttacaacaccagtaa tgaacatgtcgcatccctgcccagatctgtgcgcccattggcgcggatcgttgtgaatgccgccgaaa cacttcaggtcggtatgagagccgggaggccgccatcagcaggagtttggcgagaggtgtttgataga atgatgacagccttccgtgaccacgagcctactgcgacatttaatgctgcaaatcccattagaaaaat ggtcgagacagttctacagaataatgaagagcccccgcggacgcatgctgaaatgggtaatcgcctta tgaacattatgtactggtgttgcttgggacacgcaggacaatgctcgatatggcagttgtacgagacg aatcaggccattttaagtttattagatgaagtggttatcggcacaacaaatcccttttgcaccctcga gcaatactggaagccattatgcaccgcaatcgccaacaaggggacctcatcgcttgttgaggatgcca aagtggccgagtacctggttagcatgcgcaaattgatataacataggcacgctctgatgttacagacc acaataccgcatacatttattgtaaggttgttaataaaggtttattctatgtaagactacaatacttt cgacattgcttgtatacatattaaatactttctcaagttcctattacataaaatgggatctatcatta cattcgttaagagtctggataattttactgtttgccagcttcgatcttggaacgtactgtggatagtg ccttacttggaatcgtgaaaatttgaaacgtccattatttggatatcttccggttgtcccatatcccg ccctggtaccgctcggataccttgcccgtatggattcgtattgacagtcgcgcaatcggggaccaaca acgcgtgggtccacactcattcggaaattttccgatgattctgaatatttattgccgctcgttacgag tcgttggacatatctgtaatacatttcttcttctgaaggatcgctgcacatttgatctatacattggc caggatgttcaagtctcagatgttgcattctggcacagcacaactttatggcatttccgatgtaatcg tccggcagccctgggggagttctatattcgcatattgggatggtaaggacaatagcagatctcgcaac ctccagggaggctataataacgtttttaaaggatggatttctcataaaaatctgtcgcaaattacact gagaatatcctttactagcgccgattgagagcatcgtcgtccaattttctaaatggaaagaaaacaag gcgggcaagagtgttccaaacattttcattttcggcgaatctctcaaatcccatggcgtgcaattgat tgcaaaattggcacttccgttcacgtttgtatctccaaactctaagacacttttaattgaaaaactac gttctagtgtggaaagaaacctataggcagaccatagaactatttgacaccacatatctttttgtatg tcaaactgaccatgatcgtatgttgctgaatgcactagggcaattcgctcgcgcgactccatacattg aataattccacacgtcagctcatcggttagcaaggtccagtagttgaagtcatttatttttccccgcg gctggccaaatctacctctgggaatatccaagttgtcgaatatgatcgcaccggctctggtcatggtg aaggaactgtagcataaagacgcaggtatcataggggtaatatttttttattcactcacatactaaaa gtaacgcatattagcaccatgtatgggctatcaattgacatttgcgtagcactacatcacgattatgt acaacataatgggacaacatatggcaagtagatgcaatttcctcacactagttgggtttatctactat tgaattttcccctatctgtgatacacttgggagcctctacaagcatattgccatcatgtacgttttta tctactgtcttaacgcccatgggaacggaggcgtcgtcgtcatgtattggacggcaacataggcagca acacaaattgcgtttaggtggggtgcatgtggactcgataccaagcccctgcagctggggaacgtctg gtggagagccgataatttgatatacgcacgccatattactgtcgttgaagtacgccttatcttctatg ttttcaaatttaggttcccaagtggacgtgagaagtgtttgtatctcacatggaatggcccaaggcat tccagcccaggtgcctggtactttaatggcaaacaaacgttttggtagaggtattgattctattgcag ttctgcagatatctgcagccccgagtatccacaggctatacgatacgttatcggaggcaagctgcggc cgctctagaactagtggatcccccgggctgcagcccaatgtggaattcgcccttgcacattgttactc ctgcatcttaaaaatatatcctgtagtaattttcacagcaatgtcataacatcatctcgctaaagaat gacctgggattggagaagtaatgaatatttgcaaccaatgcattgaataaactaacattaaacgaatt cactagtggatcccccaactccgcccgttttatgactagaaccaatagtttttaatgccaaatgcact gaaatcccctaatttgcaaagccaaacgccccctatgtgagtaatacggggactttttacccaatttc ccacgcggaaagccccctaatacactcatatggcatatgaatcagcacggtcatgcactctaatggcg gcccatagggactttccacatagggggcgttcaccatttcccagcataggggtggtgactcaatggcc tttacccaagtacattgggtcaatgggaggtaagccaatgggtttttcccattactggcaagcacact gagtcaaatgggactttccactgggttttgcccaagtacattgggtcaatgggaggtgagccaatggg aaaaacccattgctgccaagtacactgactcaatagggactttccaatgggtttttccattgttggca agcatataaggtcaatgtgggtgagtcaatagggactttccattgtattctgcccagtacataaggtc aatagggggtgaatcaacaggaaagtcccattggagccaagtacactgcgtcaatagggactttccat tgggttttgcccagtacataaggtcaataggggatgagtcaatgggaaaaacccattggagccaagta cactgactcaatagggactttccattgggttttgcccagtacataaggtcaatagggggtgagtcaac aggaaagttccattggagccaagtacattgagtcaatagggactttccaatgggttttgcccagtaca taaggtcaatgggaggtaagccaatgggtttttcccattactggcacgtatactgagtcattagggac tttccaatgggttttgcccagtacataaggtcaataggggtgaatcaacaggaaagtcccattggagc caagtacactgagtcaatagggactttccattgggttttgcccagtacaaaaggtcaatagggggtga gtcaatgggtttttcccattattggcacgtacataaggtcaataggggtgagtcattgggtttttcca gccaatttaattaaaacgccatgtactttcccaccattgacgtcaatgggctattgaaactaatgcaa cgtgacctttaaacggtactttcccatagctgattaatgggaaagtaccgttctcgagccaatacacg tcaatgggaagtgaaagggcagccaaaacgtaacaccgccccggttttcccctggaaattccatattg gcacgcattctattggctgagctgcgttctacgtgggtataagaggcgcgaccagcgtcggtaccgtc gcagtcttcggtctgaccaccgtagaacgcagagctcctcgctgcaggcggccgctctagaactcgtc gatcgcagcgatgacaaacctgcaagatcaaacccaacagattgttccgttcatacggagccttctga tgccaacaaccggaccggcgtccattccggacgacaccctggagaagcacactctcaggtcagagacc tcgacctacaatttgactgtgggggacacagggtcagggctaattgtctttttccctggattccctgg ctcaattgtgggtgctcactacacactgcagagcaatgggaactacaagttcgatcagatgctcctga ctgcccagaacctaccggccagctacaactactgcagactagtgagtcggagtctcacagtgaggtca agcacactccctggtggcgtttatgcactaaacggcaccataaacgccgtgaccttccaaggaagcct gagtgaactgacagatgttagctacaatgggttgatgtctgcaacagccaacatcaacgacaaaattg ggaatgtcctggtaggggaaggggtcactgtcctcagcctacccacatcatatgatcttgggtatgtg aggcttggtgaccccattcccgctatagggcttgacccaaaaatggtagctacatgcgacagcagtga caggcccagagtctacaccataactgcagccgatgattaccaattctcatcacagtaccaaccaggtg gggtaacaatcacactgttctcagccaacattgatgctatcacaagcctcagcattgggggagagctc gtgtttcaaacaagcgtccaaggccttgtactgggcgccaccatctaccttataggctttgatgggac tgcggtaatcaccagagctgtggccgcagataatgggctgacggccggcaccgacaatcttatgccat tcaatcttgtcattccaaccaatgagataacccagccaatcacatccatcaaactggagatagtgacc tccaaaagtggtggtcaggcaggggatcagatgtcatggtcggcaagtgggagcctagcagtgacgat ccatggtggcaactatccaggggccctccgtcccgtcacactagtagcctacgaaagagtggcaacag gatccgtcgttacggtcgctggggtgagtaacttcgagctgattccaaatcctgaactagcaaagaac ctggttacagaatacggccgatttgacccaggagccatgaactacacaaaattgatactgagtgagag ggaccgtcttggcatcaagaccgtctggccaacaagggagtacactgattttcgtgagtacttcatgg aggtggccgacctcaactctcccctgaagattgcaggagcatttggcttcaaagacataatccgggct ataaggaggtaagcttcagacatgataagatacattgatgagtttggacaaaccacaactagaatgca gtgaaaaaaatgctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgca ataaacaagttaacaacaacaattgcattcattttatgtttcaggttcagggggaggtgtgggaggtt ttttcggatcctctagagtcgacggcagagtcgcagacgcccctattggacgtcaaaattgtagaggt gaagttttcaaacgatggcgaagtaacggcgacttgcgtttccaccgtcaaatctccctatagggtag aaactaattggaaagtagacctcgtagatgtaatggatgaaatttctgggaacagtcccgccggggtt tttaacagtaatgagaaatggcagaaacagctgtactacagagtaaccgatggaagaacatcggtcca gctaatgtgcctgtcgtgcacgagccattctccggaaccttactgtcttttcgacacgtctcttatag cgagggaaaaagatatcgcgccagagttatactttacctctgatccgcaaacggcatactgcacaata actctgccgtccggcgttgttccgagattcgaatggagccttaataatgtttcactgccggaatattt gacggccacgaccgttgtttcgcataccgctggccaaagtacagtgtggaagagcagcgcgagagcag gcgaggcgtggatttctggccggggaggcaatatatacgaatgcaccgtcctcatctcagacggcact cgcgttactacgcgaaaggagaggtgcttaacaaacacatggattgcggtggaaaacggtgctgctca ggcgcagctgtattcactcttttctggacttgtgtcaggattatgcgggagcatatctgctttgtacg caacgctatggaccgccatttatttttgaggaatgctttttggactatcgtactgctttcttccttcg ctagccagagcaccgccgccgtcacgtacgactacattttaggccgtcgcgcgctcgacgcgctaacc ataccggcggttggcccgtataacagatacctcactagggtatcaagaggctgcgacgttgtcgagct caacccgatttctaacgtggacgacatgatatcggcggccaaagaaaaagagaaggggggccctttcg aggcctccgtcgtctggttctacgtgattaagggcgacgacggcgaggacaagtactgtccaatctat agaaaagagtacagggaatgtggcgacgtacaactgctatctgaatgcgccgttcaatctgcacagat gtgggcagtggactatgttcctagcacccttgtatcgcgaaatggcgcgggactgactatattctccc ccactgctgcgctctctggccaatacttgctgaccctgaaaatcgggagatttgcgcaaacagctctc gtaactctagaagttaacgatcgctgtttaaagatcgggtcgcagcttaactttttaccgtcgaaatg ctggacaacagaacagtatcagactggatttcaaggcgaacacctttatccgatcgcagacaccaata cacgacacgcggacgacgtatatcggggatacgaagatattctgcagcgctggaataatttgctgagg aaaaagaatcctagcgcgccagaccctcgtccagatagcgtcccgcaagaaattcccgctgtaaccaa gaaagcggaagggcgcaccccggacgcagaaagcagcgaaaagaaggcccctccagaagactcggagg acgacatgcaggcagaggcttctggagaaaatcctgccgccctccccgaagacgacgaagtccccgag gacaccgagcacgatgatccaaactcggatcctgactattacaatgacatgcccgccgtgatcccggt ggaggagactactaaaagttctaatgccgtctccatgcccatattcgcggcgttcgtagcctgcgcgg tcgcgctcgtggggctactggtttggagcatcgtaaaatgcgcgcgtagctaatcgagcctagaatag gtggtttcttcctacatgccacgcctcacgctcataatataaatcacatggaatagcataccaatgcc tattcattgggacgttcgaaaagcatggcatcgctacttggaactctggctctccttgccgcgacgct cgcacccttcggcgcgatgggaatcgtgatcactggaaatcacgtctccgccaggattgacgacgatc acatcgtgatcgtcgcgcctcgccccgaagctacaattcaactgcagctatttttcatgcctggccag agaccccacaaaccctactcaggaaccgtccgcgtcgcgtttcggtctgatataacaaaccagtgcta ccaggaacttagcgaggagcgctttgaaaattgcactcatcgatcgtcttctgtttttgtcggctgta aagtgaccgagtacacgttctccgcctcgaacagactaaccggacctccacacccgtttaagctcact atacgaaatcctcgtccgaacgacagcgggatgttctacgtaattgttcggctagacgacaccaaaga acccattgacgtcttcgcgatccaactatcggtgtatcaattcgcgaacaccgccgcgactcgcggac tctattccaaggcttcgtgtcgcaccttcggattacctaccgtccaacttgaggcctatctcaggacc gaggaaagttggcgcaactggcaagcgtacgttgccacggaggccacgacgaccagcgccgaggcgac aaccccgacgcccgtcactgcaaccagcgcctccgaacttgaagcggaacactttacctttccctggc tagaaaatggcgtggatcattacgaaccgacacccgcaaacgaaaattcaaacgttactgtccgtetc gggacaatgagccctacgctaattggggtaaccgtggctgccgtcgtgagcgcaacgatcggcctcgt cattgtaatttccatcgtcaccagaaacatgtgcaccccgcaccgaaaattagacacggtctcgcaag acgacgaagaacgttcccaaactagaagggaatcgcgaaaatttggacccatggttgcgtgcgaaata aacaagggggctgaccaggatagtgaacttgtggaactggttgcgattgttaacccgtctgcgctaag ctcgcccgactcaataaaaatgtgattaagtctgaatgtggctctccaatcatttcgattctctaatc tcccaatcctctcaaaaggggcagtatcggacacggactgggaggggcgtacacgatagttatatggt acagcagaggcctctgaacacttaggaggagaattcagccggggagagcccctgttgagtaggcttgg gagcatattgcaggatgaacatgttagtgatagttctcgcctcttgtcttgcgcgcctaacttttgcg acgcgacacgtcctctttttggaaggcactcaggctgtcctcggggaagatgatcccagaaacgttcc ggaagggactgtaatcaaatggacaaaagtcctgcggaacgcgtgcaagatgaaggcggccgatgtct gctcttcgcctaactattgctttcatgatttaatttacgacggaggaaagaaagactgcccgcccgcg ggacccctgtctgcaaacctggtaattttactaaagcgcggcgaagcttagcttgcctccgattctag cattacatagccggtcagtagatcctgccattcggtagcgcaaccggctacatcttcaaacagtctca cgataaatgcatctctcgttcctgccaatccggaaccgggcataccactcccgcctgccgatttaatt ctcacaattgggcgatgccggcggggcaaaacgaatgtggatttggcaaaccgacacaggtctgctgt acggactaatatgggcacacccacatcattcttcagatgctccatgcattgttctatgagaaagatcc atagggtggaggcagcgtcacgagatcgcccaggcaatcgatcgcattcgtctagtaaagtgacgaga gttatcatgcacacacccatgcccacgccttccgaataactggagctgtggaagatcggaaacgtctt tttgactgccggtctcgtactactttcgcacaggtgtatacccggacgcgtactatatattttatatc atccaacgtccgaaattacatacgtggcggcgatggaagtagatgttgagtcttcgaaagtaagtgcc tcgaatatgggtattgtctgtgaaaatatcgaaagcggtacgacggttgcagaaccgtcgatgtcgcc agatactagtaacaatagcttcgataacgaagacttccgtgggcctgaatacgatgtggagataaata ccagaaaatctgctaatcttgatcgtatggaatcttcgtgccgtgaacaacgagcggcgtgcgaactt cgaaagtgttcgtgtcctacgtctgccgtgcgcatgcaatacagtattctttcatctctcgctccggg ttcagagggtcatgtatatatatgtactagatacggggacgcggaccaaaaaaaatgcatagtgaagg cagtcgttggaggaaagaatcccgggagggaagtggatattttaaaaaccatctcacataaatcaatt ataaaattaatccatgcctataaatggaaaaatgttgtgtgtatggcaatgcgtgtatatcgttatga tcttttcacatatattgacggagtcggccctatgccccttcaacagatgatctatattcaacgtggac tactagaggcgctagcatacatacatgaaaggggcatcattcaccgagacgtaaagacggagaatata ttcttggataatcacgaaaatgcagttttgggtgacttcggtgctgcatgccaactaggagattgtat agatacgccccaatgttacggttggagcggaactgtggaaacaaattcgccggaattatctgcacttg atccgtattgcacaaaaacagatatttggagtgccggattggttctatatgagatggcaattaaaaat gtaccattgtttagtaagcaggtgaaaagttcgggatctcagctgagatccataatacggtgcatgca agtgcatgaactggagtttccccgcaacgattctaccaacctctgtaaacatttcaaacaatatgcgg ttcgtgtacgaccgccttataccattcctcgagttataagaaatggggggatgccaatggatgttgaa tatgtcatttctaaaatgcttacgtttgaccaggagttcagaccttctgctaaggaaatattgaatat gcccctatttactaaggcgccgattaacctgcttaatatcacaccctctgacagtgtctaacggtata caggcgggagcgggtcgtggcgtcatcatcaccacttgagaatttatattttgaattgttgattgata aattaacctgattcattgagaactgaaacgccatattggtttcttggatatgtctacaacaattagtt aaattgctatgttctactgcgagtaacatttgataagttgtaagagacgggcgactcatgtcgaagtt gacgaatataaagtacataacgtgtttagaatacccagaatccgaatagtccgcgggggcgtcttctc gcgtgagtaccaaatactgagttgaacttgaaaatgctaaatctgtgacactctttgtgtgatgatta ttgtcaccacttcgaagatggcttcgacattcatgatgttctggtgtttgtttggaatcgtaatagcg cttgtttcgtccaagtctgacaacaaagaaaatctgaagaattatatcacggataagtcaaccaatat tagaatacccacgccattatttgtatcaacggaaaactcttatcccacaaaacatgtaatctacgatg aaaactgtggcttcgctgtactcaatcctataagtgaccccaaatatgtccttttgagccagcttcta atgggaaggcgcaaatatgatgcgacggtcgcgtggtttgttctcggtaaaatgtgtgccagattaat atatttgcgcgaattttataactgctcgacaaatgagccttttggcacatgttctatgagctctcctg gatggtgggacaggcgctacgtctcaaccagtttcatttctcgcgacgaattacagctggtttttgca gcgccgtcccgagaattagatggtttatatacgcgcgtagtagttgtcaacggggactttactacggc cgatataatgtttaatgttaaagtggcatgtgccttttcaaagactggaatagaagatgatacattat gcaaaccctttcatttctttgccaatgcaacattgcacaatttaaccatgattagatcggtaactctt cgagcgcacgaaagccatttaaaggaatgggtggcacggagaggtggtaacgtccctgcagtgctact tgagtctaccatgtatcatgcatccaatctgcctagaaatttcagggatttctacataaagtctccag atgattataagtataatcacctagatgggccatctgtaatgctcatcactgacagacctagtgaagat ttggatgggaggctcgttcaccaaagtgacatttttactactacaagtcctataaaacaggtccggta tgaagagcatcagtcacatacaaagcagtatcctgtaaacaaaatacaagctataatttttttgatag ggttaggctcgttcattggaagcatattcgtagttttggtagtatggattatacgcagatattgcaat ggagcgcggagtgggggaacgccccccagtcctcgccggtatgtgtataccaggctatgatcacgtgt gaaacttgggcggacctgtatcatatgtacaccgtccctattcgtttatagccagtacgtgttatctg cacatagaggaacatgtgtcatactgggatcgcatgcatggtatgtgtgactctaatattattctgta tcataataaaaacacagtgcatggtatatagaggatcgctggtaagcactacggtagaccaatcggct cagattgcattctttggcatcgataccgttgttaatttatatggcaaagtcttgttcatgggagatca gtatttggaggaaatatactctggaacgatggaaatactcaaatggaatcaagctaaccgctgctatt ctattgcgcatgcaacatattacgccgactgtcctataatcagttctacggtattcagaggatgccgg gacgccgttgtttatactaggccccacagcagaattc

[0398] SEQ ID NO 24: 1333-85.B6 (ILTV / Chicken β-actin pro-VP2-FHV US9pA / HVT US2 region) (13064 bp)

[0399] gaattccagactaaatgccccggcccaatttgtcaagtgtgcagtcacggaggcgtcgaccgtgtccc cggcattaaacaggaaagcgttaaagtttttgaatgttaggtcacaggtacaaacataaatgtttgta caaacaggtaacaggtacaaacataaatgccccggcataaatgtcccttacggcggatcgaaacgaca ttaggcatactcgggtaccattttgcattccgatcagcacggatgaaattaggcaggaatgcggttta tattatgcggcattggacaaacgatatggcattgattggcagtttatgaatgtcttcatgttgggcgt aaacggattcctattggttcagaagacaacgacgatatatttagagagaaaaagctacccagcatagg ataaacacacattgagcattgagagacataggtatcggtatggatgggaaaactacacacgtgaacac caaacgacttatatactcgagcggtgatactactgagcaagaatgcactgcatctgagccactgaatg aagactgtgatgaaaatgtgaccatcgatggaattggagaagaatatgcgcagttcttcatgtccccg caatgggtcccaaatctacatcgcttgagcgaggataccaaaaaggtataccgatgtatggtttccaa cagactcaattattttccctattatgaggcgttcaggcggtctttgtttgatatgtatatgctaggtc ggttggggcgtcgacttaagcgatctgactgggagactattatgcatctgtcaccaacgcaaagtcgg cgtctacatagaactttaagatttgtggagcgtagaattatcccatctaacagttatatacgcacatc gggccacgttccgccttcgagggcacttccgacagatacgaatttaaagatggatgaataattaaatt ggaaagagtaactacattaatcgagcgtcatgacggcgtcccgtgaaaatgggaattttctactcgaa acaccgtgacatttgacagacctggaattgttattctgatatatagtgggtgtgtctggccggcaaca tacataatgtgcatgcgaaaccactttttcagtgtacgctgacattgtgcaacacggaggggtagcat ctacatacaatatatgttgattaatgattggagaaaaaactatgcagctcgccgatcatatggctaac tcgccttcgtctatatggcggaccccgcgggaaaaatcgacgtaccatctgatttacaacaccagtaa tgaacatgtcgcatccctgcccagatctgtgcgcccattggcgcggatcgttgtgaatgccgccgaaa cacttcaggtcggtatgagagccgggaggccgccatcagcaggagtttggcgagaggtgtttgataga atgatgacagccttccgtgaccacgagcctactgcgacatttaatgctgcaaatcccattagaaaaat ggtcgagacagttctacagaataatgaagagcccccgcggacgcatgctgaaatgggtaatcgcctta tgaacattatgtactggtgttgcttgggacacgcaggacaatgctcgatatggcagttgtacgagacg aatcaggccattttaagtttattagatgaagtggttatcggcacaacaaatcccttttgcaccctcga gcaatactggaagccattatgcaccgcaatcgccaacaaggggacctcatcgcttgttgaggatgcca aagtggccgagtacctggttagcatgcgcaaattgatataacataggcacgctctgatgttacagacc acaataccgcatacatttattgtaaggttgttaataaaggtttattctatgtaagactacaatacttt cgacattgcttgtatacatattaaatactttctcaagttcctattacataaaatgggatctatcatta cattcgttaagagtctggataattttactgtttgccagcttcgatcttggaacgtactgtggatagtg ccttacttggaatcgtgaaaatttgaaacgtccattatttggatatcttccggttgtcccatatcccg ccctggtaccgctcggataccttgcccgtatggattcgtattgacagtcgcgcaatcggggaccaaca acgcgtgggtccacactcattcggaaattttccgatgattctgaatatttattgccgctcgttacgag tcgttggacatatctgtaatacatttcttcttctgaaggatcgctgcacatttgatctatacattggc caggatgttcaagtctcagatgttgcattctggcacagcacaactttatggcatttccgatgtaatcg tccggcagccctgggggagttctatattcgcatattgggatggtaaggacaatagcagatctcgcaac ctccagggaggctataataacgtttttaaaggatggatttctcataaaaatctgtcgcaaattacact gagaatatcctttactagcgccgattgagagcatcgtcgtccaattttctaaatggaaagaaaacaag gcgggcaagagtgttccaaacattttcattttcggcgaatctctcaaatcccatggcgtgcaattgat tgcaaaattggcacttccgttcacgtttgtatctccaaactctaagacacttttaattgaaaaactac gttctagtgtggaaagaaacctataggcagaccatagaactatttgacaccacatatctttttgtatg tcaaactgaccatgatcgtatgttgctgaatgcactagggcaattcgctcgcgcgactccatacattg aataattccacacgtcagctcatcggttagcaaggtccagtagttgaagtcatttatttttccccgcg gctggccaaatctacctctgggaatatccaagttgtcgaatatgatcgcaccggctctggtcatggtg aaggaactgtagcataaagacgcaggtatcataggggtaatatttttttattcactcacatactaaaa gtaacgcatattagcaccatgtatgggctatcaattgacatttgcgtagcactacatcacgattatgt acaacataatgggacaacatatggcaagtagatgcaatttcctcacactagttgggtttatctactat tgaattttcccctatctgtgatacacttgggagcctctacaagcatattgccatcatgtacgttttta tctactgtcttaacgcccatgggaacggaggcgtcgtcgtcatgtattggacggcaacataggcagca acacaaattgcgtttaggtggggtgcatgtggactcgataccaagcccctgcagctggggaacgtctg gtggagagccgataatttgatatacgcacgccatattactgtcgttgaagtacgccttatcttctatg ttttcaaatttaggttcccaagtggacgtgagaagtgtttgtatctcacatggaatggcccaaggcat tccagcccaggtgcctggtactttaatggcaaacaaacgttttggtagaggtattgattctattgcag ttctgcagatatctgcagccccgagtatccacaggctatacgatacgttatcggaggcaagcttaatt aagtaccgagctcgaattggcgcgcccgacggcagagtcgcagacgcccctattggacgtcaaaattg tagaggtgaagttttcaaacgatggcgaagtaacggcgacttgcgtttccaccgtcaaatctccctat agggtagaaactaattggaaagtagacctcgtagatgtaatggatgaaatttctgggaacagtcccgc cggggtttttaacagtaatgagaaatggcagaaacagctgtactacagagtaaccgatggaagaacat cggtccagctaatgtgcctgtcgtgcacgagccattctccggaaccttactgtcttttcgacacgtct cttatagcgagggaaaaagatatcgcgccagagttatactttacctctgatccgcaaacggcatactg cacaataactctgccgtccggcgttgttccgagattcgaatggagccttaataatgtttcactgccgg aatatttgacggccacgaccgttgtttcgcataccgctggccaaagtacagtgtggaagagcagcgcg agagcaggcgaggcgtggatttctggccggggaggcaatatatacgaatgcaccgtcctcatctcaga cggcactcgcgttactacgcgaaaggagaggtgcttaacaaacacatggattgcggtggaaaacggtg ctgctcaggcgcagctgtattcactcttttctggacttgtgtcaggattatgcgggagcatatctgct ttgtacgcaacgctatggaccgccatttatttttgaggaatgctttttggactatcgtactgctttct tccttcgctagccagagcaccgccgccgtcacgtacgactacattttaggccgtcgcgcgctcgacgc gctaaccataccggcggttggcccgtataacagatacctcactagggtatcaagaggctgcgacgttg tcgagctcaacccgatttctaacgtggacgacatgatatcggcggccaaagaaaaagagaaggggggc cctttcgaggcctccgtcgtctggttctacgtgattaagggcgacgacggcgaggacaagtactgtcc aatctatagaaaagagtacagggaatgtggcgacgtacaactgctatctgaatgcgccgttcaatctg cacagatgtgggcagtggactatgttcctagcacccttgtatcgcgaaatggcgcgggactgactata ttctcccccactgctgcgctctctggccaatacttgctgaccctgaaaatcgggagatttgcgcaaac agctctcgtaactctagaagttaacgatcgctgtttaaagatcgggtcgcagcttaactttttaccgt cgaaatgctggacaacagaacagtatcagactggatttcaaggcgaacacctttatccgatcgcagac accaatacacgacacgcggacgacgtatatcggggatacgaagatattctgcagcgctggaataattt gctgaggaaaaagaatcctagcgcgccagaccctcgtccagatagcgtcccgcaagaaattcccgctg taaccaagaaagcggaagggcgcaccccggacgcagaaagcagcgaaaagaaggcccctccagaagac tcggaggacgacatgcaggcagaggcttctggagaaaatcctgccgccctccccgaagacgacgaagt ccccgaggacaccgagcacgatgatccaaactcggatcctgactattacaatgacatgcccgccgtga tcccggtggaggagactactaaaagttctaatgccgtctccatgcccatattcgcggcgttcgtagcc tgcgcggtcgcgctcgtggggctactggtttggagcatcgtaaaatgcgcgcgtagctaatcgagcct agaataggtggtttcttcctacatgccacgcctcacgctcataatataaatcacatggaatagcatac caatgcctattcattgggacgttcgaaaagcatggcatcgctacttggaactctggctctccttgccg cgacgctcgcacccttcggcgcgatgggaatcgtgatcactggaaatcacgtctccgccaggattgac gacgatcacatcgtgatcgtcgcgcctcgccccgaagctacaattcaactgcagctatttttcatgcc tggccagagaccccacaaaccctactcaggaaccgtccgcgtcgcgtttcggtctgatataacaaacc agtgctaccaggaacttagcgaggagcgctttgaaaattgcactcatcgatcgtcttctgtttttgtc ggctgtaaagtgaccgagtacacgttctccgcctcgaacagactaaccggacctccacacccgtttaa gctcactatacgaaatcctcgtccgaacgacagcgggatgttctacgtaattgttcggctagacgaca ccaaagaacccattgacgtcttcgcgatccaactatcggtgtatcaattcgcgaacaccgccgcgact cgcggactctattccaaggcttcgtgtcgcaccttcggattacctaccgtccaacttgaggcctatct caggaccgaggaaagttggcgcaactggcaagcgtacgttgccacggaggccacgacgaccagcgccg aggcgacaaccccgacgcccgtcactgcaaccagcgcctccgaacttgaagcggaacactttaccttt ccctggctagaaaatggcgtggatcattacgaaccgacacccgcaaacgaaaattcaaacgttactgt ccgtctcgggacaatgagccctacgctaattggggtaaccgtggctgccgtcgtgagcgcaacgatcg gcctcgtcattgtaatttccatcgtcaccagaaacatgtgcaccccgcaccgaaaattagacacggtc tcgcaagacgacgaagaacgttcccaaactagaagggaatcgcgaaaatttggacccatggttgcgtg cgaaataaacaagggggctgaccaggatagtgaacttgtggaactggttgcgattgttaacccgtctg cgctaagctcgcccgactcaataaaaatgtgattaagtctgaatgtggctctccaatcatttcgattc tctaatctcccaatcctctcaaaaggggcagtatcggacacggactgggaggggcgtacacgatagtt atatggtacagcagaggcctctgaacacttaggaggagaattcagccggggagagcccctgttgagta ggcttgggagcatattgcaggatgaacatgttagtgatagttctcgcctcttgtcttgcgcgcctaac ttttgcgacgcgacacgtcctctttttggaaggcactcaggctgtcctcggggaagatgatcccagaa acgttccggaagggactgtaatcaaatggacaaaagtcctgcggaacgcgtgcaagatgaaggcggcc gatgtctgctcttcgcctaactattgctttcatgatttaatttacgacggaggaaagaaagactgccc gcccgcgggacccctgtctgcaaacctggtaattttactaaagcgcggcgggcgcgccggatcagatc tccatggtcgaggtgagccccacgttctgcttcactctccccatctcccccccctccccacccccaat tttgtatttatttattttttaattattttgtgcagcgatgggggcgggggggggggnnncgcgcgcca ggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcggcggcagccaatcagag cggcgcgctccgaaagtttccttttatggcgaggcggcggcggcggcggccctataaaaagcgaagcg cgcggcgggcgggagtcgctgcgcgctgccttcgccccgtgccccgctccgccgccgcctcgcgccgc ccgccccggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccggg ctgtaattagcggcaggaaggaaatgggcggggagggccttcgtgcgtcgccgcgccgccgtcccctt ctccctctccagcctcggggctgtccgcggggggacggctgccttcgggggggacggggcagggcggg gttcggcttctggcgtgtgaccggcggctctagagcctctgctaaccatgttcatgccttcttctttt tcctacagctcctgggcaacgtgctggttattgtgctgtctcatcattttggcaaagaattgcagatc tggatctatgacaaacctgcaagatcaaacccaacagattgttccgttcatacggagccttctgatgc caacaaccggaccggcgtccattccggacgacaccctggagaagcacactctcaggtcagagacctcg acctacaatttgactgtgggggacacagggtcagggctaattgtctttttccctggattccctggctc aattgtgggtgctcactacacactgcagagcaatgggaactacaagttcgatcagatgctcctgactg cccagaacctaccggccagctacaactactgcagactagtgagtcggagtctcacagtgaggtcaagc acactccctggtggcgtttatgcactaaacggcaccataaacgccgtgaccttccaaggaagcctgag tgaactgacagatgttagctacaatgggttgatgtctgcaacagccaacatcaacgacaaagttggga atgtcctggtaggggaaggggtcactgtcctcagcctacccacatcatatgatcttgggtatgtgagg cttggtgaccccattcccgctatagggcttgacccaaaaatggtagctacatgcgacagcagtgacag gcccagagtctacaccataactgcagccgatgattaccaattctcatcacagtaccaaccaggtgggg taacaatcacactgttctcagccaacattgatgctatcacaagcctcagcattgggggagagctcgtg tttcaaacaagcgtccaaggccttgtactgggcgccaccatctaccttataggctttgatgggactgc ggtaatcaccagagctgtggccgcagataatgggctgacggccggcaccgacaatcttatgccattca atcttgtcattccaaccaatgagataacccagccgatcacatccatcaaactggagatagtgacctcc aaaagtggtggtcaggcaggggatcagatgtcatggtcggcaagtgggagcctagcagtgacgatcca tggtggcaactatccaggggccctccgtcccgtcacactagtagcctacgaaagagtggcaacaggat ccgtcgttacggtcgctggggtgagtaacttcgagctgatcccaaatcctgaactagcaaagaacctg gttacagaatacggccgatttgacccaggagccatgaactacacaaaattgatactgagtgagaggga ccgtcttggcatcaagaccgtctggccaacaagggagtacactgattttcgtgagtacttcatggagg tggccgacctcaactctcccctgaagattgcaggagcatttggcttcaaagacataatccgggctata aggaggtaagatccgatctctcgattaattaacaataaacatagcatacgttatgacatggtctaccg cgtcttatatggggacgacaagcttgcctccgattctagcattacatagccggtcagtagatcctgcc attcggtagcgcaaccggctacatcttcaaacagtctcacgataaatgcatctctcgttcctgccaat ccggaaccgggcataccactcccgcctgccgatttaattctcacaattgggcgatgccggcggggcaa aacgaatgtggatttggcaaaccgacacaggtctgctgtacggactaatatgggcacacccacatcat tcttcagatgctccatgcattgttctatgagaaagatccatagggtggaggcagcgtcacgagatcgc ccaggcaatcgatcgcattcgtctagtaaagtgacgagagttatcatgcacacacccatgcccacgcc ttccgaataactggagctgtggaagatcggaaacgtctttttgactgccggtctcgtactactttcgc acaggtgtatacccggacgcgtactatatattttatatcatccaacgtccgaaattacatacgtggcg gcgatggaagtagatgttgagtcttcgaaagtaagtgcctcgaatatgggtattgtctgtgaaaatat cgaaagcggtacgacggttgcagaaccgtcgatgtcgccagatactagtaacaatagcttcgataacg aagacttccgtgggcctgaatacgatgtggagataaataccagaaaatctgctaatcttgatcgtatg gaatcttcgtgccgtgaacaacgagcggcgtgcgaacttcgaaagtgttcgtgtcctacgtctgccgt gcgcatgcaatacagtattctttcatctctcgctccgggttcagagggtcatgtatatatatgtacta gatacggggacgcggaccaaaaaaaatgcatagtgaaggcagtcgttggaggaaagaatcccgggagg gaagtggatattttaaaaaccatctcacataaatcaattataaaattaatccatgcctataaatggaa aaatgttgtgtgtatggcaatgcgtgtatatcgttatgatcttttcacatatattgacggagtcggcc ctatgccccttcaacagatgatctatattcaacgtggactactagaggcgctagcatacatacatgaa aggggcatcattcaccgagacgtaaagacggagaatatattcttggataatcacgaaaatgcagtttt gggtgacttcggtgctgcatgccaactaggagattgtatagatacgccccaatgttacggttggagcg gaactgtggaaacaaattcgccggaattatctgcacttgatccgtattgcacaaaaacagatatttgg agtgccggattggttctatatgagatggcaattaaaaatgtaccattgtttagtaagcaggtgaaaag ttcgggatctcagctgagatccataatacggtgcatgcaagtgcatgaactggagtttccccgcaacg attctaccaacctctgtaaacatttcaaacaatatgcggttcgtgtacgaccgccttataccattcct cgagttataagaaatggggggatgccaatggatgttgaatatgtcatttctaaaatgcttacgtttga ccaggagttcagaccttctgctaaggaaatattgaatatgcccctatttactaaggcgccgattaacc tgcttaatatcacaccctctgacagtgtctaacggtatacaggcgggagcgggtcgtggcgtcatcat caccacttgagaatttatattttgaattgttgattgataaattaacctgattcattgagaactgaaac gccatattggtttcttggatatgtctacaacaattagttaaattgctatgttctactgcgagtaacat ttgataagttgtaagagacgggcgactcatgtcgaagttgacgaatataaagtacataacgtgtttag aatacccagaatccgaatagtccgcgggggcgtcttctcgcgtgagtaccaaatactgagttgaactt gaaaatgctaaatctgtgacactctttgtgtgatgattattgtcaccacttcgaagatggcttcgaca ttcatgatgttctggtgtttgtttggaatcgtaatagcgcttgtttcgtccaagtctgacaacaaaga aaatctgaagaattatatcacggataagtcaaccaatattagaatacccacgccattatttgtatcaa cggaaaactcttatcccacaaaacatgtaatctacgatgaaaactgtggcttcgctgtactcaatcct ataagtgaccccaaatatgtccttttgagccagcttctaatgggaaggcgcaaatatgatgcgacggt cgcgtggtttgttctcggtaaaatgtgtgccagattaatatatttgcgcgaattttataactgctcga caaatgagccttttggcacatgttctatgagctctcctggatggtgggacaggcgctacgtctcaacc agtttcatttctcgcgacgaattacagctggtttttgcagcgccgtcccgagaattagatggtttata tacgcgcgtagtagttgtcaacggggactttactacggccgatataatgtttaatgttaaagtggcat gtgccttttcaaagactggaatagaagatgatacattatgcaaaccctttcatttctttgccaatgca acattgcacaatttaaccatgattagatcggtaactcttcgagcgcacgaaagccatttaaaggaatg ggtggcacggagaggtggtaacgtccctgcagtgctacttgagtctaccatgtatcatgcatccaatc tgcctagaaatttcagggatttctacataaagtctccagatgattataagtataatcacctagatggg ccatctgtaatgctcatcactgacagacctagtgaagatttggatgggaggctcgttcaccaaagtga catttttactactacaagtcctataaaacaggtccggtatgaagagcatcagtcacatacaaagcagt atcctgtaaacaaaatacaagctataatttttttgatagggttaggctcgttcattggaagcatattc gtagttttggtagtatggattatacgcagatattgcaatggagcgcggagtgggggaacgccccccag tcctcgccggtatgtgtataccaggctatgatcacgtgtgaaacttgggcggacctgtatcatatgta caccgtccctattcgtttatagccagtacgtgttatctgcacatagaggaacatgtgtcatactggga tcgcatgcatggtatgtgtgactctaatattattctgtatcataataaaaacacagtgcatggtatat agaggatcgctggtaagcactacggtagaccaatcggctcagattgcattctttggcatcgataccgt tgttaatttatatggcaaagtcttgttcatgggagatcagtatttggaggaaatatactctggaacga tggaaatactcaaatggaatcaagctaaccgctgctattctattgcgcatgcaacatattacgccgac tgtcctataatcagttctacggtattcagaggatgccgggacgccgttgtttatactaggccccacag cagaattc

[0400] SEQ ID NO 25: 1386-04.4#1 (ILTV / hCMV IEpro-VP2-HSV TKpA / HVT US2 region)

[0401] (13017 bp)

[0402] gaattccagactaaatgccccggcccaatttgtcaagtgtgcagtcacggaggcgtcgaccgtgtccc cggcattaaacaggaaagcgttaaagtttttgaatgttaggtcacaggtacaaacataaatgtttgta caaacaggtaacaggtacaaacataaatgccccggcataaatgtcccttacggcggatcgaaacgaca ttaggcatactcgggtaccattttgcattccgatcagcacggatgaaattaggcaggaatgcggttta tattatgcggcattggacaaacgatatggcattgattggcagtttatgaatgtcttcatgttgggcgt aaacggattcctattggttcagaagacaacgacgatatatttagagagaaaaagctacccagcatagg ataaacacacattgagcattgagagacataggtatcggtatggatgggaaaactacacacgtgaacac caaacgacttatatactcgagcggtgatactactgagcaagaatgcactgcatctgagccactgaatg aagactgtgatgaaaatgtgaccatcgatggaattggagaagaatatgcgcagttcttcatgtccccg caatgggtcccaaatctacatcgcttgagcgaggataccaaaaaggtataccgatgtatggtttccaa cagactcaattattttccctattatgaggcgttcaggcggtctttgtttgatatgtatatgctaggtc ggttggggcgtcgacttaagcgatctgactgggagactattatgcatctgtcaccaacgcaaagtcgg cgtctacatagaactttaagatttgtggagcgtagaattatcccatctaacagttatatacgcacatc gggccacgttccgccttcgagggcacttccgacagatacgaatttaaagatggatgaataattaaatt ggaaagagtaactacattaatcgagcgtcatgacggcgtcccgtgaaaatgggaattttctactcgaa acaccgtgacatttgacagacctggaattgttattctgatatatagtgggtgtgtctggccggcaaca tacataatgtgcatgcgaaaccactttttcagtgtacgctgacattgtgcaacacggaggggtagcat ctacatacaatatatgttgattaatgattggagaaaaaactatgcagctcgccgatcatatggctaac tcgccttcgtctatatggcggaccccgcgggaaaaatcgacgtaccatctgatttacaacaccagtaa tgaacatgtcgcatccctgcccagatctgtgcgcccattggcgcggatcgttgtgaatgccgccgaaa cacttcaggtcggtatgagagccgggaggccgccatcagcaggagtttggcgagaggtgtttgataga atgatgacagccttccgtgaccacgagcctactgcgacatttaatgctgcaaatcccattagaaaaat ggtcgagacagttctacagaataatgaagagcccccgcggacgcatgctgaaatgggtaatcgcctta tgaacattatgtactggtgttgcttgggacacgcaggacaatgctcgatatggcagttgtacgagacg aatcaggccattttaagtttattagatgaagtggttatcggcacaacaaatcccttttgcaccctcga gcaatactggaagccattatgcaccgcaatcgccaacaaggggacctcatcgcttgttgaggatgcca aagtggccgagtacctggttagcatgcgcaaattgatataacataggcacgctctgatgttacagacc acaataccgcatacatttattgtaaggttgttaataaaggtttattctatgtaagactacaatacttt cgacattgcttgtatacatattaaatactttctcaagttcctattacataaaatgggatctatcatta cattcgttaagagtctggataattttactgtttgccagcttcgatcttggaacgtactgtggatagtg ccttacttggaatcgtgaaaatttgaaacgtccattatttggatatcttccggttgtcccatatcccg ccctggtaccgctcggataccttgcccgtatggattcgtattgacagtcgcgcaatcggggaccaaca acgcgtgggtccacactcattcggaaattttccgatgattctgaatatttattgccgctcgttacgag tcgttggacatatctgtaatacatttcttcttctgaaggatcgctgcacatttgatctatacattggc caggatgttcaagtctcagatgttgcattctggcacagcacaactttatggcatttccgatgtaatcg tccggcagccctgggggagttctatattcgcatattgggatggtaaggacaatagcagatctcgcaac ctccagggaggctataataacgtttttaaaggatggatttctcataaaaatctgtcgcaaattacact gagaatatcctttactagcgccgattgagagcatcgtcgtccaattttctaaatggaaagaaaacaag gcgggcaagagtgttccaaacattttcattttcggcgaatctctcaaatcccatggcgtgcaattgat tgcaaaattggcacttccgttcacgtttgtatctccaaactctaagacacttttaattgaaaaactac gttctagtgtggaaagaaacctataggcagaccatagaactatttgacaccacatatctttttgtatg tcaaactgaccatgatcgtatgttgctgaatgcactagggcaattcgctcgcgcgactccatacattg aataattccacacgtcagctcatcggttagcaaggtccagtagttgaagtcatttatttttccccgcg gctggccaaatctacctctgggaatatccaagttgtcgaatatgatcgcaccggctctggtcatggtg aaggaactgtagcataaagacgcaggtatcataggggtaatatttttttattcactcacatactaaaa gtaacgcatattagcaccatgtatgggctatcaattgacatttgcgtagcactacatcacgattatgt acaacataatgggacaacatatggcaagtagatgcaatttcctcacactagttgggtttatctactat tgaattttcccctatctgtgatacacttgggagcctctacaagcatattgccatcatgtacgttttta tctactgtcttaacgcccatgggaacggaggcgtcgtcgtcatgtattggacggcaacataggcagca acacaaattgcgtttaggtggggtgcatgtggactcgataccaagcccctgcagctggggaacgtctg gtggagagccgataatttgatatacgcacgccatattactgtcgttgaagtacgccttatcttctatg ttttcaaatttaggttcccaagtggacgtgagaagtgtttgtatctcacatggaatggcccaaggcat tccagcccaggtgcctggtactttaatggcaaacaaacgttttggtagaggtattgattctattgcag ttctgcagatatctgcagccccgagtatccacaggctatacgatacgttatcggaggcaagcttgtta attaagtcgacggcagagtcgcagacgcccctattggacgtcaaaattgtagaggtgaagttttcaaa cgatggcgaagtaacggcgacttgcgtttccaccgtcaaatctccctatagggtagaaactaattgga aagtagacctcgtagatgtaatggatgaaatttctgggaacagtcccgccggggtttttaacagtaat gagaaatggcagaaacagctgtactacagagtaaccgatggaagaacatcggtccagctaatgtgcct gtcgtgcacgagccattctccggaaccttactgtcttttcgacacgtctcttatagcgagggaaaaag atatcgcgccagagttatactttacctctgatccgcaaacggcatactgcacaataactctgccgtcc ggcgttgttccgagattcgaatggagccttaataatgtttcactgccggaatatttgacggccacgac cgttgtttcgcataccgctggccaaagtacagtgtggaagagcagcgcgagagcaggcgaggcgtgga tttctggccggggaggcaatatatacgaatgcaccgtcctcatctcagacggcactcgcgttactacg cgaaaggagaggtgcttaacaaacacatggattgcggtggaaaacggtgctgctcaggcgcagctgta ttcactcttttctggacttgtgtcaggattatgcgggagcatatctgctttgtacgcaacgctatgga ccgccatttatttttgaggaatgctttttggactatcgtactgctttcttccttcgctagccagagca ccgccgccgtcacgtacgactacattttaggccgtcgcgcgctcgacgcgctaaccataccggcggtt ggcccgtataacagatacctcactagggtatcaagaggctgcgacgttgtcgagctcaacccgatttc taacgtggacgacatgatatcggcggccaaagaaaaagagaaggggggccctttcgaggcctccgtcg tctggttctacgtgattaagggcgacgacggcgaggacaagtactgtccaatctatagaaaagagtac agggaatgtggcgacgtacaactgctatctgaatgcgccgttcaatctgcacagatgtgggcagtgga ctatgttcctagcacccttgtatcgcgaaatggcgcgggactgactatattctcccccactgctgcgc tctctggccaatacttgctgaccctgaaaatcgggagatttgcgcaaacagctctcgtaactctagaa gttaacgatcgctgtttaaagatcgggtcgcagcttaactttttaccgtcgaaatgctggacaacaga acagtatcagactggatttcaaggcgaacacctttatccgatcgcagacaccaatacacgacacgcgg acgacgtatatcggggatacgaagatattctgcagcgctggaataatttgctgaggaaaaagaatcct agcgcgccagaccctcgtccagatagcgtcccgcaagaaattcccgctgtaaccaagaaagcggaagg gcgcaccccggacgcagaaagcagcgaaaagaaggcccctccagaagactcggaggacgacatgcagg cagaggcttctggagaaaatcctgccgccctccccgaagacgacgaagtccccgaggacaccgagcac gatgatccaaactcggatcctgactattacaatgacatgcccgccgtgatcccggtggaggagactac taaaagttctaatgccgtctccatgcccatattcgcggcgttcgtagcctgcgcggtcgcgctcgtgg ggctactggtttggagcatcgtaaaatgcgcgcgtagctaatcgagcctagaataggtggtttcttcc tacatgccacgcctcacgctcataatataaatcacatggaatagcataccaatgcctattcattggga cgttcgaaaagcatggcatcgctacttggaactctggctctccttgccgcgacgctcgcacccttcgg cgcgatgggaatcgtgatcactggaaatcacgtctccgccaggattgacgacgatcacatcgtgatcg tcgcgcctcgccccgaagctacaattcaactgcagctatttttcatgcctggccagagaccccacaaa ccctactcaggaaccgtccgcgtcgcgtttcggtctgatataacaaaccagtgctaccaggaacttag cgaggagcgctttgaaaattgcactcatcgatcgtcttctgtttttgtcggctgtaaagtgaccgagt acacgttctccgcctcgaacagactaaccggacctccacacccgtttaagctcactatacgaaatcct cgtccgaacgacagcgggatgttctacgtaattgttcggctagacgacaccaaagaacccattgacgt cttcgcgatccaactatcggtgtatcaattcgcgaacaccgccgcgactcgcggactctattccaagg cttcgtgtcgcaccttcggattacctaccgtccaacttgaggcctatctcaggaccgaggaaagttgg cgcaactggcaagcgtacgttgccacggaggccacgacgaccagcgccgaggcgacaaccccgacgcc cgtcactgcaaccagcgcctccgaacttgaagcggaacactttacctttccctggctagaaaatggcg tggatcattacgaaccgacacccgcaaacgaaaattcaaacgttactgtccgtctcgggacaatgagc cctacgctaattggggtaaccgtggctgccgtcgtgagcgcaacgatcggcctcgtcattgtaatttc catcgtcaccagaaacatgtgcaccccgcaccgaaaattagacacggtctcgcaagacgacgaagaac gttcccaaactagaagggaatcgcgaaaatttggacccatggttgcgtgcgaaataaacaagggggct gaccaggatagtgaacttgtggaactggttgcgattgttaacccgtctgcgctaagctcgcccgactc aataaaaatgtgattaagtctgaatgtggctctccaatcatttcgattctctaatctcccaatcctct caaaaggggcagtatcggacacggactgggaggggcgtacacgatagttatatggtacagcagaggcc tctgaacacttaggaggagaattcagccggggagagcccctgttgagtaggcttgggagcatattgca ggatgaacatgttagtgatagttctcgcctcttgtcttgcgcgcctaacttttgcgacgcgacacgtc ctctttttggaaggcactcaggctgtcctcggggaagatgatcccagaaacgttccggaagggactgt aatcaaatggacaaaagtcctgcggaacgcgtgcaagatgaaggcggccgatgtctgctcttcgccta actattgctttcatgatttaatttacgacggaggaaagaaagactgcccgcccgcgggacccctgtct gcaaacctggtaattttactaaagcgcggcgaaagcttaggtcaattccctggcattatgcccagtac atgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgat gcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccacc ccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaac tccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctcgttt agtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggcgc gccggatctatgacaaacctgcaagatcaaacccaacagattgttccgttcatacggagccttctgat gccaacaaccggaccggcgtccattccggacgacaccctggagaagcacactctcaggtcagagacct cgacctacaatttgactgtgggggacacagggtcagggctaattgtctttttccctggattccctggc tcaattgtgggtgctcactacacactgcagagcaatgggaactacaagttcgatcagatgctcctgac tgcccagaacctaccggccagctacaactactgcagactagtgagtcggagtctcacagtgaggtcaa gcacactccctggtggcgtttatgcactaaacggcaccataaacgccgtgaccttccaaggaagcctg agtgaactgacagatgttagctacaatgggttgatgtctgcaacagccaacatcaacgacaaagttgg gaatgtcctggtaggggaaggggtcactgtcctcagcctacccacatcatatgatcttgggtatgtga ggcttggtgaccccattcccgctatagggcttgacccaaaaatggtagctacatgcgacagcagtgac aggcccagagtctacaccataactgcagccgatgattaccaattctcatcacagtaccaaccaggtgg ggtaacaatcacactgttctcagccaacattgatgctatcacaagcctcagcattgggggagagctcg tgtttcaaacaagcgtccaaggccttgtactgggcgccaccatctaccttataggctttgatgggact gcggtaatcaccagagctgtggccgcagataatgggctgacggccggcaccgacaatcttatgccatt caatcttgtcattccaaccaatgagataacccagccgatcacatccatcaaactggagatagtgacct ccaaaagtggtggtcaggcaggggatcagatgtcatggtcggcaagtgggagcctagcagtgacgatc catggtggcaactatccaggggccctccgtcccgtcacactagtagcctacgaaagagtggcaacagg atccgtcgttacggtcgctggggtgagtaacttcgagctgatcccaaatcctgaactagcaaagaacc tggttacagaatacggccgatttgacccaggagccatgaactacacaaaattgatactgagtgagagg gaccgtcttggcatcaagaccgtctggccaacaagggagtacactgattttcgtgagtacttcatgga ggtggccgacctcaactctcccctgaagattgcaggagcatttggcttcaaagacataatccgggcta taaggaggtaagatccataattgattgacgggagatgggggaggctaactgaaacacggaaggagaca ataccggaaggaacccgcgctatgacggcaataaaaagacagaataaaacgcacgggtgttgggtcgt ttgttcataaacgcggggttcggtcccagggctggcactctgtcgataccccaccgagaccccattgg ggccaatacgcccgcgtttcttccttttccccaccccaccccccaagttcgggtgaaggcccagggct cgcagccaacgtcggggcggcaggccctgccatagccactggccccgtgggttagggacggggtcccc catggggaatggtttatggttcgtgggggttattattttgaagcttgcctccgattctagcattacat agccggtcagtagatcctgccattcggtagcgcaaccggctacatcttcaaacagtctcacaataaat gcatctctcgttcctgccaatccggaaccgggcataccactcccgcctgccgatttaattctcacaat tgggcgatgccggcggggcaaaacgaatgtggatttggcaaaccgacacaggtctgctgtacggacta atatgggcacacccacatcattcttcagatgctccatgcattgttctatgagaaagatccatagggtg gaggcagcgtcacgagatcgcccaggcaatcgatcgcattcgtctagtaaagtgacgagagttatcat gcacacacccatgcccacgccttccgaataactggagctgtggaagatcggaaacgtctttttgactg ccggtctcgtactactttcgcacaggtgtatacccggacgcgtactatatattttatatcatccaacg tccgaaattacatacgtggcggcgatggaagtagatgttgagtcttcgaaagtaagtgcctcgaatat gggtattgtctgtgaaaatatcgaaagcggtacgacggttgcagaaccgtcgatgtcgccagatacta gtaacaatagcttcgataacgaagacttccgtgggcctgaatacgatgtggagataaataccagaaaa tctgctaatcttgatcgtatggaatcttcgtgccgtgaacaacgagcggcgtgcgaacttcgaaagtg ttcgtgtcctacgtctgccgtgcgcatgcaatacagtattctttcatctctcgctccgggttcagagg gtcatgtatatatatgtactagatacggggacgcggaccaaaaaaaatgcatagtgaaggcagtcgtt ggaggaaagaatcccgggagggaagtggatattttaaaaaccatctcacataaatcaattataaaatt aatccatgcctataaatggaaaaatgttgtgtgtatggcaatgcgtgtatatcgttatgatcttttca catatattgacggagtcggccctatgccccttcaacagatgatctatattcaacgtggactactagag gcgctagcatacatacatgaaaggggcatcattcaccgagacgtaaagacggagaatatattcttgga taatcacgaaaatgcagttttgggtgacttcggtgctgcatgccaactaggagattgtatagatacgc cccaatgttacggttggagcggaactgtggaaacaaattcgccggaattatctgcacttgatccgtat tgcacaaaaacagatatttggagtgccggattggttctatatgagatggcaattaaaaatgtaccatt gtttagtaagcaggtgaaaagttcgggatctcagctgagatccataatacggtgcatgcaagtgcatg aactggagtttccccgcaacgattctaccaacctctgtaaacatttcaaacaatatgcggttcgtgta cgaccgccttataccattcctcgagttataagaaatggggggatgccaatggatgttgaatatgtcat ttctaaaatgcttacgtttgaccaggagttcagaccttctgctaaggaaatattgaatatgcccctat ttactaaggcgccgattaacctgcttaatatcacaccctctgacagtgtctaacggtatacaggcggg agcgggtcgtggcgtcatcatcaccacttgagaatttatattttgaattgttgattgataaattaacc tgattcattgagaactgaaacgccatattggtttcttggatatgtctacaacaattagttaaattgct atgttctactgcgagtaacatttgataagttgtaagagacgggcgactcatgtcgaagttgacgaata taaagtacataacgtgtttagaatacccagaatccgaatagtccgcgggggcgtcttctcgcgtgagt accaaatactgagttgaacttgaaaatgctaaatctgtgacactctttgtgtgatgattattgtcacc acttcgaagatggcttcgacattcatgatgttctggtgtttgtttggaatcgtaatagcgcttgtttc gtccaagtctgacaacaaagaaaatctgaagaattatatcacggataagtcaaccaatattagaatac ccacgccattatttgtatcaacggaaaactcttatcccacaaaacatgtaatctacgatgaaaactgt ggcttcgctgtactcaatcctataagtgaccccaaatatgtccttttgagccagcttctaatgggaag gcgcaaatatgatgcgacggtcgcgtggtttgttctcggtaaaatgtgtgccagattaatatatttgc gcgaattttataactgctcgacaaatgagccttttggcacatgttctatgagctctcctggatggtgg gacaggcgctacgtctcaaccagtttcatttctcgcgacgaattacagctggtttttgcagcgccgtc ccgagaattagatggtttatatacgcgcgtagtagttgtcaacggggactttactacggccgatataa tgtttaatgttaaagtggcatgtgccttttcaaagactggaatagaagatgatacattatgcaaaccc tttcatttctttgccaatgcaacattgcacaatttaaccatgattagatcggtaactcttcgagcgca cgaaagccatttaaaggaatgggtggcacggagaggtggtaacgtccctgcagtgctacttgagtcta ccatgtatcatgcatccaatctgcctagaaatttcagggatttctacataaagtctccagatgattat aagtataatcacctagatgggccatctgtaatgctcatcactgacagacctagtgaagatttggatgg gaggctcgttcaccaaagtgacatttttactactacaagtcctataaaacaggtccggtatgaagagc atcagtcacatacaaagcagtatcctgtaaacaaaatacaagctataatttttttgatagggttaggc tcgttcattggaagcatattcgtagttttggtagtatggattatacgcagatattgcaatggagcgcg gagtgggggaacgccccccagtcctcgccggtatgtgtataccaggctatgatcacgtgtgaaacttg ggcggacctgtatcatatgtacaccgtccctattcgtttatagccagtacgtgttatctgcacataga ggaacatgtgtcatactgggatcgcatgcatggtatgtgtgactctaatattattctgtatcataata aaaacacagtgcatggtatatagaggatcgctggtaagcactacggtagaccaatcggctcagattgc attctttggcatcgataccgttgttaatttatatggcaaagtcttgttcatgggagatcagtatttgg aggaaatatactctggaacgatggaaatactcaaatggaatcaagctaaccgctgctattctattgcg catgcaacatattacgccgactgtcctataatcagttctacggtattcagaggatgccgggacgccgt tgtttatactaggccccacagcagaattc

[0403] SEQ ID NO 26: 654-45:325341 JE-F / 1C1 (HVT / IBDV / ILT / NDV #2 virus)

[0404] HCMV lEpro-F-IEpA / HVT UL54.5 region (11,017 bp)

[0405] ggcgcgccactggagaacggcatgaccgcaaaaggcgttgtagagatcgatcccacgaactctcaggc gatcgtgtcagtcgccataaacagcgacgatcgtctccaggatctgaacggttttcttctcaacgatc atcagtatatgaggaactgaacctgatatttagccgagggaaacgcaggttaaaaaccctatcaagcg attgcgattttcgcgtatctagtaaaaatagatgggcttcggtactagccttcgccgccaactctgaa tatgcccttcgtggacctcatataacatggcattgtttgttggatgcggggccggaattaagaagaac attcgaaatacgagcaaaaatttcggccctggcatgtgctgcgcgagaatcggtacttcggggagaaa gttttatcggagctttgggtagtgcagaggaaactctatcttggttgaaaatgcatgcgaccctgcac ttgattctggttaaccacgatccaatttttaagacggctggcgcggtcctagataacctccgcttaaa actagccccaatattgatgtgcagatataacacagaaaaacgatcaatggaagacatgctacggcggt catctcccgaagacatcaccgattccctaacaatgtgcctgattatgttatcgcgcattcgtcgtacc atgcgcaccgcaggaaataaatatagctatatgatagatccaatgaatcgtatgtctaattacactcc aggcgaatgtatgacaggtatattgcgatatattgacgaacatgctagaaggtgtcctgatcacatat gtaatttgtatatcacatgtacacttatgccgatgtatgtgcacgggcgatatttctattgtaattca tttttttgttagtaaactaccacaggctgtccggaaatctaagttaatgaataaagtagatggttaat actcattgcttagaattggactacttttaattctctttaatgttcgtattaaataaaaacatctttaa taaacttcagcctcttcgcttattgtagaaattgagtattcaaaatcatgttcaaagccgtcttcgga gagtgtactcgccacggtggttggaacatcactatgtctacacgtcaaatttaagcacgtcaggtctg tcgaggacaagaaatggttaactagtgtttcaattattcttataaacgttaagcattgtaagcccccc ggccgtccgcagcaacaatttactagtatgccgtgggctccgggactatcacggatgtccaattcgca catgcatataatttttctagggtctctcatttcgagaaatcttcggggatccatcagcaatgcgggct gtagtcccgattcccgtttcaaatgaaggtgctccaacacggtcttcaaagcaaccggcataccagca aacacagactgcaactccccgctgcaatgattggttataaacagtaatctgtcttctggaagtatatt tcgcccgacaatccacggcgcccccaaagttaaaaaccatccatgtgtatttgcgtcttctctgttaa aagaatattgactggcattttcccgttgaccgccagatatccaaagtacagcacgatgttgcacggac gactttgcagtcaccagccttcctttccacccccccaccaacaaaatgtttatcgtaggacccatatc cgtaataaggatgggtctggcagcaaccccataggcgcctcggcgtggtagttctcgaggccttaatt aagtaccgagctcgaattggcgcgccaggtcaattccctggcattatgcccagtacatgaccttatgg gactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggca gtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtca atgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattg acgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctcgtttagtgaaccgtca gatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggcgcgccggatccatg ggccccagaccttctaccaagaacccagtacctatgatgctgactgtccgagtcgcgctggtactgag ttgcatctgtccggcaaactccattgatggcaggcctcttgcggctgcaggaattgtggttacaggag acaaagccgtcaacatatacacctcatcccagacaggatcaatcatagttaagctcctcccgaatctg cccaaggataaggaggcatgtgcgaaagcccccttggatgcatacaacaggacattgaccactttgct caccccccttggtgactctatccgtaggatacaagagtctgtgactacatctggaggggggagacagg ggcgccttataggcgccattattggcggtgtggctcttggggttgcaactgccgcacaaataacagcg gccgcagctctgatacaagccaaacaaaatgctgccaacatcctccgacttaaagagagcattgccgc aaccaatgaggctgtgcatgaggtcactgacggattatcgcaactagcagtggcagttgggaagatgc agcagtttgttaatgaccaatttaataaaacagctcaggaattagactgcatcaaaattgcacagcaa gttggtgtagagctcaacctgtacctaaccgaattgactacagtattcggaccacaaatcacttcacc tgctttaaacaagctgactattcaggcactttacaatctagctggtggaaatatggattacttattga ctaagttaggtgtagggaacaatcaactcagctcattaatcggtagcggcttaatcaccggtaaccct attctatacgactcacagactcaactcttgggtatacaggtaactctaccttcagtcgggaacctaaa taatatgcgtgccacctacttggaaaccttatccgtaagcacaaccaggggatttgcctcggcacttg tcccaaaagtggtgacacaggtcggttctgtgatagaagaacttgacacctcatactgtatagaaact gacttagatttatattgtacaagaatagtaacgttccctatgtcccctggtatttattcctgcttgag cggcaatacgtcggcctgtatgtactcaaagaccgaaggcgcacttactacaccatacatgactatca aaggttcagtcatcgccaactgcaagatgacaacatgtagatgtgtaaaccccccgggtatcatatcg caaaactatggagaagccgtgtctctaatagataaacaatcatgcaatgttttatccttaggcgggat aactttaaggctcagtggggaattcgatgtaacttatcagaagaatatctcaatacaagattctcaag taataataacaggcaatcttgatatctcaactgagcttgggaatgtcaacaactcgatcagtaatgct ttgaataagttagaggaaagcaacagaaaactagacaaagtcaatgtcaaactgactagcacatctgc tctcattacctatatcgttttgactatcatatctcttgtttttggtatacttagcccgattctagcat gctacctaatgtacaagcaaaaggcgcaacaaaagaccttattatggcttgggaataatactctagat cagatgagagccactacaaaaatgtgaggatctctcgaggaattctagatcccacgtcactattgtat actctatattatactctatgttatactctgtaatcctactcaataaacgtgtcacgcctgtgaaaccg tactaagtctcccgtgtcttcttatcaccatcaggtgacatcctcgcccaggctgtcaatcatgccgg tatcgattccagtagcaccggccccacgctgacaacccactcttgcagcgttagcagcgcccctctta acaagccgacccccaccagcgtcgcggttactaacactcctctcccctcgaggatacatccaaagagg ttgagtattctctctacacttcttgttaaatggaaagtgcatttgcttgttcttacaatcggcccgag tctcgttcacagcgcctcgttcacacttaaaccacaaatagtctacaggctatatgggagccagactg aaactcacatatgactaatattcgggggtgttagtcacgtgtagcccattgtgtgcatataacgatgt tggacgcgtccttattcgcggtgtacttgatactatggcagcgagcatgggatattcatcctcgtcat cgttaacatctctacgggttcagaatgtttggcatgtcgtcgatcctttgcccatcgttgcaaattac aagtccgatcgccatgaccgcgataagcctgtaccatgtggcattagggtgacatctcgatcatacat tataagaccaacgtgcgagtcttccaaagacctgcacgccttcttcttcggattgtcaacgggttctt cagaatctatgcccatatctggcgttgagaccattgtgcgtttaatgaacaataaagcggcatgccat ggaaaggagggctgcagatctccattttctcacgccactatcctggacgctgtagacgataattatac catgaatatagagggggtatgtttccactgccactgtgatgataagttttctccagattgttggatat ctgcattttctgctgccgaacaaacttcatcgctatgcaaagagatgcgtgtgtacacgcgccgttga gtatacgggaaactaaatgttcatagaggtctttgggctatatgttattaaataaaataattgaccag tgaacaatttgtttaatgttagtttattcaatgcattggttgcaaatatteattacttctccaatccc aggtcattctttagcgagatgatgttatgacattgctgtgaaaattactacaggatatatttttaaga tgcaggagtaacaatgtgcatagtaggcgtagttatcgcagacgtgcaacgcttcgcatttgagttac cgaagtgcccaacagtgctgcggttatggtttatgcgcacagaatccatgcatgtcctaattgaacca tccgatttttcttttaatcgcgatcgttgtttgggcaactgcgttatttcagatctaaaaaatttacc ctttatgaccatcacatctctctggctcataccccgcttggataagatatcatgtagattccgcccta agaaatgcaaactaacattattgtcggttccatatacacttccatcttgtccttcgaaaataacaaac tcgcgcaatagaccgtccgtacatgcatggccgatgtgtgtcaacatcattggtctgctagatcccga tgggacgaatcgtacagtcgtcgctccagcattggcaaaaatccccagataccctccatgcggcaaat ctaaattgcgaccccgaagagactgcaccaaagtcttatcgacgcacgctgatttttttgaacagcgg gagcccattatcttcagtggagcgtagacgggcgaggctaattatgtgacatagcaacactgcatgta tgtttttataaatcaataagagtacataatttattacgtatcatttccgtttgtaatatactgtatac atcatccacactattagtcagcactagcgcgcgggcgcacgttacaatagcagcgtgcccgttatcta tattgtccgatatttacacataacatttcatcgacatgattaaatacctaagtactgcacacagatgt ttaatgtatatcgtcatataaattatatcgctaggacagacccaaacgacctttatcccaaacagtca gatcctcttctcaagtgtcgatttctgttatggaatatgcataccctggcccagaaattgcacgcacg agcgtagtgaatgcgtcattggttttacatttaaaggctaaatgcacaaattctttagacgacagcac atcgttaaatagcatctctagcgttcttatgaatgctaagcattggagtcctcctggtcggccacaat aacagctgagtatcataccctgagctccggggttgtcgcacatagcggattcgtataaacataggatt ttccgcgaatccatcagttgcaaaaatctgttaggctccatcaacaacgctggatttacttcagatcc acgcgtaaagtaatggtgctcgaataccgtttttagagttgtcggcatttcaaggaacaaagaattca tttcttcattgcaacgacgcgccagaaatcccaagacctctttgggtagtatgttcttgcctataaaa cacggcgttccaagtgccaggaaccacgcatgtgttactgttggggcgtattcagaaataaagcgggg tttatgcggcttttgaagctcggatatccaaagtatcgcttgctgatgaacgagcgatgtagctgtta caaaacctcctttccatcctccagtcaacataatatttatcggcctacctatgtccgtaataagtatt ggtcgggcaattattccgtatgaggtcttgcaggaataagctcttagggacagccagcttggatatgg tgcgaaacagaccttctcggcttcagaatgtcgctccgcagtctcttcgtgtcggtgcatcttagate caccatcaatgtgtgcagcattgactcccgcccgtcgaatattccttttgttacgatgcagtaatgag cacgatcatgggcggggcgatgacgttctatttgcatgtctgcgaacaatttgcgtcagtcatacagc tatggagtgggccatttctggccgtcaacttaaaaacgcgaaccgcagacatatgtatttgcatgcaa agacgtatcttcgtatttctgggcatcttcaaatgctctggccaatatggcaatgaatttggattcgt ttgacgccgatggtatgcagtgcaaatgtgccaatagcccacatccgaaaaagttatttgtcatacaa gcaggtgttaagtagcaatcacataaaggcaccagacgcctcatggcatcataatgaatagctccttc tccccactggaaccactgacaaaatctgcgagtatattccgcaaaccacattttatttctcatagaaa ctaccctaaatccttttaacgggaagaagaatcctagatagtgcttgaagtcatgactgttactgctg caataacactgtatattatttataaattccgtttgtctaggtatctgatgtaggcattccgatccctt tactattgcgtcttcacgaccaaatgggaatgcgccaaaatccccacacctcatcaccctggaggcag attgtgtattattaatatccgccgattgaagcacaaaacggtacggtactgttcctaattctggtata gattctatggtcaaaagtctgcatatccccgacattgccatgagatcacacagtccaagtagcatgtt tattgagtcactcagactgtcaacgtccctcgccgcaccaccaatcgaaaataaagtatctacgcaag ttatagctccgcattttctatcgctagcagcaatcgcgacgcaaaacataaaggccatgttgggattt gaactctctggggggcttgttatcttctgcaccgtcgcagtcgcagttttccgaaatttatgtctaat atattttccggccgtgctccaatcggccgaaaagaatctgcgtattaccagactcattgacgggccga taaagaccataaaacaaaattcctgtgcactccctcctccagttttgccatcgtccaagtcccgtaac tttttttgcgtttcgaggagcaagcgttcgttatccctacccacacttgttttccaccgttttcttat tataagcggttgtatcgccaacgcgtcaccgcaggttgtcacatacagtgatggcatacttgaacgtg caacaacgcgctcgctttgcaaatctaagtcattgaccatcaaatcgcgttgagaggatagccaggca tcttttttcctagtatggtgacggtgcagccaccccaactcagttcttgtaaaaaaagctattggcgg gaatttatgttctgaggtgcattctatatttatgagtccatcaaatgccattaaccagattcgtattt tttcgctcgacccggcatcactatggatacaatacctttctatggcccatttcagctctcgaaccaac cacacggacaattgactaacataagtatgatctttatcacagtcgcacccatctgagttatatttatg gcatccgagcgctcttactgtacggtcggatacacccatggtttttcctttatatagtcgggttatag tctgtcgggtttggcggtagcacggagtagtttgatttttaagaatcgaaaaccggcttggagagacc actgtcgaatatttgtccgtatactctacacgtgagtgttgtccattcctaggtatattcatctgttc ggataccttcaattgctgttcaggcataaccttaaagcatatgttatgttgtacatcaaaacttggtg agttatgttcgattgccgcgcataaagaatcgtacatgagcgtttctgctaacatactatctatattc tcacacgcccctgcatatactgttcctattccaaattcacgttttgccccatcggctatctgctccca aaaagttgtaatataggtgccgctgggtgcgaaattttcatcagttgtattcctgataaactgaatca ctttacataatttttgccacatatctgcgtgcagccatagtatcgaacccgtgggctcggagacgaca gtgcgtacaatgggtattttacctttccccaacaaaataatggtatacaagttaggtccgtacctaga ccttaatgtttccaattcttctgaatcactgcactctcgtaggggagtaacggtaataatttcgtctc tgagccccgttttgcgttgaaaactaatcacattagataatgtgcaatcggtttcttttatccggata catctaagtattatgacatcggtggtcattgtttccatcaacgaccatcttttacgatcgcccatact actcatggacgttgtcggtgttgaaaaatcaccagaattgcaacggatctctgggtaccatgctgctg atggaattggcggttttaattgttgtttcagtctattattgctatctttggcggggttgaataatgtg gggggagagtgattgcaggaatccgaatgggtcaataaaacgaccgtgctccgttctgccggcgccga tccgattgaagctatatacttcgcttctctccccacttttccaatttgatccggaaataaaacggccc cggacaacagtatcgtacgatccggatccggatcctgcttgcctacagaagaatcaacatctcgcccc aatattctggtcaaaactggctcgctcatggcaacgcggacgtttcccccggtggccagtcttaatgg ttaatgttcttttcggcaatcttatacatcagcgggttgcgtgaatactggtcacagttcagtcattt actacacaccagcaatacgacgacggacagtaccgtcccgacgaacgcgacgcccaaaattgctatcg cgaccgcgtccgaggcgatgtcgtacgggcggtgcggggttggatcctcggcaaagagatcctcgtaa ttcggcggtgggagcggagggtaaagacgcgggtggggatctccctccggaccgcgcgccgggcgcgg ttcgaaaatgctttccgcctcgctcagtgtcaacgccaagtattcgggcgggctgggggccggaatat ctcccgcgacttcttctatcggcgcggaattggagtcgcggtcgtggcgcgcttctagcgtcgtcaac ggaagtccattttcggggtctcccggtgggcgttcagcgtccatcgtcgtatatgctctaacacacgt ctcgctatattaaaaaaaagaagagtatcggtcagtgtcgagtgtcgccgacaatgtcgcgagttctc ggcgatttaatttttggaactgctccctatgaatcccgtaactgtagcgcccgcgcagaaagccgcca tcagaccaactacgtgtctgttcgatgtttgcccgccgatcgctttaccgattaaggttccggcgaga aatgacatgctcgatccaagaacaaagtttttcgcggtaaacaacaacatagttaccgtgcgagatgg agaaaccacatctcccgaattagtagaggaaagcccgcgctgtcggtttggggacatatcgatctttt ttgtgtttttcctaggacccttttgccagatcgtacaaagtcgcgtcttatgagcggacgttcttact gcagctcggtaggagtggggcagggttagatttcgtcggcgtttcggcccccgtatgcgccgcgccac cctcttcgccgagctctttatgcgcggtgggggtgagcgcttccggagttgcgatctccgatctcgag ccgcagcccggcggtgtctctttcagtggagcgttagcgccatcatgtggttcgtggcggtggaaagg ctattatgtgttaggggagagaccacgtgatcggcatgcaaatgagcaaggcgaacgcgtcagcgttc gcactgcgaaccaataatatatatattatactattggctttaggtgcgaacgtccggctagtccaata gcggggtcgcgtttcgtaccacgtgttatagaccgccctaaactcgcactcgggggtccggccgcgcc cagacagggcggagacgtgccacaggggctttaaaacaccgcttcgggcaccgttcatctcggcgcgc c

[0406] SEQ ID NO 27: VP2 / 1 C1#8 (HVT / IBDV / ILT / NDV # 3 virus)

[0407] MCMV IEpro-VP2-SV40pA / HVT UL54.5 region (1 1 ,665 bp)

[0408] ggcgcgccactggagaacggcatgaccgcaaaaggcgttgtagagatcgatcccacgaactctcaggc gatcgtgtcagtcgccataaacagcgacgatcgtctccaggatctgaacggttttcttctcaacgatc atcagtatatgaggaactgaacctgatatttagccgagggaaacgcaggttaaaaaccctatcaagcg attgcgattttcgcgtatctagtaaaaatagatgggcttcggtactagccttcgccgccaactctgaa tatgcccttcgtggacctcatataacatggcattgtttgttggatgcggggccggaattaagaagaac attcgaaatacgagcaaaaatttcggccctggcatgtgctgcgcgagaatcggtacttcggggagaaa gttttatcggagctttgggtagtgcagaggaaactctatcttggttgaaaatgcatgcgaccctgcac ttgattctggttaaccacgatccaatttttaagacggctggcgcggtcctagataacctccgcttaaa actagccccaatattgatgtgcagatataacacagaaaaacgatcaatggaagacatgctacggcggt catctcccgaagacatcaccgattccctaacaatgtgcctgattatgttatcgcgcattcgtcgtacc atgcgcaccgcaggaaataaatatagctatatgatagatccaatgaatcgtatgtctaattacactcc aggcgaatgtatgacaggtatattgcgatatattgacgaacatgctagaaggtgtcctgatcacatat gtaatttgtatatcacatgtacacttatgccgatgtatgtgcacgggcgatatttctattgtaattca tttttttgttagtaaactaccacaggctgtccggaaatctaagttaatgaataaagtagatggttaat actcattgcttagaattggactacttttaattctctttaatgttcgtattaaataaaaacatctttaa taaacttcagcctcttcgcttattgtagaaattgagtattcaaaatcatgttcaaagccgtcttcgga gagtgtactcgccacggtggttggaacatcactatgtctacacgtcaaatttaagcacgtcaggtctg tcgaggacaagaaatggttaactagtgtttcaattattcttataaacgttaagcattgtaagcccccc ggccgtccgcagcaacaatttactagtatgccgtgggctccgggactatcacggatgtccaattcgca catgcatataatttttctagggtctctcatttcgagaaatcttcggggatccatcagcaatgcgggct gtagtcccgattcccgtttcaaatgaaggtgctccaacacggtcttcaaagcaaccggcataccagca aacacagactgcaactccccgctgcaatgattggttataaacagtaatctgtcttctggaagtatatt tcgcccgacaatccacggcgcccccaaagttaaaaaccatccatgtgtatttgcgtcttctctgttaa aagaatattgactggcattttcccgttgaccgccagatatccaaagtacagcacgatgttgcacggac gactttgcagtcaccagccttcctttccacccccccaccaacaaaatgtttatcgtaggacccatatc cgtaataaggatgggtctggcagcaaccccataggcgcctcggcgtggtagttctcgaggccttaagc ttaaggatcccccaactccgcccgttttatgactagaaccaatagtttttaatgccaaatgcactgaa atcccctaatttgcaaagccaaacgccccctatgtgagtaatacggggactttttacccaatttccca cgcggaaagccccctaatacactcatatggcatatgaatcagcacggtcatgcactctaatggcggcc catagggactttccacatagggggcgttcaccatttcccagcataggggtggtgactcaatggccttt acccaagtacattgggtcaatgggaggtaagccaatgggtttttcccattactggcaagcacactgag tcaaatgggactttccactgggttttgcccaagtacattgggtcaatgggaggtgagccaatgggaaa aacccattgctgccaagtacactgactcaatagggactttccaatgggtttttccattgttggcaagc atataaggtcaatgtgggtgagtcaatagggactttccattgtattctgcccagtacataaggtcaat agggggtgaatcaacaggaaagtcccattggagccaagtacactgcgtcaatagggactttccattgg gttttgcccagtacataaggtcaataggggatgagtcaatgggaaaaacccattggagccaagtacac tgactcaatagggactttccattgggttttgcccagtacataaggtcaatagggggtgagtcaacagg aaagttccattggagccaagtacattgagtcaatagggactttccaatgggttttgcccagtacataa ggtcaatgggaggtaagccaatgggtttttcccattactggcacgtatactgagtcattagggacttt ccaatgggttttgcccagtacataaggtcaataggggtgaatcaacaggaaagtcccattggagccaa gtacactgagtcaatagggactttccattgggttttgcccagtacaaaaggtcaatagggggtgagtc aatgggtttttcccattattggcacgtacataaggtcaataggggtgagtcattgggtttttccagcc aatttaattaaaacgccatgtactttcccaccattgacgtcaatgggctattgaaactaatgcaacgt gacctttaaacggtactttcccatagctgattaatgggaaagtaccgttctcgagccaatacacgtca atgggaagtgaaagggcagccaaaacgtaacaccgccccggttttcccctggaaattccatattggca cgcattctattggctgagctgcgttctacgtgggtataagaggcgcgaccagcgtcggtaccgtcgca gtcttcggtctgaccaccgtagaacgcagagctcctcgctgcaggcggccgctctagaactcgtcgat cgcagcgatgacaaacctgcaagatcaaacccaacagattgttccgttcatacggagccttctgatgc caacaaccggaccggcgtccattccggacgacaccctggagaagcacactctcaggtcagagacctcg acctacaatttgactgtgggggacacagggtcagggctaattgtctttttccctggattccctggctc aattgtgggtgctcactacacactgcagagcaatgggaactacaagttcgatcagatgctcctgactg cccagaacctaccggccagctacaactactgcagactagtgagtcggagtctcacagtgaggtcaagc acactccctggtggcgtttatgcactaaacggcaccataaacgccgtgaccttccaaggaagcctgag tgaactgacagatgttagctacaatgggttgatgtctgcaacagccaacatcaacgacaaaattggga atgtcctggtaggggaaggggtcactgtcctcagcctacccacatcatatgatcttgggtatgtgagg cttggtgaccccattcccgctatagggcttgacccaaaaatggtagctacatgcgacagcagtgacag gcccagagtctacaccataactgcagccgatgattaccaattctcatcacagtaccaaccaggtgggg taacaatcacactgttctcagccaacattgatgctatcacaagcctcagcattgggggagagctcgtg tttcaaacaagcgtccaaggccttgtactgggcgccaccatctaccttataggctttgatgggactgc ggtaatcaccagagctgtggccgcagataatgggctgacggccggcaccgacaatcttatgccattca atcttgtcattccaaccaatgagataacccagccaatcacatccatcaaactggagatagtgacctcc aaaagtggtggtcaggcaggggatcagatgtcatggtcggcaagtgggagcctagcagtgacgatcca tggtggcaactatccaggggccctccgtcccgtcacactagtagcctacgaaagagtggcaacaggat ccgtcgttacggtcgctggggtgagtaacttcgagctgattccaaatcctgaactagcaaagaacctg gttacagaatacggccgatttgacccaggagccatgaactacacaaaattgatactgagtgagaggga ccgtcttggcatcaagaccgtctggccaacaagggagtacactgattttcgtgagtacttcatggagg tggccgacctcaactctcccctgaagattgcaggagcatttggcttcaaagacataatccgggctata aggaggtagatccagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtga aaaaaatgctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataa acaagttaacaacaacaattgcattcattttatgtttcaggttcagggggaggtgtgggaggtttttt cggatcctctagagtcgaggatacatccaaagaggttgagtattctctctacacttcttgttaaatgg aaagtgcatttgcttgttcttacaatcggcccgagtctcgttcacagcgcctcgttcacacttaaacc acaaatagtctacaggctatatgggagccagactgaaactcacatatgactaatattcgggggtgtta gtcacgtgtagcccattgtgtgcatataacgatgttggacgcgtccttattcgcggtgtacttgatac tatggcagcgagcatgggatattcatcctcgtcatcgttaacatctctacgggttcagaatgtttggc atgtcgtcgatcctttgcccatcgttgcaaattacaagtccgatcgccatgaccgcgataagcctgta ccatgtggcattagggtgacatctcgatcatacattataagaccaacgtgcgagtcttccaaagacct gcacgccttcttcttcggattgtcaacgggttcttcagaatctatgcccatatctggcgttgagacca ttgtgcgtttaatgaacaataaagcggcatgccatggaaaggagggctgcagatctccattttctcac gccactatcctggacgctgtagacgataattataccatgaatatagagggggtatgtttccactgcca ctgtgatgataagttttctccagattgttggatatctgcattttctgctgccgaacaaacttcatcgc tatgcaaagagatgcgtgtgtacacgcgccggtggagtatacgggaaactaaatgttcatagaggtct ttgggctatatgttattaaataaaataattgaccagtgaacaatttgtttaatgttagtttattcaat gcattggttgcaaatattcattacttctccaatcccaggtcattctttagcgagatgatgttatgaca ttgctgtgaaaattactacaggatatatttttaagatgcaggagtaacaatgtgcatagtaggcgtag ttatcgcagacgtgcaacgcttcgcatttgagttaccgaagtgcccaacagtgctgcggttatggttt atgcgcacagaatccatgcatgtcctaattgaaccatccgatttttcttttaatcgcgatcgatgttt gggcaactgcgttatttcagatctaaaaaatttaccctttatgaccatcacatctctctggctcatac cccgcttggataagatatcatgtagattccgccctaagaaatgcaaactaacattattgtcggttcca tatacacttccatcttgtccttcgaaaataacaaactcgcgcaatagaccgtccgtacatgcatggcc gatgtgtgtcaacatcattggtctgctagatcccgatgggacgaatcgtacagtcgtcgctccagcat tggcaaaaatccccagataccctccatgcggcaaatctaaattgcgaccccgaagagactgcaccaaa gtcttatcgacgcacgctgatttttttgaacagcgggagcccattatcttcagtggagcgtagacggg cgaggctaattatgtgacatagcaacactgcatgtatgtttttataaatcaataagagtacataattt attacgtatcatttccgtttgtaatatactgtatacatcatccacactattagtcagcactagcgcgc gggcgcacgttacaatagcagcgtgcccgttatctatattgtccgatatttacacataacatttcatc gacatgattaaatacctaagtactgcacacagatgtttaatgtatatcgtcatataaattatatcgct aggacagacccaaacgacctttatcccaaacagtcagatcctcttctcaagtgtcgatttctgttatg gaatatgcataccctggcccagaaattgcacgcacgagcgtagtgaatgcgtcattggttttacattt aaaggctaaatgcacaaattctttagacgacagcacatcgttaaatagcatctctagcgttcttatga atgctaagcattggagtcctcctggtcggccacaataacagctgagtatcataccctgagctccgggg ttgtcgcacatagcggattcgtataaacataggattttccgcgaatccatcagttgcaaaaatctgtt aggctccatcaacaacgctggatttacttcagatccacgcgtaaagtaatggtgetcgaataccgttt ttagagttgtcggcatttcaaggaacaaagaattcatttcttcattgcaacgacgcgccagaaatccc aagacctctttgggtagtatgttcttgcctataaaacacggcgttccaagtgccaggaaccacgcatg tgttactgttggggcgtattcagaaataaagcggggtttatgcggcttttgaagctcggatatccaaa gtatcgcttgctgatgaacgagcgatgtagctgttacaaaacctcctttccatcctccagtcaacata atatttatcggcctacctatgtccgtaataagtattggtcgggcaattattccgtatgaggtcttgca ggaataagctcttagggacagccagcttggatatggtgcgaaacagaccttctcggcttcagaatgtc gctccgcagtctcttcgtgtcggtgcatcttagatccaccatcaatgtgtgcagcattgactcccgcc cgtcgaatattccttttgttacgatgcagtaatgagcacgatcatgggcggggcgatgacgttctatt tgcatgtctgcgaacaatttgcgtcagtcatacagctatggagtgggccatttctggccgtcaactta aaaacgcgaaccgcagacatatgtatttgcatgcaaagacgtatcttcgtatttctgggcatcttcaa atgctctggccaatatggcaatgaatttggattcgtttgacgccgatggtatgcagtgcaaatgtgcc aatagcccacatccgaaaaagttatttgtcatacaagcaggtgttaagtagcaatcacataaaggcac cagacgcctcatggcatcataatgaatagctccttctccccactggaaccactgacaaaatctgcgag tatattccgcaaaccacattttatttctcatagaaactaccctaaatccttttaacgggaagaagaat cctagatagtgcttgaagtcatgactgttactgctgcaataacactgtatattatttataaattccgt ttgtctaggtatctgatgtaggcattccgatccctttactattgcgtcttcacgaccaaatgggaatg cgccaaaatccccacacctcatcaccctggaggcagattgtgtattattaatatccgccgattgaagc acaaaacggtacggtactgttcctaattctggtatagattctatggtcaaaagtctgcatatccccga cattgccatgagatcacacagtccaagtagcatgtttattgagtcactcagactgtcaacgtccctcg ccgcaccaccaatcgaaaataaagtatctacgcaagttatagctccgcattttctatcgctagcagca atcgcgacgcaaaacataaaggccatgttgggatttgaactctctggggggcttgttatcttctgcac cgtcgcagtcgcagttttccgaaatttatgtctaatatattttccggccgtgctccaatcggccgaaa agaatctgcgtattaccagactcattgacgggccgataaagaccataaaacaaaattcctgtgcactc cctcctccagttttgccatcgtccaagtcccgtaactttttttgcgtttcgaggagcaagcgttcgtt atccctacccacacttgttttccaccgttttcttattataagcggttgtatcgccaacgcgtcaccgc aggttgtcacatacagtgatggcatacttgaacgtgcaacaacgcgctcgctttgcaaatctaagtca ttgaccatcaaatcgcgttgagaggatagccaggcatcttttttcctagtatggtgacggtgcagcca ccccaactcagttcttgtaaaaaaagctattggcgggaatttatgttctgaggtgcattctatattta tgagtccatcaaatgccattaaccagattcgtattttttcgctcgacccggcatcactatggatacaa tacctttctatggcccatttcagctctcgaaccaaccacacggacaattgactaacataagtatgatc tttatcacagtcgcacccatctgagttatatttatggcatccgagcgctcttactgtacggtcggata cacccatggtttttcctttatatagtcgggttatagtctgtcgggtttggcggtagcacggagtagtt tgatttttaagaatcgaaaaccggcttggagagaccactgtcgaatatttgtccgtatactctacacg tgagtgttgtccattcctaggtatattcatctgttcggataccttcaattgctgttcaggcataacct taaagcatatgttatgttgtacatcaaaacttggtgagttatgttcgattgccgcgcataaagaatcg tacatgagcgtttctgctaacatactatctatattctcacacgcccctgcatatactgttcctattcc aaattcacgttttgccccatcggctatctgctcccaaaaagttgtaatataggtgccgctgggtgcga aattttcatcagttgtattcctgataaactgaatcactttacataatttttgccacatatctgcgtgc agccatagtatcgaacccgtgggctcggagacgacagtgcgtacaatgggtattttacctttccccaa caaaataatggtatacaagttaggtccgtacctagaccttaatgtttccaattcttctgaatcactgc actctcgtaggggagtaacggtaataatttcgtctctgagccccgttttgcgttgaaaactaatcaca ttagataatgtgcaatcggtttcttttatccggatacatctaagtattatgacatcggtggtcattgt ttccatcaacgaccatcttttacgatcgcccatactactcatggacgttgtcggtgttgaaaaatcac cagaattgcaacggatctctgggtaccatgctgctgatggaattggcggttttaattgttgtttcagt ctattattgctatctttggcggggttgaataatgtggggggagagtgattgcaggaatccgaatgggt caataaaacgaccgtgctccgttctgccggcgccgatccgattgaagctatatacttcgcttctctcc ccacttttccaatttgatccggaaataaaacggccccggacaacagtatcgtacgatccggatccgga tcctgcttgcctacagaagaatcaacatctcgccccaatattctggtcaaaactggctcgctcatggc aacgcggacgtttcccccggtggccagtcttaatggttaatgttcttttcggcaatcttatacatcag cgggttgcgtgaatactggtcacagttcagtcatttactacacaccagcaatacgacgacggacagta ccgtcccgacgaacgcgacgcccaaaattgctatcgcgaccgcgtccgaggcgatgtcgtacgggcgg tgcggggttggatcctcggcaaagagatcctcgtaattcggcggtgggagcggagggtaaagacgcgg gtggggatctccctccggaccgcgcgccgggcgcggttcgaaaatgctttccgcctcgctcagtgtca acgccaagtattcgggcgggctgggggccggaatatctcccgcgacttcttctatcggcgcggaattg gagtcgcggtcgtggcgcgcttctagcgtcgtcaacggaagtccattttcggggtctcccggtgggcg ttcagcgtccatcgtcgtatatgctctaacacacgtctcgctatattaaaaaaaagaagagtatcggt cagtgtcgagtgtcgccgacaatgtcgcgagttctcggcgatttaatttttggaactgctccctatga atcccgtaactgtagcgcccgcgcagaaagccgccatcagaccaactacgtgtctgttcgatgtttgc ccgccgatcgctttaccgattaaggttccggcgagaaatgacatgctcgatccaagaacaaagttttt cgcggtaaacaacaacatagttaccgtgcgagatggagaaaccacatctcccgaattagtagaggaaa gcccgcgctgtcggtttggggacatatcgatcttttttgtgtttttcctaggacccttttgccagatc gtacaaagtcgcgtcttatgagcggacgttcttactgcagctcggtaggagtggggcagggttagatt tcgtcggcgtttcggcccccgtatgcgccgcgccaccctcttcgccgagctctttatgcgcggtgggg gtgagcgcttccggagttgcgatctccgatctcgagccgcagcccggcggtgtctctttcagtggagc gttagcgccatcatgtggttcgtggcggtggaaaggctattatgtgttaggggagagaccacgtgatc ggcatgcaaatgagcaaggcgaacgcgtcagcgttcgcactgcgaaccaataatatatatattatact attggctttaggtgcgaacgtccggctagtccaatagcggggtcgcgtttcgtaccacgtgttataga ccgccctaaactcgcactcgggggtccggccgcgcccagacagggcggagacgtgccacaggggcttt aaaacaccgcttcgggcaccgttcatctcggcgcgcc

[0409] SEQ ID NO 28: 1332-47.A2 (HVT / IBDV / ILT / NDV # 3 virus)

[0410] ILT / hCMV IEpro-F-IE(term) / HVT US2 region (13,253 bp)

[0411] aattccagactaaatgccccggcccaatttgtcaagtgtgcagtcacggaggcgtcgaccgtgtcccc ggcattaaacaggaaagcgttaaagtttttgaatgttaggtcacaggtacaaacataaatgtttgtac aaacaggtaacaggtacaaacataaatgccccggcataaatgtcccttacggcggatcgaaacgacat taggcatactcgggtaccattttgcattccgatcagcacggatgaaattaggcaggaatgcggtttat attatgcggcattggacaaacgatatggcattgattggcagtttatgaatgtcttcatgttgggcgta aacggattcctattggttcagaagacaacgacgatatatttagagagaaaaagctacccagcatagga taaacacacattgagcattgagagacataggtatcggtatggatgggaaaactacacacgtgaacacc aaacgacttatatactcgagcggtgatactactgagcaagaatgcactgcatctgagccactgaatga agactgtgatgaaaatgtgaccatcgatggaattggagaagaatatgcgcagttcttcatgtccccgc aatgggtcccaaatctacatcgcttgagcgaggataccaaaaaggtataccgatgtatggtttccaac agactcaattattttccctattatgaggcgttcaggcggtctttgtttgatatgtatatgctaggtcg gttggggcgtcgacttaagcgatctgactgggagactattatgcatctgtcaccaacgcaaagtcggc gtctacatagaactttaagatttgtggagcgtagaattatcccatctaacagttatatacgcacatcg ggccacgttccgccttcgagggcacttccgacagatacgaatttaaagatggatgaataattaaattg gaaagagtaactacattaatcgagcgtcatgacggcgtcccgtgaaaatgggaattttctactcgaaa caccgtgacatttgacagacctggaattgttattctgatatatagtgggtgtgtctggccggcaacat acataatgtgcatgcgaaaccactttttcagtgtacgctgacattgtgcaacacggaggggtagcatc tacatacaatatatgttgattaatgattggagaaaaaactatgcagctcgccgatcatatggctaact cgccttcgtctatatggcggaccccgcgggaaaaatcgacgtaccatctgatttacaacaccagtaat gaacatgtcgcatccctgcccagatctgtgcgcccattggcgcggatcgttgtgaatgccgccgaaac acttcaggtcggtatgagagccgggaggccgccatcagcaggagtttggcgagaggtgtttgatagaa tgatgacagccttccgtgaccacgagcctactgcgacatttaatgctgcaaatcccattagaaaaatg gtcgagacagttctacagaataatgaagagcccccgcggacgcatgctgaaatgggtaatcgccttat gaacattatgtactggtgttgcttgggacacgcaggacaatgctcgatatggcagttgtacgagacga atcaggccattttaagtttattagatgaagtggttatcggcacaacaaatcccttttgcaccctcgag caatactggaagccattatgcaccgcaatcgccaacaaggggacctcatcgcttgttgaggatgccaa agtggccgagtacctggttagcatgcgcaaattgatataacataggcacgctctgatgttacagacca caataccgcatacatttattgtaaggttgttaataaaggtttattctatgtaagactacaatactttc gacattgcttgtatacatattaaatactttctcaagttcctattacataaaatgggatctatcattac attcgttaagagtctggataattttactgtttgccagcttcgatcttggaacgtactgtggatagtgc cttacttggaatcgtgaaaatttgaaacgtccattatttggatatcttccggttgtcccatatcccgc cctggtaccgctcggataccttgcccgtatggattcgtattgacagtcgcgcaatcggggaccaacaa cgcgtgggtccacactcattcggaaattttccgatgattctgaatatttattgccgctcgttacgagt cgttggacatatctgtaatacatttcttcttctgaaggatcgctgcacatttgatctatacattggcc aggatgttcaagtctcagatgttgcattctggcacagcacaactttatggcatttccgatgtaatcgt ccggcagccctgggggagttctatattcgcatattgggatggtaaggacaatagcagatctcgcaacc tccagggaggctataataacgtttttaaaggatggatttctcataaaaatctgtcgcaaattacactg agaatatcctttactagcgccgattgagagcatcgtcgtccaattttctaaatggaaagaaaacaagg cgggcaagagtgttccaaacattttcattttcggcgaatctctcaaatcccatggcgtgcaattgatt gcaaaattggcacttccgttcacgtttgtatctccaaactctaagacacttttaattgaaaaactacg ttctagtgtggaaagaaacctataggcagaccatagaactatttgacaccacatatctttttgtatgt caaactgaccatgatcgtatgttgctgaatgcactagggcaattcgctcgcgcgactccatacattga ataattccacacgtcagctcatcggttagcaaggtccagtagttgaagtcatttatttttccccgcgg ctggccaaatctacctctgggaatatccaagttgtcgaatatgatcgcaccggctctggtcatggtga aggaactgtagcataaagacgcaggtatcataggggtaatatttttttattcactcacatactaaaag taacgcatattagcaccatgtatgggctatcaattgacatttgcgtagcactacatcacgattatgta caacataatgggacaacatatggcaagtagatgcaatttcctcacactagttgggtttatctactatt gaattttcccctatctgtgatacacttgggagcctctacaagcatattgccatcatgtacgtttttat ctactgtcttaacgcccatgggaacggaggcgtcgtcgtcatgtattggacggcaacataggcagcaa cacaaattgcgtttaggtggggtgcatgtggactcgataccaagcccctgcagctggggaacgtctgg tggagagccgataatttgatatacgcacgccatattactgtcgttgaagtacgccttatcttctatgt tttcaaatttaggttcccaagtggacgtgagaagtgtttgtatctcacatggaatggcccaaggcatt ccagcccaggtgcctggtactttaatggcaaacaaacgttttggtagaggtattgattctattgcagt tctgcagatatctgcagccccgagtatccacaggctatacgatacgttatcggaggcaagcttgttaa ttaagtcgacggcagagtcgcagacgcccctattggacgtcaaaattgtagaggtgaagttttcaaac gatggcgaagtaacggcgacttgcgtttccaccgtcaaatctccctatagggtagaaactaattggaa agtagacctcgtagatgtaatggatgaaatttctgggaacagtcccgccggggtttttaacagtaatg agaaatggcagaaacagctgtactacagagtaaccgatggaagaacatcggtccagctaatgtgcctg tcgtgcacgagccattctccggaaccttactgtcttttcgacacgtctcttatagcgagggaaaaaga tatcgcgccagagttatactttacctctgatccgcaaacggcatactgcacaataactctgccgtccg gcgttgttccgagattcgaatggagccttaataatgtttcactgccggaatatttgacggccacgacc gttgtttcgcataccgctggccaaagtacagtgtggaagagcagcgcgagagcaggcgaggcgtggat ttctggccggggaggcaatatatacgaatgcaccgtcctcatctcagacggcactcgcgttactacgc gaaaggagaggtgcttaacaaacacatggattgcggtggaaaacggtgctgctcaggcgcagctgtat tcactcttttctggacttgtgtcaggattatgcgggagcatatctgctttgtacgcaacgctatggac cgccatttatttttgaggaatgctttttggactatcgtactgctttcttccttcgctagccagagcac cgccgccgtcacgtacgactacattttaggccgtcgcgcgctcgacgcgctaaccataccggcggttg gcccgtataacagatacctcactagggtatcaagaggctgcgacgttgtcgagctcaacccgatttct aacgtggacgacatgatatcggcggccaaagaaaaagagaaggggggccctttcgaggcctccgtcgt ctggttctacgtgattaagggcgacgacggcgaggacaagtactgtccaatctatagaaaagagtaca gggaatgtggcgacgtacaactgctatctgaatgcgccgttcaatctgcacagatgtgggcagtggac tatgttcctagcacccttgtatcgcgaaatggcgcgggactgactatattctcccccactgctgcgct ctctggccaatacttgctgaccctgaaaatcgggagatttgcgcaaacagctctcgtaactctagaag ttaacgatcgctgtttaaagatcgggtcgcagcttaactttttaccgtcgaaatgctggacaacagaa cagtatcagactggatttcaaggcgaacacctttatccgatcgcagacaccaatacacgacacgcgga cgacgtatatcggggatacgaagatattctgcagcgctggaataatttgctgaggaaaaagaatccta gcgcgccagaccctcgtccagatagcgtcccgcaagaaattcccgctgtaaccaagaaagcggaaggg cgcaccccggacgcagaaagcagcgaaaagaaggcccctccagaagactcggaggacgacatgcaggc agaggcttctggagaaaatcctgccgccctccccgaagacgacgaagtccccgaggacaccgagcacg atgatccaaactcggatcctgactattacaatgacatgcccgccgtgatcccggtggaggagactact aaaagttctaatgccgtctccatgcccatattcgcggcgttcgtagcctgcgcggtcgcgctcgtggg gctactggtttggagcatcgtaaaatgcgcgcgtagctaatcgagcctagaataggtggtttcttcct acatgccacgcctcacgctcataatataaatcacatggaatagcataccaatgcctattcattgggac gttcgaaaagcatggcatcgctacttggaactctggctctccttgccgcgacgctcgcacccttcggc gcgatgggaatcgtgatcactggaaatcacgtctccgccaggattgacgacgatcacatcgtgatcgt cgcgcctcgccccgaagctacaattcaactgcagctatttttcatgcctggccagagaccccacaaac cctactcaggaaccgtccgcgtcgcgtttcggtctgatataacaaaccagtgctaccaggaacttagc gaggagcgctttgaaaattgcactcatcgatcgtcttctgtttttgtcggctgtaaagtgaccgagta cacgttctccgcctcgaacagactaaccggacctccacacccgtttaagctcactatacgaaatcctc gtccgaacgacagcgggatgttctacgtaattgttcggctagacgacaccaaagaacccattgacgtc ttcgcgatccaactatcggtgtatcaattcgcgaacaccgccgcgactcgcggactctattccaaggc ttcgtgtcgcaccttcggattacctaccgtccaacttgaggcctatctcaggaccgaggaaagttggc gcaactggcaagcgtacgttgccacggaggccacgacgaccagcgccgaggcgacaaccccgacgccc gtcactgcaaccagcgcctccgaacttgaagcggaacactttacctttccctggctagaaaatggcgt ggatcattacgaaccgacacccgcaaacgaaaattcaaacgttactgtccgtctcgggacaatgagcc ctacgctaattggggtaaccgtggctgccgtcgtgagcgcaacgatcggcctcgtcattgtaatttcc atcgtcaccagaaacatgtgcaccccgcaccgaaaattagacacggtctcgcaagacgacgaagaacg ttcccaaactagaagggaatcgcgaaaatttggacccatggttgcgtgcgaaataaacaagggggctg accaggatagtgaacttgtggaactggttgcgattgttaacccgtctgcgctaagctcgcccgactca ataaaaatgtgattaagtctgaatgtggctctccaatcatttcgattctctaatctcccaatcctctc aaaaggggcagtatcggacacggactgggaggggcgtacacgatagttatatggtacagcagaggcct ctgaacacttaggaggagaattcagccggggagagcccctgttgagtaggcttgggagcatattgcag gatgaacatgttagtgatagttctcgcctcttgtcttgcgcgcctaacttttgcgacgcgacacgtcc tctttttggaaggcactcaggctgtcctcggggaagatgatcccagaaacgttccggaagggactgta atcaaatggacaaaagtcctgcggaacgcgtgcaagatgaaggcggccgatgtctgctcttcgcctaa ctattgctttcatgatttaatttacgacggaggaaagaaagactgcccgcccgcgggacccctgtctg caaacctggtaattttactaaagcgcggcgaaagcttcgcgccaggtcaattccctggcattatgccc agtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatg gtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtct ccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgta acaactccgccccattgacgcaaatgggcggtagcgtgtacggtgggaggtctatataagcagagctc gtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgg ttgcgccgccaccatgggccccagaccttctaccaagaacccagtacctatgatgctgactgtccgag tcgcgctggtactgagttgcatctgtccggcaaactccattgatggcaggcctcttgcggctgcagga attgtggttacaggagacaaagccgtcaacatatacacctcatcccagacaggatcaatcatagttaa gctcctcccgaatctgcccaaggataaggaggcatgtgcgaaagcccccttggatgcatacaacagga cattgaccactttgctcaccccccttggtgactctatccgtaggatacaagagtctgtgactacatct ggaggggggagacaggggcgccttataggcgccattattggcggtgtggctcttggggttgcaactgc cgcacaaataacagcggccgcagctctgatacaagccaaacaaaatgctgccaacatcctccgactta aagagagcattgccgcaaccaatgaggctgtgcatgaggtcactgacggattatcgcaactagcagtg gcagttgggaagatgcagcagtttgttaatgaccaatttaataaaacagctcaggaattagactgcat caaaattgcacagcaagttggtgtagagctcaacctgtacctaaccgaattgactacagtattcggac cacaaatcacttcacctgctttaaacaagctgactattcaggcactttacaatctagctggtggaaat atggattacttattgactaagttaggtgtagggaacaatcaactcagctcattaatcggtagcggctt aatcaccggtaaccctattctatacgactcacagactcaactcttgggtatacaggtaactctacctt cagtcgggaagctaaataatatgcgtgccacctacttggaaaccttatccgtaagcacaaccagggga tttgcctcggcacttgtcccaaaagtggtgacacaggtcggttctgtgatagaagaacttgacacctc atactgtatagaaactgacttacatttatattgtacaagaatagtaacgttccctatgtcccctggta tttattcctgcttgagcggcaatacgtcggcctgtatgtactcaaagaccgaaggcgcacttactaca ccatacatgactatcaaaggttcagtcatcgccaactgcaagatgacaacatgtagatgtgtaaaccc cccgggtatcatatcgcaaaactatggagaagccgtgtctctaatagataaacaatcatgcaatgttt tatccttaggcgggataactttaaggctcagtggggaattcgatgtaacttatcagaagaatatctca atacaagattctcaagtaataataacaggcaatcttgatatctcaactgagcttgggaatgtcaacaa ctcgatcagtaatgctttgaataagttagaggaaagcaacagaaaactagacaaagtcaatgtcaaac tgactagcacatctgctctcattacctatatcgtgttgactatcatatctcttgtttttggtatactt agcctgattctagcatgctacctaatgtacaagcaaaaggcgcaacaaaagaccttattatggcttgg gaataatactctagatcagatgagagccactacaaaaatgtgaggatctctcgaggaattctagatcc cacgtcactattgtatactctatattatactctatgttatactctgtaatcctactcaataaacgtgt cacgcctgtgaaaccgtactaagtctcccgtgtcttcttatcaccatcaggtgacatcctcgcccagg ctgtcaatcatgccggtatcgattccagtagcaccggccccacgctgacaacccactcttgcagcgtt agcagcgcccctcttaacaagccgacccccaccagcgtcgcggttactaacactcctctccccgacct gcaactagtaagcttgcctccgattctagcattacatagccggtcagtagatcctgccattcggtagc gcaaccggctacatcttcaaacagtctcacaataaatgcatctctcgttcctgccaatccggaaccgg gcataccactcccgcctgccgatttaattctcacaattgggcgatgccggcggggcaaaacgaatgtg gatttggcaaaccgacacaggtctgctgtacggactaatatgggcacacccacatcattcttcagatg ctccatgcattgttctatgagaaagatccatagggtggaggcagcgtcacgagatcgcccaggcaatc gatcgcattcgtctagtaaagtgacgagagttatcatgcacacacccatgcccacgccttccgaataa ctggagctgtggaagatcggaaacgtctttttgactgccggtctcgtactactttcgcacaggtgtat acccggacgcgtactatatattttatatcatccaacgtccgaaattacatacgtggcggcgatggaag tagatgttgagtcttcgaaagtaagtgcctcgaatatgggtattgtctgtgaaaatatcgaaagcggt acgacggttgcagaaccgtcgatgtcgccagatactagtaacaatagcttcgataacgaagacttccg tgggcctgaatacgatgtggagataaataccagaaaatctgctaatcttgatcgtatggaatcttcgt gccgtgaacaacgagcggcgtgcgaacttcgaaagtgttcgtgtcctacgtctgccgtgcgcatgcaa tacagtattctttcatctctcgctccgggttcagagggtcatgtatatatatgtactagatacgggga cgcggaccaaaaaaaatgcatagtgaaggcagtcgttggaggaaagaatcccgggagggaagtggata ttttaaaaaccatctcacataaatcaattataaaattaatccatgcctataaatggaaaaatgttgtg tgtatggcaatgcgtgtatatcgttatgatcttttcacatatattgacggagtcggccctatgcccct tcaacagatgatctatattcaacgtggactactagaggcgctagcatacatacatgaaaggggcatca ttcaccgagacgtaaagacggagaatatattcttggataatcacgaaaatgcagttttgggtgacttc ggtgctgcatgccaactaggagattgtatagatacgccccaatgttacggttggagcggaactgtgga aacaaattcgccggaattatctgcacttgatccgtattgcacaaaaacagatatttggagtgccggat tggttctatatgagatggcaattaaaaatgtaccattgtttagtaagcaggtgaaaagttcgggatct cagctgagatccataatacggtgcatgcaagtgcatgaactggagtttccccgcaacgattctaccaa cctctgtaaacatttcaaacaatatgcggttcgtgtacgaccgccttataccattcctcgagttataa gaaatggggggatgccaatggatgttgaatatgtcatttctaaaatgcttacgtttgaccaggagttc agaccttctgctaaggaaatattgaatatgcccctatttactaaggcgccgattaacctgcttaatat cacaccctctgacagtgtctaacggtatacaggcgggagcgggtcgtggcgtcatcatcaccacttga gaatttatattttgaattgttgattgataaattaacctgattcattgagaactgaaacgccatattgg tttcttggatatgtctacaacaattagttaaattgctatgttctactgcgagtaacatttgataagtt gtaagagacgggcgactcatgtcgaagttgacgaatataaagtacataacgtgtttagaatacccaga atccgaatagtccgcgggggcgtcttctcgcgtgagtaccaaatactgagttgaacttgaaaatgcta aatctgtgacactctttgtgtgatgattattgtcaccacttcgaagatggcttcgacattcatgatgt tctggtgtttgtttggaatcgtaatagcgcttgtttcgtccaagtctgacaacaaagaaaatctgaag aattatatcacggataagtcaaccaatattagaatacccacgccattatttgtatcaacggaaaactc ttatcccacaaaacatgtaatctacgatgaaaactgtggcttcgctgtactcaatcctataagtgacc ccaaatatgtccttttgagccagcttctaatgggaaggcgcaaatatgatgcgacggtcgcgtggttt gttctcggtaaaatgtgtgccagattaatatatttgcgcgaattttataactgctcgacaaatgagcc ttttggcacatgttctatgagctctcctggatggtgggacaggcgctacgtctcaaccagtttcattt ctcgcgacgaattacagctggtttttgcagcgccgtcccgagaattagatggtttatatacgcgcgta gtagttgtcaacggggactttactacggccgatataatgtttaatgttaaagtggcatgtgccttttc aaagactggaatagaagatgatacattatgcaaaccctttcatttctttgccaatgcaacattgcaca atttaaccatgattagatcggtaactcttcgagcgcacgaaagccatttaaaggaatgggtggcacgg agaggtggtaacgtccctgcagtgctacttgagtctaccatgtatcatgcatccaatctgcctagaaa tttcagggatttctacataaagtctccagatgattataagtataatcacctagatgggccatctgtaa tgctcatcactgacagacctagtgaagatttggatgggaggctcgttcaccaaagtgacatttttact actacaagtcctataaaacaggtccggtatgaagagcatcagtcacatacaaagcagtatcctgtaaa caaaatacaagctataatttttttgatagggttaggctcgttcattggaagcatattcgtagttttgg tagtatggattatacgcagatattgcaatggagcgcggagtgggggaacgccccccagtcctcgccgg tatgtgtataccaggctatgatcacgtgtgaaacttgggcggacctgtatcatatgtacaccgtccct attcgtttatagccagtacgtgttatctgcacatagaggaacatgtgtcatactgggatcgcatgcat ggtatgtgtgactctaatattattctgtatcataataaaaacacagtgcatggtatatagaggatcgc tggtaagcactacggtagaccaatcggctcagattgcattctttggcatcgataccgttgttaattta tatggcaaagtcttgttcatgggagatcagtatttggaggaaatatactctggaacgatggaaatact caaatggaatcaagctaaccgctgctattctattgcgcatgcaacatattacgccgactgtcctataa tcagttctacggtattcagaggatgccgggacgccgttgtttatactaggccccacagcag

[0412] SEQ ID NO 29: 1332-23.7(HVT / IBDV / ILT / NDV # 4 virus)

[0413] ILT / HVT UL54.5 region (12,248 bp)

[0414] ggcgcgccactggagaacggcatgaccgcaaaaggcgttgtagagatcgatcccacgaactctcaggc gatcgtgtcagtcgccataaacagcgacgatcgtctccaggatctgaacggttttcttctcaacgatc atcagtatatgaggaactgaacctgatatttagccgagggaaacgcaggttaaaaaccctatcaagcg attgcgattttcgcgtatctagtaaaaatagatgggcttcggtactagccttcgccgccaactctgaa tatgcccttcgtggacctcatataacatggcattgtttgttggatgcggggccggaattaagaagaac attcgaaatacgagcaaaaatttcggccctggcatgtgctgcgcgagaatcggtacttcggggagaaa gttttatcggagctttgggtagtgcagaggaaactctatcttggttgaaaatgcatgcgaccctgcac ttgattctggttaaccacgatccaatttttaagacggctggcgcggtcctagataacctccgcttaaa actagccccaatattgatgtgcagatataacacagaaaaacgatcaatggaagacatgctacggcggt catctcccgaagacatcaccgattccctaacaatgtgcctgattatgttatcgcgcattcgtcgtacc atgcgcaccgcaggaaataaatatagctatatgatagatccaatgaatcgtatgtctaattacactcc aggcgaatgtatgacaggtatattgcgatatattgacgaacatgctagaaggtgtcctgatcacatat gtaatttgtatatcacatgtacacttatgccgatgtatgtgcacgggcgatatttctattgtaattca tttttttgttagtaaactaccacaggctgtccggaaatctaagttaatgaataaagtagatggttaat actcattgcttagaattggactacttttaattctctttaatgttcgtattaaataaaaacatctttaa taaacttcagcctcttcgcttattgtagaaattgagtattcaaaatcatgttcaaagccgtcttcgga gagtgtactcgccacggtggttggaacatcactatgtctacacgtcaaatttaagcacgtcaggtctg tcgaggacaagaaatggttaactagtgtttcaattattcttataaacgttaagcattgtaagcccccc ggccgtccgcagcaacaatttactagtatgccgtgggctccgggactatcacggatgtccaattcgca catgcatataatttttctagggtctctcatttcgagaaatcttcggggatccatcagcaatgcgggct gtagtcccgattcccgtttcaaatgaaggtgctccaacacggtcttcaaagcaaccggcataccagca aacacagactgcaactccccgctgcaatgattggttataaacagtaatctgtcttctggaagtatatt tcgcccgacaatccacggcgcccccaaagttaaaaaccatccatgtgtatttgcgtcttctctgttaa aagaatattgactggcattttcccgttgaccgccagatatccaaagtacagcacgatgttgcacggac gactttgcagtcaccagccttcctttccacccccccaccaacaaaatgtttatcgtaggacccatatc cgtaataaggatgggtctggcagcaaccccataggcgcctcggcgtggtagttctcgaggccttaatt aagtcgacggcagagtcgcagacgcccctattggacgtcaaaattgtagaggtgaagttttcaaacga tggcgaagtaacggcgacttgcgtttccaccgtcaaatctccctatagggtagaaactaattggaaag tagacctcgtagatgtaatggatgaaatttctgggaacagtcccgccggggtttttaacagtaatgag aaatggcagaaacagctgtactacagagtaaccgatggaagaacatcggtccagctaatgtgcctgtc gtgcacgagccattctccggaaccttactgtcttttcgacacgtctcttatagcgagggaaaaagata tcgcgccagagttatactttacctctgatccgcaaacggcatactgcacaataactctgccgtccggc gttgttccgagattcgaatggagccttaataatgtttcactgccggaatatttgacggccacgaccgt tgtttcgcataccgctggccaaagtacagtgtggaagagcagcgcgagagcaggcgaggcgtggattt ctggccggggaggcaatatatacgaatgcaccgtcctcatctcagacggcactcgcgttactacgcga aaggagaggtgcttaacaaacacatggattgcggtggaaaacggtgctgctcaggcgcagctgtattc actcttttctggacttgtgtcaggattatgcgggagcatatctgctttgtacgcaacgctatggaccg ccatttatttttgaggaatgctttttggactatcgtactgctttcttccttcgctagccagagcaccg ccgccgtcacgtacgactacattttaggccgtcgcgcgctcgacgcgctaaccataccggcggttggc ccgtataacagatacctcactagggtatcaagaggctgcgacgttgtcgagctcaacccgatttctaa cgtggacgacatgatatcggcggccaaagaaaaagagaaggggggccctttcgaggcctccgtcgtct ggttctacgtgattaagggcgacgacggcgaggacaagtactgtccaatctatagaaaagagtacagg gaatgtggcgacgtacaactgctatctgaatgcgccgttcaatctgcacagatgtgggcagtggacta tgttcctagcacccttgtatcgcgaaatggcgcgggactgactatattctcccccactgctgcgctct ctggccaatacttgctgaccctgaaaatcgggagatttgcgcaaacagctctcgtaactctagaagtt aacgatcgctgtttaaagatcgggtcgcagcttaactttttaccgtcgaaatgctggacaacagaaca gtatcagactggatttcaaggcgaacacctttatccgatcgcagacaccaatacacgacacgcggacg acgtatatcggggatacgaagatattctgcagcgctggaataatttgctgaggaaaaagaatcctagc gcgccagaccctcgtccagatagcgtcccgcaagaaattcccgctgtaaccaagaaagcggaagggcg caccccggacgcagaaagcagcgaaaagaaggcccctccagaagactcggaggacgacatgcaggcag aggcttctggagaaaatcctgccgccctccccgaagacgacgaagtccccgaggacaccgagcacgat gatccaaactcggatcctgactattacaatgacatgcccgccgtgatcccggtggaggagactactaa aagttctaatgccgtctccatgcccatattcgcggcgttcgtagcctgcgcggtcgcgctcgtggggc tactggtttggagcatcgtaaaatgcgcgcgtagctaatcgagcctagaataggtggtttcttcctac atgccacgcctcacgctcataatataaatcacatggaatagcataccaatgcctattcattgggacgt tcgaaaagcatggcatcgctacttggaactctggctctccttgccgcgacgctcgcacccttcggcgc gatgggaatcgtgatcactggaaatcacgtctccgccaggattgacgacgatcacatcgtgatcgtcg cgcctcgccccgaagctacaattcaactgcagctatttttcatgcctggccagagaccccacaaaccc tactcaggaaccgtccgcgtcgcgtttcggtctgatataacaaaccagtgctaccaggaacttagcga ggagcgctttgaaaattgcactcatcgatcgtcttctgtttttgtcggctgtaaagtgaccgagtaca cgttctccgcctcgaacagactaaccggacctccacacccgtttaagctcactatacgaaatcctcgt ccgaacgacagcgggatgttctacgtaattgttcggctagacgacaccaaagaacccattgacgtctt cgcgatccaactatcggtgtatcaattcgcgaacaccgccgcgactcgcggactctattccaaggctt cgtgtcgcaccttcggattacctaccgtccaacttgaggcctatctcaggaccgaggaaagttggcgc aactggcaagcgtacgttgccacggaggccacgacgaccagcgccgaggcgacaaccccgacgcccgt cactgcaaccagcgcctccgaacttgaagcggaacactttacctttccctggctagaaaatggcgtgg atcattacgaaccgacacccgcaaacgaaaattcaaacgttactgtccgtctcgggacaatgagccct acgctaattggggtaaccgtggctgccgtcgtgagcgcaacgatcggcctcgtcattgtaatttccat cgtcaccagaaacatgtgcaccccgcaccgaaaattagacacggtctcgcaagacgacgaagaacgtt cccaaactagaagggaatcgcgaaaatttggacccatggttgcgtgcgaaataaacaagggggctgac caggatagtgaacttgtggaactggttgcgattgttaacccgtctgcgctaagctcgcccgactcaat aaaaatgtgattaagtctgaatgtggctctccaatcatttcgattctctaatctcccaatcctctcaa aaggggcagtatcggacacggactgggaggggcgtacacgatagttatatggtacagcagaggcctct gaacacttaggaggagaattcagccggggagagcccctgttgagtaggcttgggagcatattgcagga tgaacatgttagtgatagttctcgcctcttgtcttgcgcgcctaacttttgcgacgcgacacgtcctc tttttggaaggcactcaggctgtcctcggggaagatgatcccagaaacgttccggaagggactgtaat caaatggacaaaagtcctgcggaacgcgtgcaagatgaaggcggccgatgtctgctcttcgcctaact attgctttcatgatttaatttacgacggaggaaagaaagactgcccgcccgcgggacccctgtctgca aacctggtaattttactaaagcgcggcgaaagcttcccgggttaattaaggccctcgaggatacatcc aaagaggttgagtattctctctacacttcttgttaaatggaaagtgcatttgcttgttcttacaatcg gcccgagtctcgttcacagcgcctcgttcacacttaaaccacaaatagtctacaggctatatgggagc cagactgaaactcacatatgactaatattcgggggtgttagtcacgtgtagcccattgtgtgcatata acgatgttggacgcgtccttattcgcggtgtacttgatactatggcagcgagcatgggatattcatcc tcgtcatcgttaacatctctacgggttcagaatgtttggcatgtcgtcgatcctttgcccatcgttgc aaattacaagtccgatcgccatgaccgcgataagcctgtaccatgtggcattagggtgacatctcgat catacattataagaccaacgtgcgagtcttccaaagacctgcacgccttcttcttcggattgtcaacg ggttcttcagaatctatgcccatatctggcgttgagaccattgtgcgtttaatgaacaataaagcggc atgccatggaaaggagggctgcagatctccattttctcacgccactatcctggacgctgtagacgata attataccatgaatatagagggggtatgtttccactgccactgtgatgataagttttctccagattgt tggatatctgcattttctgctgccgaacaaacttcatcgctatgcaaagagatgcgtgtgtacacgcg ccgttgagtatacgggaaactaaatgttcatagaggtctttgggctatatgttattaaataaaataat tgaccagtgaacaatttgtttaatgttagtttattcaatgcattggttgcaaatattcattacttctc caatcccaggtcattctttagcgagatgatgttatgacattgctgtgaaaattactacaggatatatt tttaagatgcaggagtaacaatgtgcatagtaggcgtagttatcgcagacgtgcaacgcttcgcattt gagttaccgaagtgcccaacagtgctgcggttatggtttatgcgcacagaatccatgcatgtcctaat tgaaccatccgatttttcttttaatcgcgatcgttgtttgggcaactgcgttatttcagatctaaaaa atttaccctttatgaccatcacatctctctggctcataccccgcttggataagatatcatgtagattc cgccctaagaaatgcaaactaacattattgtcggttccatatacacttccatcttgtccttcgaaaat aacaaactcgcgcaatagaccgtccgtacatgcatggccgatgtgtgtcaacatcattggtctgctag atcccgatgggacgaatcgtacagtcgtcgctccagcattggcaaaaatccccagataccctccatgc ggcaaatctaaattgcgaccccgaagagactgcaccaaagtcttatcgacgcacgctgatttttttga acagcgggagcccattatcttcagtggagcgtagacgggcgaggctaattatgtgacatagcaacact gcatgtatgtttttataaatcaataagagtacataatttattacgtatcatttccgtttgtaatatac tgtatacatcatccacactattagtcagcactagcgcgcgggcgcacgttacaatagcagcgtgcccg ttatctatattgtccgatatttacacataacatttcatcgacatgattaaatacctaagtactgcaca cagatgtttaatgtatatcgtcatataaattatatcgctaggacagacccaaacgacctttatcccaa acagtcagatcctcttctcaagtgtcgatttctgttatggaatatgcataccctggcccagaaattgc acgcacgagcgtagtgaatgcgtcattggttttacatttaaaggctaaatgcacaaattctttagacg acagcacatcgttaaatagcatctctagcgttcttatgaatgctaagcattggagtcctcctggtcgg ccacaataacagctgagtatcataccctgagctccggggttgtcgcacatagcggattcgtataaaca taggattttccgcgaatccatcagttgcaaaaatctgttaggctccatcaacaacgctggatttactt cagatccacgcgtaaagtaatggtgctcgaataccgtttttagagttgtcggcatttcaaggaacaaa gaattcatttcttcattgcaacgacgcgccagaaatcccaagacctctttgggtagtatgttcttgcc tataaaacacggcgttccaagtgccaggaaccacgcatgtgttactgttggggcgtattcagaaataa agcggggtttatgcggcttttgaagctcggatatccaaagtatcgcttgctgatgaacgagcgatgta gctgttacaaaacctcctttccatcctccagtcaacataatatttatcggcctacctatgtccgtaat aagtattggtcgggcaattattccgtatgaggtcttgcaggaataagctcttagggacagccagcttg gatatggtgcgaaacagaccttctcggcttcagaatgtcgctccgcagtctcttcgtgtcggtgcatc ttagatccaccatcaatgtgtgcagcattgactcccgcccgtcgaatattccttttgttacgatgcag taatgagcacgatcatgggcggggcgatgacgttctatttgcatgtctgcgaacaatttgcgtcagtc atacagctatggagtgggccatttctggccgtcaacttaaaaacgcgaaccgcagacatatgtatttg catgcaaagacgtatcttcgtatttctgggcatcttcaaatgctctggccaatatggcaatgaatttg gattcgtttgacgccgatggtatgcagtgcaaatgtgccaatagcccacatccgaaaaagttatttgt catacaagcaggtgttaagtagcaatcacataaaggcaccagacgcctcatggcatcataatgaatag ctccttctccccactggaaccactgacaaaatctgcgagtatattccgcaaaccacattttatttctc atagaaactaccctaaatccttttaacgggaagaagaatcctagatagtgcttgaagtcatgactgtt actgctgcaataacactgtatattatttataaattccgtttgtctaggtatctgatgtaggcattccg atccctttactattgcgtcttcacgaccaaatgggaatgcgccaaaatccccacacctcatcaccctg gaggcagattgtgtattattaatatccgccgattgaagcacaaaacggtacggtactgttcctaattc tggtatagattctatggtcaaaagtctgcatatccccgacattgccatgagatcacacagtccaagta gcatgtttattgagtcactcagactgtcaacgtccctcgccgcaccaccaatcgaaaataaagtatct acgcaagttatagctccgcattttctatcgctagcagcaatcgcgacgcaaaacataaaggccatgtt gggatttgaactctctggggggcttgttatcttctgcaccgtcgcagtcgcagttttccgaaatttat gtctaatatattttccggccgtgctccaatcggccgaaaagaatctgcgtattaccagactcattgac gggccgataaagaccataaaacaaaattcctgtgcactccctcctccagttttgccatcgtccaagtc ccgtaactttttttgcgtttcgaggagcaagcgttcgttatccctacccacacttgttttccaccgtt ttcttattataagcggttgtatcgccaacgcgtcaccgcaggttgtcacatacagtgatggcatactt gaacgtgcaacaacgcgctcgctttgcaaatctaagtcattgaccatcaaatcgcgttgagaggatag ccaggcatcttttttcctagtatggtgacggtgcagccaccccaactcagttcttgtaaaaaaagcta ttggcgggaatttatgttctgaggtgcattctatatttatgagtccatcaaatgccattaaccagatt cgtattttttcgctcgacccggcatcactatggatacaatacctttctatggcccatttcagctctcg aaccaaccacacggacaattgactaacataagtatgatctttatcacagtcgcacccatctgagttat atttatggcatccgagcgctcttactgtacggtcggatacacccatggtttttcctttatatagtcgg gttatagtctgtcgggtttggcggtagcacggagtagtttgatttttaagaatcgaaaaccggcttgg agagaccactgtcgaatatttgtccgtatactctacacgtgagtgttgtccattcctaggtatattca tctgttcggataccttcaattgctgttcaggcataaccttaaagcatatgttatgttgtacatcaaaa cttggtgagttatgttcgattgccgcgcataaagaatcgtacatgagcgtttctgctaacatactatc tatattctcacacgcccctgcatatactgttcctattccaaattcacgttttgccccatcggctatct gctcccaaaaagttgtaatataggtgccgctgggtgcgaaattttcatcagttgtattcctgataaac tgaatcactttacataatttttgccacatatctgcgtgcagccatagtatcgaacccgtgggctcgga gacgacagtgcgtacaatgggtattttacctttccccaacaaaataatggtatacaagttaggtccgt acctagaccttaatgtttccaattcttctgaatcactgcactctcgtaggggagtaacggtaataatt tcgtctctgagccccgttttgcgttgaaaactaatcacattagataatgtgcaatcggtttcttttat ccggatacatctaagtattatgacatcggtggtcattgtttccatcaacgaccatcttttacgatcgc ccatactactcatggacgttgtcggtgttgaaaaatcaccagaattgcaacggatctctgggtaccat gctgctgatggaattggcggttttaattgttgtttcagtctattattgctatctttggcggggttgaa taatgtggggggagagtgattgcaggaatccgaatgggtcaataaaacgaccgtgctccgttctgccg gcgccgatccgattgaagctatatacttcgcttctctccccacttttccaatttgatccggaaataaa acggccccggacaacagtatcgtacgatccggatccggatcctgcttgcctacagaagaatcaacatc tcgccccaatattctggtcaaaactggctcgctcatggcaacgcggacgtttcccccggtggccagtc ttaatggttaatgttcttttcggcaatcttatacatcagcgggttgcgtgaatactggtcacagttca gtcatttactacacaccagcaatacgacgacggacagtaccgtcccgacgaacgcgacgcccaaaatt gctatcgcgaccgcgtccgaggcgatgtcgtacgggcggtgcggggttggatcctcggcaaagagatc ctcgtaattcggcggtgggagcggagggtaaagacgcgggtggggatctccctccggaccgcgcgccg ggcgcggttcgaaaatgctttccgcctcgctcagtgtcaacgccaagtattcgggcgggctgggggcc ggaatatctcccgcgacttcttctatcggcgcggaattggagtcgcggtcgtggcgcgcttctagcgt cgtcaacggaagtccattttcggggtctcccggtgggcgttcagcgtccatcgtcgtatatgctctaa cacacgtctcgctatattaaaaaaaagaagagtatcggtcagtgtcgagtgtcgccgacaatgtcgcg agttctcggcgatttaatttttggaactgctccctatgaatcccgtaactgtagcgcccgcgcagaaa gccgccatcagaccaactacgtgtctgttcgatgtttgcccgccgatcgctttaccgattaaggttcc ggcgagaaatgacatgctcgatccaagaacaaagtttttcgcggtaaacaacaacatagttaccgtgc gagatggagaaaccacatctcccgaattagtagaggaaagcccgcgctgtcggtttggggacatatcg atcttttttgtgtttttcctaggacccttttgccagatcgtacaaagtcgcgtcttatgagcggacgt tcttactgcagctcggtaggagtggggcagggttagatttcgtcggcgtttcggcccccgtatgcgcc gcgccaccctcttcgccgagctctttatgcgcggtgggggtgagcgcttccggagttgcgatctccga tctcgagccgcagcccggcggtgtctctttcagtggagcgttagcgccatcatgtggttcgtggcggt ggaaaggctattatgtgttaggggagagaccacgtgatcggcatgcaaatgagcaaggcgaacgcgtc agcgttcgcactgcgaaccaataatatatatattatactattggctttaggtgcgaacgtccggctag tccaatagcggggtcgcgtttcgtaccacgtgttatagaccgccctaaactcgcactcgggggtccgg ccgcgcccagacagggcggagacgtgccacaggggctttaaaacaccgcttcgggcaccgtteatetc ggcgcgcc SEQ ID NO 30: 435Vec60 (HVT / IBDV / ILT / NDV # 4 virus)

[0415] mCMV IEpro-VP2-SV40pA / hCMV IEpro-F-IE(term) / HVT US2 region (13,068 bp)

[0416] aattccagactaaatgccccggcccaatttgtcaagtgtgcagtcacggaggcgtcgaccgtgtcccc ggcattaaacaggaaagcgttaaagtttttgaatgttaggtcacaggtacaaacataaatgtttgtac aaacaggtaacaggtacaaacataaatgccccggcataaatgtcccttacggcggatcgaaacgacat taggcatactcgggtaccattttgcattccgatcagcacggatgaaattaggcaggaatgcggtttat attatgcggcattggacaaacgatatggcattgattggcagtttatgaatgtcttcatgttgggcgta aacggattcctattggttcagaagacaacgacgatatatttagagagaaaaagctacccagcatagga taaacacacattgagcattgagagacataggtatcggtatggatgggaaaactacacacgtgaacacc aaacgacttatatactcgagcggtgatactactgagcaagaatgcactgcatctgagccactgaatga agactgtgatgaaaatgtgaccatcgatggaattggagaagaatatgcgcagttcttcatgtccccgc aatgggtcccaaatctacatcgcttgagcgaggataccaaaaaggtataccgatgtatggtttccaac agactcaattattttccctattatgaggcgttcaggcggtctttgtttgatatgtatatgctaggtcg gttggggcgtcgacttaagcgatctgactgggagactattatgcatctgtcaccaacgcaaagtcggc gtctacatagaactttaagatttgtggagcgtagaattatcccatctaacagttatatacgcacatcg ggccacgttccgccttcgagggcacttccgacagatacgaatttaaagatggatgaataattaaattg gaaagagtaactacattaatcgagcgtcatgacggcgtcccgtgaaaatgggaattttctactcgaaa caccgtgacatttgacagacctggaattgttattctgatatatagtgggtgtgtctggccggcaacat acataatgtgcatgcgaaaccactttttcagtgtacgctgacattgtgcaacacggaggggtagcatc tacatacaatatatgttgattaatgattggagaaaaaactatgcagctcgccgatcatatggctaact cgccttcgtctatatggcggaccccgcgggaaaaatcgacgtaccatctgatttacaacaccagtaat gaacatgtcgcatccctgcccagatctgtgcgcccattggcgcggatcgttgtgaatgccgccgaaac acttcaggtcggtatgagagccgggaggccgccatcagcaggagtttggcgagaggtgtttgatagaa tgatgacagccttccgtgaccacgagcctactgcgacatttaatgctgcaaatcccattagaaaaatg gtcgagacagttctacagaataatgaagagcccccgcggacgcatgctgaaatgggtaatcgccttat gaacattatgtactggtgttgcttgggacacgcaggacaatgctcgatatggcagttgtacgagacga atcaggccattttaagtttattagatgaagtggttatcggcacaacaaatcccttttgcaccctcgag caatactggaagccattatgcaccgcaatcgccaacaaggggacctcatcgcttgttgaggatgccaa agtggccgagtacctggttagcatgcgcaaattgatataacataggcacgctctgatgttacagacca caataccgcatacatttattgtaaggttgttaataaaggtttattctatgtaagactacaatactttc gacattgcttgtatacatattaaatactttctcaagttcctattacataaaatgggatctatcattac attcgttaagagtctggataattttactgtttgccagcttcgatcttggaacgtactgtggatagtgc cttacttggaatcgtgaaaatttgaaacgtccattatttggatatcttccggttgtcccatatcccgc cctggtaccgctcggataccttgcccgtatggattcgtattgacagtcgcgcaatcggggaccaacaa cgcgtgggtccacactcattcggaaattttccgatgattctgaatatttattgccgctcgttacgagt cgttggacatatctgtaatacatttcttcttctgaaggatcgctgcacatttgatctatacattggcc aggatgttcaagtctcagatgttgcattctggcacagcacaactttatggcatttccgatgtaatcgt ccggcagccctgggggagttctatattcgcatattgggatggtaaggacaatagcagatctcgcaacc tccagggaggctataataacgtttttaaaggatggatttctcataaaaatctgtcgcaaattacactg agaatatcctttactagcgccgattgagagcatcgtcgtccaattttctaaatggaaagaaaacaagg cgggcaagagtgttccaaacattttcattttcggcgaatctctcaaatcccatggcgtgcaattgatt gcaaaattggcacttccgttcacgtttgtatctccaaactctaagacacttttaattgaaaaactacg ttctagtgtggaaagaaacctataggcagaccatagaactatttgacaccacatatctttttgtatgt caaactgaccatgatcgtatgttgctgaatgcactagggcaattcgctcgcgcgactccatacattga ataattccacacgtcagctcatcggttagcaaggtccagtagttgaagtcatttatttttccccgcgg ctggccaaatctacctctgggaatatccaagttgtcgaatatgatcgcaccggctctggtcatggtga aggaactgtagcataaagacgcaggtatcataggggtaatatttttttattcactcacatactaaaag taacgcatattagcaccatgtatgggctatcaattgacatttgcgtagcactacatcacgattatgta caacataatgggacaacatatggcaagtagatgcaatttcctcacactagttgggtttatctactatt gaattttcccctatctgtgatacacttgggagcctctacaagcatattgccatcatgtacgtttttat ctactgtcttaacgcccatgggaacggaggcgtcgtcgtcatgtattggacggcaacataggcagcaa cacaaattgcgtttaggtggggtgcatgtggactcgataccaagcccctgcagctggggaacgtctgg tggagagccgataatttgatatacgcacgccatattactgtcgttgaagtacgccttatcttctatgt tttcaaatttaggttcccaagtggacgtgagaagtgtttgtatctcacatggaatggcccaaggcatt ccagcccaggtgcctggtactttaatggcaaacaaacgttttggtagaggtattgattctattgcagt tctgcagatatctgcagccccgagtatccacaggctatacgatacgttatcggaggcaagctgcggcc gctctagaactagtggatcccccgggctgcagcccaatgtggaattcgcccttgcacattgttactcc tgcatcttaaaaatatatcctgtagtaattttcacagcaatgtcataacatcatctcgctaaagaatg acctgggattggagaagtaatgaatatttgcaaccaatgcattgaataaactaacattaaacgaattc actagtggatcccccaactccgcccgttttatgactagaaccaatagtttttaatgccaaatgcactg aaatcccctaatttgcaaagccaaacgccccctatgtgagtaatacggggactttttacccaatttcc caagcggaaagccccctaatacactcatatggcatatgaatcagcacggtcatgcactctaatggcgg cccatagggactttccacatagggggcgttcaccatttcccagcataggggtggtgactcaatggcct ttacccaagtacattgggtcaatgggaggtaagccaatgggtttttcccattactggcaagcacactg agtcaaatgggactttccactgggttttgcccaagtacattgggtcaatgggaggtgagccaatggga aaaacccattgctgccaagtacactgactcaatagggactttccaatgggtttttccattgttggcaa gcatataaggtcaatgtgggtgagtcaatagggactttccattgtattctgcccagtacataaggtca atagggggtgaatcaacaggaaagtcccattggagccaagtacactgcgtcaatagggactttccatt gggttttgcccagtacataaggtcaataggggatgagtcaatgggaaaaacccattggagccaagtac actgactcaatagggactttccattgggttttgcccagtacataaggtcaatagggggtgagtcaaca ggaaagtcccattggagccaagtacattgagtcaatagggactttccaatgggttttgcccagtacat aaggtcaatgggaggtaagccaatgggtttttcccattactggcacgtatactgagtcattagggact ttccaatgggttttgcccagtacataaggtcaataggggtgaatcaacaggaaagtcccattggagcc aagtacactgagtcaatagggactttccattgggttttgcccagtacaaaaggtcaatagggggtgag tcaatgggtttttcccattattggcacgtacataaggtcaataggggtgagtcattgggtttttccag ccaatttaattaaaacgccatgtactttcccaccattgacgtcaatgggctattgaaactaatgcaac gtgacctttaaacggtactttcccatagctgattaatgggaaagtaccgttctcgagccaatacacgt caatgggaagtgaaagggcagccaaaacgtaacaccgccccggttttcccctggaaattccatattgg cacgcattctattggctgagctgcgttctacgtgggtataagaggcgcgaccagcgtcggtaccgtcg cagtcttcggtctgaccaccgtagaacgcagagctcctcgctgcaggcggccgctctagaactcgtcg atcgcagcgatgacaaacctgcaagatcaaacccaacagattgttccgttcatacggagccttctgat gccaacaaccggaccggcgtccattccggacgacaccctggagaagcacactctcaggtcagagacct cgacctacaatttgactgtgggggacacagggtcagggctaattgtctttttccctggattccctggc tcaattgtgggtgctcactacacactgcagagcaatgggaactacaagttcgatcagatgctcctgac tgcccagaacctaccggccagctacaactactgcagactagtgagtcggagtctcacagtgaggtcaa gcacactccctggtggcgtttatgcactaaacggcaccataaacgccgtgaccttccaaggaagcctg agtgaactgacagatgttagctacaatgggttgatgtctgcaacagccaacatcaacgacaaaattgg gaatgtcctggtaggggaaggggtcactgtcctcagcctacccacatcatatgatcttgggtatgtga ggcttggtgaccccattcccgctatagggcttgacccaaaaatggtagctacatgcgacagcagtgac aggcccagagtctacaccataactgcagccgatgattaccaattctcatcacagtaccaaccaggtgg ggtaacaatcacactgttctcagccaacattgatgctatcacaagcctcagcattgggggagagctcg tgtttcaaacaagcgtccaaggccttgtactgggcgccaccatctaccttataggctttgatgggact gcggtaatcaccagagctgtagccgcagataatgggctgacggccggcaccgacaatcttatgccatt caatcttgtcattccaaccaatgagataacccagccaatcacatccatcaaactggagatagtgacct ccaaaagtggtggtcaggcaggggatcagatgtcatggtcggcaagtgggagcctagcagtgacgatc catggtggcaactatccaggggccctccgtcccgtcacactagtagcctacgaaagagtggcaacagg atccgtcgttacggtcgctggggtgagtaacttcgagctgattccaaatcctgaactagcaaagaacc tggttacagaatacggccgatttgacccaggagccatgaactacacaaaattgatactgagtgagagg gaccgtcttggcatcaagaccgtctggccaacaagggagtacactgattttcgtgagtacttcatgga ggtggccgacctcaactctcccctgaagattgcaggagcatttggcttcaaagacataatccgggcta taaggaggtaagcttgatctagagcggccgcggggatccagacatgataagatacattgatgagtttg gacaaaccacaactagaatgcagtgaaaaaaatgctttatttgtgaaatttgtgatgctattgcttta tttgtaaccattataagctgcaataaacaagttaacaacaacaattgcattcattttatgtttcaggt tcagggggaggtgtgggaggttttttcggatcctctagagtcgacaattatttcatttaataacatat agcccaaagacctctatgaacatttagtttcccgtatactcaacggcgcgtgtacacacaagggcgaa ttccacagtggatatcaagcttaattaagtaccgagctcgaattggcgcgccaggtcaattccctggc attatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgct attaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcgg...

Claims

WE CLAIM:1 . A recombinant nonpathogenic Marek's Disease Virus (rMDVnp) that comprises at least three heterologous nucleotide sequences;wherein a first heterologous nucleotide sequence encodes one or more antigens from a first chicken pathogen, a second heterologous nucleotide sequence encodes one or more antigens from a second chicken pathogen, and a third heterologous nucleotide sequence encodes one or more antigens from a third chicken pathogen;wherein the first heterologous nucleotide sequence, the second heterologous nucleotide sequence, and the third heterologous nucleotide sequence are each located in a nonessential site of the rMDVnpgenome; andwherein the first chicken pathogen, the second chicken pathogen, and the third chicken pathogen are all different viral species from each other and a different viral species than Marek's Disease Virus (MDV).

2. The rMDVnpof Claim 1 , wherein the first chicken pathogen is Infectious Bursal Disease Virus (IBDV), the second chicken pathogen is Infectious Laryngotracheitis Virus (ILTV), and the third chicken pathogen is Newcastle Disease Virus (NDV).

3. The rMDVnp of Claim 2, wherein the first heterologous nucleotide sequence comprises a coding sequence for an Infectious Bursal Disease Virus viral protein 2 (IBDV VP2), the second heterologous nucleotide sequence comprises a coding sequence for an Infectious Laryngotracheitis Virus glycoprotein D (ILTV gD) and a coding sequence for an Infectious Laryngotracheitis Virus glycoprotein I (ILTV gl), and the third heterologous nucleotide sequence comprises a coding sequence for a Newcastle Disease Virus fusion protein (NDV F).

4. The rMDVnp of Claim 1 , 2, or 3, wherein the first heterologous nucleotide sequence is comprised by a first heterologous nucleic acid or a second heterologous nucleic acid, the second heterologous nucleotide sequence is comprised by the first heterologous nucleic acid or the second heterologous nucleic acid, and the third heterologous nucleotide sequence is comprised by the first heterologous nucleic acid or the second heterologous nucleic acid;wheren the first heterologous nucleic acid is located in a first nonessential site in the rMDVnp genome, and the second heterologous nucleic acid is located in a second nonessential site in the rMDVnpgenome; andwherein the first nonessential site and the second nonessential site are either the same or different.

5. The rMDVnp Of Claim 4, wherein when the first nonessential site and the second nonessential site are the same site, and is selected from the group consisting of the US2 site, the UL54.5 site, the UL7 / 8 site, the UL40 site, the UL43 site, the UL45 / 46 site, the UL55 site, the US10 site, the region between US10 and SORF3, the region between US2 and SORF3, the intergenic region 1 (IG1 ) site, the intergenic region 2 (IG2) site, and the intergenic region 3 (IG3) site.

6. The rMDVnp Of Claim 4, wherein when the first nonessential site and the second nonessential site are two different sites; wherein the two different sites are individually selected from the group consisting of the US2 site, the UL54.5 site, the UL7 / 8 site, the UL40 site, the UL43 site, the UL45 / 46 site, the UL55 site, the US10 site, the region between US10 and SORF3, the region between US2 and SORF3, the intergenic region 1 (IG1 ) site, the intergenic region 2 (IG2) site, and the intergenic region 3 (IG3) site.

7. The rMDVnp of Claim 4, 5, or 6, wherein the first heterologous nucleic acid comprises the first heterologous nucleotide sequence and the second heterologous nucleotide sequence; wherein the second heterologous nucleic acid comprises the third heterologous nucleotide sequence; andwherein the first heterologous nucleotide sequence comprises a coding sequence for IBDV VP2, the second heterologous nucleotide sequence comprises a coding sequence for ILTV gD and a coding sequence for ILTV gl, and the third heterologous nucleotide sequence comprises a coding sequence for NDV F.

8. The rMDVnp of Claim 7, wherein the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 21 and wherein the second heterologous nucleic acid comprises a nucleotide sequence of SEQ ID NO: 22.

9. The rMDVnp of Claim 7, wherein the first heterologous nucleic acid comprises the nucleotide sequence selected from the group conssting of SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25 and wherein the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 26.

10. The rMDVnp of Claim 4, 5, or 6, wherein the first heterologous nucleic acid comprises the second heterologous nucleotide sequence and the third heterologous nucleotidesequence; wherein the second heterologous nucleic acid comprises the first heterologous nucleotide sequence; andwherein the first heterologous nucleotide sequence comprises a coding sequence for IBDV VP2, the second heterologous nucleotide sequence comprises a coding sequence for1 LTV gD and a coding sequence for I LTV gl, and the third heterologous nucleotide sequence comprises a coding sequence for NDV F.1 1 . The rMDVnp of Claim 10, wherein the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 28 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 27, or the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 31 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 32.

12. The rMDVnp of Claim 4, 5, or 6, wherein the first heterologous nucleic acid comprises the first heterologous nucleotide sequence and the third heterologous nucleotide sequence; wherein the second heterologous nucleic acid comprises the second heterologous nucleotide sequence; andand wherein the first heterologous nucleotide sequence comprises a coding sequence for IBDV VP2, the second heterologous nucleotide sequence comprises a coding sequence for I LTV gD and a coding sequence for I LTV gl, and the third heterologous nucleotide sequence comprises a coding sequence for NDV F.

13. The rMDVnp of Claim 12, wherein the first heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 30 and the second heterologous nucleic acid comprises the nucleotide sequence of SEQ ID NO: 29.

14. The rMDVnp of Claim 1 , 2, or 3, wherein first heterologous nucleotide sequence, and the second heterologous nucleotide sequence, and the third heterologous nucleotide sequence are all located in the same nonessential site.

15. The rMDVnp of Claim 14, wherein when the nonessential site is selected from the group consisting of the US2 site, the UL54.5 site, the UL7 / 8 site, the UL40 site, the UL43 site, the UL45 / 46 site, the UL55 site, the US10 site, the region between US10 and SORF3, the region between US2 and SORF3, the intergenic region 1 (IG1 ) site, the intergenic region2 (IG2) site, and the intergenic region 3 (IG3) site.

16. The rMDVnp of Claim 1 , 2, or 3, wherein first heterologous nucleotide sequence, the second heterologous nucleotide sequence, and the third heterologous nucleotide sequence are all located in different nonessential sites.

17. The rMDVnp of Claim 16, wherein when the three different nonessential sites are individually selected from the group consisting of the US2 site, the UL54.5 site, the UL7 / 8 site, the UL40 site, the UL43 site, the UL45 / 46 site, the UL55 site, the US10 site, the region between US10 and SORF3, the region between US2 and SORF3, the IG1 site, and the IG2 site.

18. The rMDVnp of Claim 1 , 2, or 3, wherein the first heterologous nucleotide sequence and the second heterologous nucleotide sequence are located in a first nonessential site and the third heterologous nucleotide sequence is located in a second nonessential site.

19. The rMDVnp of Claim 1 , 2, or 3, wherein the first heterologous nucleotide sequence and the third heterologous nucleotide sequence are located in a first nonessential site and the second heterologous nucleotide sequence is located in a second nonessential site.

20. The rMDVnp of Claim 1 , 2, or 3, wherein the second heterologous nucleotide sequence and the third heterologous nucleotide sequence are located in a first nonessential site and the first heterologous nucleotide sequence is located in a second nonessential site.21 . The rMDVnp of Claim 18, 19, or 20, wherein the first nonessential site and the second nonessential site are individually selected from the group consisting of the US2 site, the UL54.5 site, the UL7 / 8 site, the UL40 site, the UL43 site, the UL45 / 46 site, the UL55 site, the US10 site, the region between US10 and SORF3, the region between US2 and SORF3, the intergenic region 1 (IG1 ) site, the intergenic region 2 (IG2) site, and the intergenic region 3 (IG3) site.

22. The rMDVnp of Claim 3, 4, 5, 6, 7, 10, 12, 14,15, 16, 17, 18, 19, 20, or 21 , wherein the coding sequence of the IBDV VP2 protein of the first heterologous nucleotide sequence is operatively under the control of a first promoter; the coding sequence of the I LTV gD protein of the second heterologous nucleotide sequence is operatively under the control of a second promoter; the coding sequence of the ILTV gl protein of the second heterologous nucleotide sequence is operatively under the control of a third promoter; and the third heterologous nucleotide sequence that encodes the NDV F is operatively under the control of a fourth promoter.

23. The rMDVnpof Claim 22, wherein the first promoter, the second promoter, the third promoter, and the fourth promoter are all different.

24. The rMDVnpof Claim 22 or 23, wherein the second promoter is the endogenous I LTV gD promoter, the third promoter is the endogenous I LTV gl promoter, and wherein the first promoter and the fourth promoter are individually selected from the group consisting of the murine cytomegalovirus immediate early 1 gene (mCMV-IE1 ) promoter, the human cytomegalovirus immediate early 1 gene (hCMV-IE1 ) promoter, and the chicken β-actin promoter.

25. The rMDVnpof Claim 24, wherein the first promoter is mCMV-IE1 ; and the fourth promoter is the hCMV-IE1.

26. The rMDVnp of Claim 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 21 , 22, 23, 24, or 25, wherein the first nonessential site is the US2 site and the second nonessential site is the UL54.5 site.

27. The rMDVnp of Claim 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 21 , 22, 23, 24, or 25, wherein the first nonessential site is the UL54.5 site and the second nonessential site is the US2 site.

28. The rMDVnp of any preceding claim, wherein the rMDVnpis a recombinant herpesvirus of turkeys (rHVT).

29. The rMDVnp of Claim 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, or 27, wherein the rMDVnpis a recombinant Marek's Disease Virus serotype 2 (rMDV2).

30. An immunogenic composition comprising the rMDVnpof any preceding claim.31 . A vaccine comprising the immunogenic composition of Claim 30.

32. A method for aiding in the protection of a chicken against a virus selected from the group consisting of NDV, ILTV, IBDV, MDV, and any combination thereof comprising administering the vaccine of Claim 31.